WO2008131921A1 - Silylated, substituted benzotriazolylphenol compounds - Google Patents
Silylated, substituted benzotriazolylphenol compounds Download PDFInfo
- Publication number
- WO2008131921A1 WO2008131921A1 PCT/EP2008/003356 EP2008003356W WO2008131921A1 WO 2008131921 A1 WO2008131921 A1 WO 2008131921A1 EP 2008003356 W EP2008003356 W EP 2008003356W WO 2008131921 A1 WO2008131921 A1 WO 2008131921A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- unsubstituted
- alkyl
- radical
- substituted
- mono
- Prior art date
Links
- YHCGGLXPGFJNCO-UHFFFAOYSA-N 2-(2H-benzotriazol-4-yl)phenol Chemical class OC1=CC=CC=C1C1=CC=CC2=C1N=NN2 YHCGGLXPGFJNCO-UHFFFAOYSA-N 0.000 title abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 143
- 150000001875 compounds Chemical class 0.000 claims abstract description 57
- 230000005855 radiation Effects 0.000 claims abstract description 50
- 229920000642 polymer Polymers 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000004611 light stabiliser Substances 0.000 claims abstract description 16
- 238000011321 prophylaxis Methods 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000002537 cosmetic Substances 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 8
- -1 benzotriazolylphenol compound Chemical class 0.000 claims description 326
- 150000003254 radicals Chemical class 0.000 claims description 260
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 189
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 157
- 125000001424 substituent group Chemical group 0.000 claims description 121
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 111
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 105
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 97
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 97
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 93
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 82
- 229910052801 chlorine Inorganic materials 0.000 claims description 80
- 229910052794 bromium Inorganic materials 0.000 claims description 76
- 229910052731 fluorine Inorganic materials 0.000 claims description 76
- 150000003839 salts Chemical class 0.000 claims description 73
- 229910006069 SO3H Inorganic materials 0.000 claims description 72
- 125000000217 alkyl group Chemical group 0.000 claims description 72
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 67
- 229910052740 iodine Inorganic materials 0.000 claims description 66
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 66
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 62
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 57
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 53
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 53
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 53
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 50
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 50
- 229920006395 saturated elastomer Polymers 0.000 claims description 49
- 125000005842 heteroatom Chemical group 0.000 claims description 39
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 39
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 38
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 35
- 239000012453 solvate Substances 0.000 claims description 35
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 29
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 29
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 29
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 24
- 239000003054 catalyst Substances 0.000 claims description 20
- 125000004122 cyclic group Chemical group 0.000 claims description 20
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 19
- 229910003849 O-Si Inorganic materials 0.000 claims description 18
- 229910003872 O—Si Inorganic materials 0.000 claims description 18
- 150000005840 aryl radicals Chemical class 0.000 claims description 18
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 18
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 18
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 16
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 16
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 15
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 14
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 12
- 239000005864 Sulphur Substances 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 238000009835 boiling Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 206010042496 Sunburn Diseases 0.000 claims description 9
- 206010072578 Chronic actinic dermatitis Diseases 0.000 claims description 8
- 241000282414 Homo sapiens Species 0.000 claims description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 8
- 206010036087 Polymorphic light eruption Diseases 0.000 claims description 8
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims description 8
- 208000009621 actinic keratosis Diseases 0.000 claims description 8
- 208000017983 photosensitivity disease Diseases 0.000 claims description 8
- 206010041307 solar urticaria Diseases 0.000 claims description 8
- 239000008096 xylene Substances 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 6
- MKIKTNMRDXYWMB-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-6-[3-[dimethyl(trimethylsilyloxy)silyl]-2-methylpropyl]-4-phenylphenol Chemical compound C=1C(N2N=C3C=CC=CC3=N2)=C(O)C(CC(C)C[Si](C)(C)O[Si](C)(C)C)=CC=1C1=CC=CC=C1 MKIKTNMRDXYWMB-UHFFFAOYSA-N 0.000 claims description 5
- 239000012752 auxiliary agent Substances 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- JFITVYNWWPGVJQ-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-6-[2-methyl-3-[methyl-bis(trimethylsilyloxy)silyl]propyl]-4-phenylphenol Chemical compound C=1C(N2N=C3C=CC=CC3=N2)=C(O)C(CC(C)C[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C)=CC=1C1=CC=CC=C1 JFITVYNWWPGVJQ-UHFFFAOYSA-N 0.000 claims description 4
- HKILKDFBPGMKPP-UHFFFAOYSA-N 2-[3-[dimethyl(trimethylsilyloxy)silyl]-2-methylpropyl]-6-(5-methoxybenzotriazol-2-yl)-4-phenylphenol Chemical compound N1=C2C=C(OC)C=CC2=NN1C(C(=C(CC(C)C[Si](C)(C)O[Si](C)(C)C)C=1)O)=CC=1C1=CC=CC=C1 HKILKDFBPGMKPP-UHFFFAOYSA-N 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 238000006459 hydrosilylation reaction Methods 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 230000002633 protecting effect Effects 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000005493 quinolyl group Chemical group 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- YUDKHFRTQMTQIB-UHFFFAOYSA-N 2-(5-chlorobenzotriazol-2-yl)-6-[3-[dimethyl(trimethylsilyloxy)silyl]-2-methylpropyl]-4-phenylphenol Chemical compound C=1C(N2N=C3C=C(Cl)C=CC3=N2)=C(O)C(CC(C)C[Si](C)(C)O[Si](C)(C)C)=CC=1C1=CC=CC=C1 YUDKHFRTQMTQIB-UHFFFAOYSA-N 0.000 claims description 3
- KNMMNMWJMSMUHD-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-4-cyclohexyl-6-[2-methyl-3-[methyl-bis(trimethylsilyloxy)silyl]propyl]phenol Chemical compound C=1C(N2N=C3C=CC=CC3=N2)=C(O)C(CC(C)C[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C)=CC=1C1CCCCC1 KNMMNMWJMSMUHD-UHFFFAOYSA-N 0.000 claims description 3
- 229910018963 Pt(O) Inorganic materials 0.000 claims description 3
- 229910019020 PtO2 Inorganic materials 0.000 claims description 3
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 claims description 3
- 239000004753 textile Substances 0.000 claims description 3
- 229910052723 transition metal Inorganic materials 0.000 claims description 3
- 150000003624 transition metals Chemical class 0.000 claims description 3
- LXCMZTTUTFWPOQ-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-4-cyclohexyl-6-[3-[dimethyl(trimethylsilyloxy)silyl]-2-methylpropyl]phenol Chemical compound C=1C(N2N=C3C=CC=CC3=N2)=C(O)C(CC(C)C[Si](C)(C)O[Si](C)(C)C)=CC=1C1CCCCC1 LXCMZTTUTFWPOQ-UHFFFAOYSA-N 0.000 claims description 2
- 229910018583 Ni(O) Inorganic materials 0.000 claims description 2
- 230000000875 corresponding effect Effects 0.000 claims 22
- AURXOKIBVQQLIQ-UHFFFAOYSA-N 2-[3-[3-[dimethyl(trimethylsilyloxy)silyl]-2-methylpropyl]-2-hydroxy-5-phenylphenyl]benzotriazole-5-carboxylic acid Chemical compound C=1C(N2N=C3C=C(C=CC3=N2)C(O)=O)=C(O)C(CC(C)C[Si](C)(C)O[Si](C)(C)C)=CC=1C1=CC=CC=C1 AURXOKIBVQQLIQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000010 aprotic solvent Substances 0.000 claims 1
- 239000000460 chlorine Substances 0.000 description 73
- 239000011734 sodium Substances 0.000 description 64
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 25
- 229920001577 copolymer Polymers 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 229920001971 elastomer Polymers 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 11
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical compound C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 229920001187 thermosetting polymer Polymers 0.000 description 10
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 8
- 239000004743 Polypropylene Substances 0.000 description 8
- 239000010408 film Substances 0.000 description 8
- 229920001155 polypropylene Polymers 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- 229920001169 thermoplastic Polymers 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 239000000806 elastomer Substances 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229920005862 polyol Polymers 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 0 C[C@]1IC(C)(*)C1C1CCCC1 Chemical compound C[C@]1IC(C)(*)C1C1CCCC1 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- HUVYTMDMDZRHBN-UHFFFAOYSA-N drometrizole trisiloxane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)CC(C)CC1=CC(C)=CC(N2N=C3C=CC=CC3=N2)=C1O HUVYTMDMDZRHBN-UHFFFAOYSA-N 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000005060 rubber Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000004634 thermosetting polymer Substances 0.000 description 5
- KGVHAZMHOQLBEQ-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-4-phenylphenol Chemical compound C1=C(N2N=C3C=CC=CC3=N2)C(O)=CC=C1C1=CC=CC=C1 KGVHAZMHOQLBEQ-UHFFFAOYSA-N 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 239000003974 emollient agent Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 150000002978 peroxides Chemical class 0.000 description 4
- 229920001084 poly(chloroprene) Polymers 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000012429 reaction media Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- HLTGSTMLOFDGTD-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-6-(2-methylprop-2-enyl)-4-phenylphenol Chemical compound C=1C(N2N=C3C=CC=CC3=N2)=C(O)C(CC(=C)C)=CC=1C1=CC=CC=C1 HLTGSTMLOFDGTD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229940123457 Free radical scavenger Drugs 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 239000004594 Masterbatch (MB) Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- 239000004721 Polyphenylene oxide Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 229920006172 Tetrafluoroethylene propylene Polymers 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 229920001795 coordination polymer Polymers 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 125000001303 disiloxanyl group Chemical group [H][Si]([*])([H])O[Si]([H])([H])[H] 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000008821 health effect Effects 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 229920006375 polyphtalamide Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229960003975 potassium Drugs 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- DPJCXCZTLWNFOH-UHFFFAOYSA-N 2-nitroaniline Chemical compound NC1=CC=CC=C1[N+]([O-])=O DPJCXCZTLWNFOH-UHFFFAOYSA-N 0.000 description 2
- OHXAOPZTJOUYKM-UHFFFAOYSA-N 3-Chloro-2-methylpropene Chemical compound CC(=C)CCl OHXAOPZTJOUYKM-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- NYYSPVRERVXMLJ-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-one Chemical compound FC1(F)CCC(=O)CC1 NYYSPVRERVXMLJ-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000005821 Claisen rearrangement reaction Methods 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229920002943 EPDM rubber Polymers 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 229920000181 Ethylene propylene rubber Polymers 0.000 description 2
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 2
- 244000043261 Hevea brasiliensis Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 229920000106 Liquid crystal polymer Polymers 0.000 description 2
- 239000004977 Liquid-crystal polymers (LCPs) Substances 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 229920006169 Perfluoroelastomer Polymers 0.000 description 2
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004696 Poly ether ether ketone Substances 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000005062 Polybutadiene Substances 0.000 description 2
- 239000004697 Polyetherimide Substances 0.000 description 2
- 239000004734 Polyphenylene sulfide Substances 0.000 description 2
- 239000004954 Polyphthalamide Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000003849 aromatic solvent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000003725 azepanyl group Chemical group 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- UUAGAQFQZIEFAH-UHFFFAOYSA-N chlorotrifluoroethylene Chemical group FC(F)=C(F)Cl UUAGAQFQZIEFAH-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 125000005959 diazepanyl group Chemical group 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229920005558 epichlorohydrin rubber Polymers 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 229920006168 hydrated nitrile rubber Polymers 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 229920001526 metallocene linear low density polyethylene Polymers 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- SWGZAKPJNWCPRY-UHFFFAOYSA-N methyl-bis(trimethylsilyloxy)silicon Chemical compound C[Si](C)(C)O[Si](C)O[Si](C)(C)C SWGZAKPJNWCPRY-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000006053 organic reaction Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920001748 polybutylene Polymers 0.000 description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 description 2
- 229920001123 polycyclohexylenedimethylene terephthalate Polymers 0.000 description 2
- 229920002530 polyetherether ketone Polymers 0.000 description 2
- 229920001601 polyetherimide Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920001470 polyketone Polymers 0.000 description 2
- 229920006380 polyphenylene oxide Polymers 0.000 description 2
- 229920000069 polyphenylene sulfide Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 229940070891 pyridium Drugs 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229920002725 thermoplastic elastomer Polymers 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZPFAVCIQZKRBGF-UHFFFAOYSA-N 1,3,2-dioxathiolane 2,2-dioxide Chemical compound O=S1(=O)OCCO1 ZPFAVCIQZKRBGF-UHFFFAOYSA-N 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical class CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- MVRPPTGLVPEMPI-UHFFFAOYSA-N 2-cyclohexylphenol Chemical compound OC1=CC=CC=C1C1CCCCC1 MVRPPTGLVPEMPI-UHFFFAOYSA-N 0.000 description 1
- VSKJLJHPAFKHBX-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 VSKJLJHPAFKHBX-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OAHMVZYHIJQTQC-UHFFFAOYSA-N 4-cyclohexylphenol Chemical compound C1=CC(O)=CC=C1C1CCCCC1 OAHMVZYHIJQTQC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- WLPJTZLAJRXABV-UHFFFAOYSA-N CC(C1C)C1(C1C(C)(C)C)C1C1=CC(C)CC1 Chemical compound CC(C1C)C1(C1C(C)(C)C)C1C1=CC(C)CC1 WLPJTZLAJRXABV-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 description 1
- 239000004638 Duroplast Substances 0.000 description 1
- 229920000965 Duroplast Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920007925 Ethylene chlorotrifluoroethylene (ECTFE) Polymers 0.000 description 1
- 241001553290 Euphorbia antisyphilitica Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004609 Impact Modifier Substances 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- XPJVKCRENWUEJH-UHFFFAOYSA-N Isobutylparaben Chemical compound CC(C)COC(=O)C1=CC=C(O)C=C1 XPJVKCRENWUEJH-UHFFFAOYSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229920010126 Linear Low Density Polyethylene (LLDPE) Polymers 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229920000459 Nitrile rubber Polymers 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 239000004962 Polyamide-imide Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 229920002433 Vinyl chloride-vinyl acetate copolymer Polymers 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000004164 Wax ester Chemical class 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- BGYHLZZASRKEJE-UHFFFAOYSA-N [3-[3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyloxy]-2,2-bis[3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyloxymethyl]propyl] 3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoate Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(CCC(=O)OCC(COC(=O)CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)(COC(=O)CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)COC(=O)CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 BGYHLZZASRKEJE-UHFFFAOYSA-N 0.000 description 1
- ZGSDJMADBJCNPN-UHFFFAOYSA-N [S-][NH3+] Chemical compound [S-][NH3+] ZGSDJMADBJCNPN-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 238000001720 action spectrum Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940088990 ammonium stearate Drugs 0.000 description 1
- 229920006125 amorphous polymer Polymers 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 239000012431 aqueous reaction media Substances 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical compound [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 239000002610 basifying agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Chemical class 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229920005557 bromobutyl Polymers 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001201 calcium disodium ethylene diamine tetra-acetate Substances 0.000 description 1
- 235000011188 calcium disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 239000002967 calcium-L-ascorbate Substances 0.000 description 1
- 235000005937 calcium-L-ascorbate Nutrition 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-L calcium;disodium;2-[2-[bis(carboxylatomethyl)azaniumyl]ethyl-(carboxylatomethyl)azaniumyl]acetate Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-L 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229940093528 cetearyl ethylhexanoate Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229920005556 chlorobutyl Polymers 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- STORWMDPIHOSMF-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O STORWMDPIHOSMF-UHFFFAOYSA-N 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
- IRWLSEJAVLQSDF-UHFFFAOYSA-N dimethyl-silyloxy-trimethylsilyloxysilane Chemical compound C[Si](C)(C)O[Si](C)(C)O[SiH3] IRWLSEJAVLQSDF-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 235000010386 dodecyl gallate Nutrition 0.000 description 1
- 239000000555 dodecyl gallate Substances 0.000 description 1
- 229940080643 dodecyl gallate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003063 flame retardant Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229920001973 fluoroelastomer Polymers 0.000 description 1
- 229920005560 fluorosilicone rubber Polymers 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920005555 halobutyl Polymers 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 239000012760 heat stabilizer Substances 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 239000003752 hydrotrope Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920002681 hypalon Polymers 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229920000554 ionomer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940099367 lanolin alcohols Drugs 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000006078 metal deactivator Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-O morpholinium Chemical compound [H+].C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-O 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- GQEZCXVZFLOKMC-UHFFFAOYSA-N n-alpha-hexadecene Natural products CCCCCCCCCCCCCCC=C GQEZCXVZFLOKMC-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- ZHALDANPYXAMJF-UHFFFAOYSA-N octadecanoate;tris(2-hydroxyethyl)azanium Chemical compound OCC[NH+](CCO)CCO.CCCCCCCCCCCCCCCCCC([O-])=O ZHALDANPYXAMJF-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 235000010387 octyl gallate Nutrition 0.000 description 1
- 239000000574 octyl gallate Substances 0.000 description 1
- NRPKURNSADTHLJ-UHFFFAOYSA-N octyl gallate Chemical compound CCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 NRPKURNSADTHLJ-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000002530 phenolic antioxidant Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- XRBCRPZXSCBRTK-UHFFFAOYSA-N phosphonous acid Chemical class OPO XRBCRPZXSCBRTK-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 238000001782 photodegradation Methods 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920005559 polyacrylic rubber Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920013639 polyalphaolefin Polymers 0.000 description 1
- 229920002312 polyamide-imide Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001225 polyester resin Polymers 0.000 description 1
- 239000004645 polyester resin Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920003225 polyurethane elastomer Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003303 reheating Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium erythorbate Chemical compound [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- VCLVUNFJTOOMIR-UHFFFAOYSA-M sodium;acetyl sulfate Chemical compound [Na+].CC(=O)OS([O-])(=O)=O VCLVUNFJTOOMIR-UHFFFAOYSA-M 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 229920006302 stretch film Polymers 0.000 description 1
- 229920006132 styrene block copolymer Polymers 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940029614 triethanolamine stearate Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940117958 vinyl acetate Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000004636 vulcanized rubber Substances 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
Definitions
- the present invention relates to silylated substituted benzotriazolylphenol compounds of general formula (I)
- a process for their preparation, a pharmaceutical and/or cosmetic composition comprising these compounds, their use for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of diseases caused by and/or associated with exposure to ultraviolet radiation, their use for the prophylaxis and/or care against non-desired skin conditions, as well as their use as a light-stabilizer in polymer compositions.
- UV radiation is part of the electromagnetic spectrum emitted by the sun.
- UV-A and UV-B radiation is of considerable concern to human health.
- UV-A radiation penetrates the human skin more deeply than UV-B radiation
- action spectra for biological responses indicate that it is radiation in the UV-B range that is absorbed by DNA - subsequent damage to DNA appears to be a key factor in the initiation of the carcinogenic process in skin.
- UV-A not only may be an important factor in photoaging but also causes genetic damage to skin cells that can lead to skin cancer.
- sunscreens which are preferably effective in the UV-A and/or the UV-B and/or optionally in the UV-C radiation range, more preferably in the UV-A and the UV-B and in the UV-C radiation range, since the sunlight radiation intensity, and in consequence the UV radiation, has been increasing continuously.
- sunscreens which are preferably effective in the UV-A and/or the UV-B and/or optionally in the UV-C radiation range, more preferably in the UV-A and the UV-B and in the UV-C radiation range, since the sunlight radiation intensity, and in consequence the UV radiation, has been increasing continuously.
- a sufficient protection against such increased UV radiation in order to reduce the risk of suffering of diseases such as e.g.
- UV- A and/or UV-B radiation and optionally UV-C radiation skin cancer, malignant melanoma, polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing, sunburn and/or chronic actinic dermatitis caused by UV- A and/or UV-B radiation and optionally UV-C radiation.
- UV-absorbing properties in the UV-A and/or the UV-B and/or optionally in the UV-C radiation range, preferably in the UV-A and UV-B radiation and optionally in the UV-C radiation range, in order to provide sufficient protection against these UV radiations, especially in order to provide sufficient care and prophylaxis against diseases caused by or associated with the exposure to UV radiation.
- substituted, silylated benzotriazolylphenol compounds of general formula (I) given below show remarkable absorption capacities in the UV-A and/or the UV-B and/or UV-C radiation range. These compounds are therefore particularly suitable as UV protecting agents in pharmaceutical and/or cosmetic compositions as well as light-stabilizers in polymer compositions, preferably in textile fibers.
- the present invention refers to at least one silylated substituted benzotriazolylphenol compound of general formula (I)
- an unsubstituted or at least mono-substituted aryl radical which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono- substituted, saturated or aromatic mono- or bicyclic ring system;
- R 1 and R 2 are fused to form together an additional aromatic mono- or polycyclic ring system having from 4 to 10 carbon atoms;
- R 3 represents an unsubstituted or at least mono-substituted, saturated, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be condensed with an unsubstituted or at least mono-substituted saturated or aromatic mono- or bicyclic ring system;
- an unsubstituted or at least mono-substituted aryl or heteroaryl radical which may be condensed with an unsubstituted or at least mono-substituted, saturated or aromatic mono- or bicyclic ring system;
- R 4 represents a hydrogen atom; a linear or branched, saturated, unsubstituted or at least mono-substituted CM S aliphatic radical;
- R 5 and R 6 and R 7 independently from one another, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted CM S aliphatic radical; a linear or branched, saturated, unsubstituted or at least mono-substituted -O-Ci-18 aliphatic radical;
- an unsubstituted or at least mono-substituted, saturated cycloaliphatic radical an unsubstituted or at least mono-substituted aryl radical, which may be condensed with an unsubstituted or at least mono-substituted aromatic mono- or bicyclic ring system;
- R 5 , R 6 and R 7 independently from one another, each represents a radical of general formula (II)
- R 25 , R 26 , R 27 , R 28 and R 29 independently from one another, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted C MS aliphatic radical; a linear or branched, saturated, unsubstituted or at least mono-substituted -O-Ci- 18 aliphatic radical; an unsubstituted or at least mono-substituted aryl radical; or an -O-Si(R 30 ) 3 radical, with R 30 representing a linear or branched, unsubstituted or at least mono-substituted C-MS alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -O-Ci-i 8 alkyl radical or an unsubstituted or at least mono-substituted aryl radical;
- radicals R 5 , R 6 and R 7 represents a radical of general formula (II) as defined above;
- R 7 represents a radical of general formula (III)
- n 0, 1 , 2, 3, 4 or 5;
- X represents an oxygen atom or an unsubstituted or at least mono-substituted
- Ci- 6 alkylene radical Ci- 6 alkylene radical
- R 31 , R 32 , R 33 and R 34 independently of one another, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted Ci-i 8 aliphatic radical; a linear or branched, saturated, unsubstituted or at least mono-substituted -O-Ci-1 8 aliphatic radical;
- an unsubstituted or at least mono-substituted aryl radical which may be condensed with an unsubstituted or at least mono-substituted aromatic mono- or bicyclic ring system;
- R 30 representing a linear or branched, unsubstituted or at least mono-substituted Ci-i 8 alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -O-Ci-i 8 alkyl radical or an unsubstituted or at least mono-substituted aryl radical; R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 23 and R 24 , independent of one another, each represents a hydrogen atom; a linear or branched, saturated, unsubstituted or at least mono-substituted Ci-i 8 aliphatic radical, an unsubstituted or at least mono-substituted, saturated, optionally at least one heteroatom as ring member containing cycloalipha
- R 20 and R 21 independently of one another, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted C M8 aliphatic radical, an unsubstituted or at least mono-substituted, saturated, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an unsubstituted or at least mono-substituted aryl radical;
- R 22 independent of one another, each represents a hydrogen atom; or an unsubstituted or at least mono-substituted, saturated, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an unsubstituted or at least mono-substituted aryl radical;
- any of the substituents in any of the herein defined formulae represents a saturated Ci -18 -aliphatic radical, i.e. an alkyl radical
- said aliphatic radical is - if not defined otherwise - unsubstituted or substituted with one or more substituents, preferably unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituent(s).
- said substituent(s) is/are preferably independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH 2 , -CN, -CF 3 , -OCF 3 , -SCF 3 , -SO 3 Na, -SO 3 K, -SO 3 H, -O-CH 3 , -0-C 2 H 5 , -0-CH 2 -CH 2 -CH 3 , -O-CH(CH 3 ) 2 , -O-C(CH 3 ) 3 , -S-CH 3 , -S-C 2 H 5 , -S-CH 2 -CH 2 -CH 3 , -S-CH(CH 3 ) 2 , -S-C(CH 3 ) 3 , -O-Si-(CH 3 ) 3l -O-Si-(CH 2 -CH 3 ) 3 , -O-Si-[CH(-CH 3 ) 2 ]
- Suitable alkyl radicals which may be substituted by one or more substituents are preferably selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl.
- any of the substituents in any of the herein defined formulae represents an -0-Ci -I8 alkyl radical
- said -O-Ci-i 8 alkyl radical is - if not defined otherwise - unsubstituted or substituted with one or more substituents, preferably unsubstituted or optionally substituted with 1 , 2, 3, 4 or 5 substituent(s).
- substituent(s) are preferably independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH 2 , -CN, -CF 3 , -OCF 3 , -SCF 3 , -SO 3 Na, -SO 3 K, -SO 3 H, -0-CH 3 , -0-C 2 H 5 , -0-CH 2 -CH 2 -CH 3 , -O-CH(CH 3 ) 2 , -O-C(CH 3 ) 3) -S-CH 3 , -S-C 2 H 5 , -S-CH 2 -CH 2 -CH 3 , -S-CH(CH 3 J 2 , -S-C(CH 3 ) 3 , -O-Si-(CH 3 ) 3 , -O-Si-(CH 2 -CH 3 ) 3 , -O-Si-[CH(-CH 3 ) 2 ] 3 ,
- any of the substituent(s) in any of the herein defined formulae represents or comprises a (hetero)cycloaliphatic radical, i.e. a cycloaliphatic radical or a heterocycloaliphatic, including a C 3 .g (hetero)cycloalkyl radical, i.e. a C 3- g cycloalkyl or a C 3- 9 heterocycloalkyl radical
- said (hetero)cycloaliphatic radical is - if not defined otherwise - unsubstituted or optionally substituted with one or more substituents, preferably unsubstituted or optionally substituted with 1 , 2, 3, 4 or 5 substituent(s).
- substituent(s) are preferably independently selected from the group consisting Of -CH 3 , -C 2 H 5 , -CH 2 -CH 2 -CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3> F, Cl, Br, I, -OH, -SH, -NH 2 , -CN, -CF 3 , -OCF 3 , -SCF 3 , -SO 3 Na, -SO 3 K, -SO 3 H, -0-CH 3 , -0-C 2 H 5 , -0-CH 2 -CH 2 -CH 3 , -O-CH(CH 3 ) 2 , -O-C(CH 3 ) 3 , -S-CH 3 , -S-C 2 H 5 , -S-CH 2 -CH 2 -CH 3 , -S-CH(CHa) 2 , -S-C(CH 3 ) 3 , -O-Si
- any of the substituent(s) in any of the herein defined formulae represents or comprises a (hetero)cycloaliphatic radical, i.e. a cycloaliphatic or a heterocycloaliphatic radical, including a C 3-g (hetero)cycloalkyl radical, i.e. a C 3-9 cycloalkyl radical or a C 3- g heterocycloalkyl radical, which contains one or more, preferably 1 , 2 or 3 heteroa- tom(s) as ring member(s), unless defined otherwise, each of these heteroatom(s) is/are preferably independently selected from the group consisting of nitrogen, oxygen and sulphur.
- a (hetero)cycloaliphatic radical i.e. a cycloaliphatic or a heterocycloaliphatic radical
- a C 3-g (hetero)cycloalkyl radical i.e. a C 3-9 cycloalkyl radical or a C 3- g heterocycl
- any of the substituent(s) in any of the herein defined formulae represents or comprises a C 3-9 (hetero)cycloalkyl radical, i.e. a C 3-9 cycloalkyl or a C 3-9 heterocycloalkyl radical, which contains optionally 1 or 2 additional heteroatom(s) as ring member(s), unless defined otherwise, each of these heteroatom(s) is/are preferably independently selected from the group consisting of nitrogen, oxygen and sulphur.
- C 3-9 cycloalkyl or C 3-9 heterocycloalkyl radicals are preferably selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, azetidinyl, tetrahydrofuranyl, azepanyl, diazepanyl and azocanyl.
- any of the substituents in any of the herein defined formulae represents an alkylene group, including an C- ⁇ - 6 alkylene group said alkylene group or C-i- ⁇ alkylene group, is unsubstituted or substituted with one or more substituents, preferably unsubstituted or optionally substituted with 1 , 2, 3, 4 or 5 substituent(s).
- Said substituent(s) is/are preferably independently selected from the group consisting of -O-C 1-5 -alkyl, -S-Ci -5 - alkyl, -F, Cl, Br, I 1 -CN, -CF 3 , -OCF 3 , -SCF 3 , -OH, -SH, -NH 2 , -NH(C 1-5 -alkyl) and -N(Ci -5 -alkyl) 2 , whereby in each occurrence C- ⁇ -5-alkyl may be linear or branched.
- Suitable alkylene groups include -(CH 2 )-, -CH(CH 3 )-, -(CH 2 J 2 -, -(CH 2 ) 3 -, -(CH 2 J 4 -, -(CH 2 J 5 and -(CH 2 J 6 -.
- any of the substituents in any of the herein defined formulae represents or comprises an aryl radical, including a 6-membered aryl radical such as phenyl or a 10- membered aryl radical such as naphthyl or a 14-membered aryl radical such as an- thracenyl radical, said aryl radical is - if not defined otherwise - unsubstituted or substituted with one or more substituents, preferably unsubstituted or optionally substituted with 1 , 2, 3, 4 or 5 substituent(s).
- aryl radical including a 6-membered aryl radical such as phenyl or a 10- membered aryl radical such as naphthyl or a 14-membered aryl radical such as an- thracenyl radical
- said aryl radical is - if not defined otherwise - unsubstituted or substituted with one or more substituents, preferably unsubstituted or optionally substituted with
- said substituent(s) is/are preferably independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH 2 , -CN, -CF 3 , -OCF 3 , -SCF 3 , -SO 3 Na, -SO 3 K, -SO 3 H, -O-CH 3 , -0-C 2 H 5 , -0-CH 2 -CH 2 -CH 3 , -O-CH(CH 3 ) 2 , -O-C(CH 3 ) 3 , -S-CH 3 , -S-C 2 H 5 , -S-CH 2 -CH 2 -CH 3 , -S-CH(CH 3 ) 2 , -S-C(CH 3 ) 3 , -O-Si-(CH 3 ) 3 , -O-Si-(CH 2 -CH 3 ) 3 , -O-Si-[CH(-CH 3 ) 2
- Preferred aryl radicals which are unsubstituted or at least mono-substituted, are phenyl and naphthyl.
- any of the substituents in any of the herein defined formulae represents or comprises a heteroaryl radical, including a monocyclic 5- or 6-membered heteroaryl radical or a bi- or tricyclic 8-, 9-, 10-, 11-, 12-, 13- or 14- membered heteroaryl radical
- said heteroaryl radical is - if not defined otherwise - unsubstituted or substituted with one or more substituents, preferably unsubstituted or optionally substituted with 1 , 2, 3, 4 or 5 substituent(s).
- said substituent(s) is/are preferably independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH 2 , -CN, -CF 3 , -OCF 3 , -SCF 3 , -SO 3 Na, -SO 3 K, -SO 3 H, -CH 3 , -C 2 H 5 , -CH 2 -CH 2 -CH 3 , -0-CH 3 , -O-C 2 H 5 , -0-CH 2 -CH 2 -CH 3 , -O-CH(CH 3 ) 2 , -O-C(CH 3 ) 3 , -S-CH 3 , -S-C 2 H 5 , -S-CH 2 -CH 2 -CH 3 , -S-CH(CH 3 ) 2) -S-C(CH 3 J 3 , -O-Si-(CH 3 ) 3 , -O-Si-(CH 2 ) 2
- 8 -alkyl is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, I -CN, - CF 3 , -OCF 3 , -SCF 3 , -SO 3 Na, -SO 3 K, -SO 3 H, -OH, -SH, -NH 2 and -NO 2 .
- heteroatom(s), which are present as ring member(s) in the heteroaryl radical may, unless defined otherwise, independently be selected from the group consisting of nitrogen, oxygen and sulphur.
- the heteroaryl radical comprises 1 , 2, 3 or 4 heteroatom(s).
- Suitable heteroaryl radicals which are optionally at least mono-substituted, are preferably selected from the group consisting of pyridinyl, pyrrolyl, imidazolyl, pyrazolyl, indolyl, benzotriazolyl, quinolyl and isoquinolyl.
- Suitable monocyclic 5- or 6-membered heteroaryl radicals which are unsubstituted or at least mono-substituted, are preferably selected from the group consisting of pyridinyl, pyrrolyl, imidazolyl and pyrazolyl.
- a mono-, bi-, or polycyclic ring system according to the present invention - if not defined otherwise - means a mono-, bi-, or polycyclic hydrocarbon ring system that is saturated or aromatic.
- each of the rings of the mono- or bicyclic ring system may contain one or more, preferably 1 , 2 or 3, heteroatom(s) as ring member(s), which may be independent from one another and which can preferably be selected from the group consisting of nitrogen, oxygen and sulphur.
- the rings of the mono- or bicyclic ring system are preferably 5-, 6- or 7-membered.
- an aromatic mono-or bicyclic ring system is a phenyl or naphthyl ring system.
- condensed means that a ring or ring system is attached to another ring or ring system, whereby the terms “annulated” or “annelated” are also used by those skilled in the art to designate this kind of attachment.
- Such a mono-, bi-, or polycyclic ring system is - if not defined otherwise - unsubstituted or substituted with one or more substituents, preferably unsubstituted or optionally substituted with 1 , 2, 3, 4 or 5 substituent(s).
- said substituent(s) is/are preferably independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH 2 , -CN, -CF 3 , -OCF 3 , -SCF 3 , -SO 3 Na, -SO 3 K, -SO 3 H, -CH 3 , -C 2 H 5 , -CH 2 -CH 2 -CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -0-CH 3 , -0-C 2 H 5 , -0-CH 2 -CH 2 -CH 3 , -O-CH(CH 3 ) 2 , -O-C(CH 3 ) 3 , -S-CH 3 , -S-C 2 H 5 , -S-CH 2 -CH 2 -CH 3 , -S-CH(CH 3 ) 2 , -S-C(CHa) 3 , -O
- R 1 and R 2 independently from one another, each represents a hydrogen atom; a halogen atom; -NO 2 ; -OR 8 ; -SR 9 ; -CN; -NR 10 R 11 ; -COOR 12 ; -COR 13 ; -CONR 14 R 15 ; -OCOR 16 ; -NR 17 -COR 18 ; -NR 19 -COO-R 20 ; -SO 2 -R 21 ; -SO 2 -O-R 22 ; -SO 2 -NR 23 R 24 ;
- an unsubstituted or at least mono-substituted 6-, 10- or 14-membered mono-, bi- or tricyclic aryl radical which may be bonded via a linear or branched, unsubstituted or at least mono-substituted group and/or which may be condensed with an unsubstituted or at least mono-substituted, saturated or aromatic mono- or bicyclic ring system; or
- R 1 and R 2 are fused to form together an additional aromatic mono- or polycyclic ring system having from 4 to 10 carbon atoms;
- R 3 represents an unsubstituted or at least mono-substituted, saturated, optionally at least one heteroatom as ring member containing C 3-9 (hetero)cycloalkyl radical, which may be condensed with an unsubstituted or at least mono-substituted saturated or aromatic mono- or bicyclic ring system;
- R 4 represents a hydrogen atom; a linear or branched, unsubstituted or at least mono- substituted C- 1 - 6 alkyl radical;
- R 5 , R 6 and R 7 independently from one another, each represents a linear or branched, unsubstituted or at least mono-substituted Ci- 6 alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -O-C- ⁇ -6 alkyl radical;
- an unsubstituted or at least mono-substituted 6-, 10- or 14-membered mono-, bi- or tricyclic aryl radical which may be condensed with an unsubstituted or at least mono-substituted aromatic mono- or bicyclic ring system;
- R 5 , R 6 and R 7 independently from one another, each represents a radical of general formula (II)
- R 25 , R 26 , R 27 , R 28 and R 29 independently from one another, each represents a linear or branched, unsubstituted C 1-6 alkyl radical; a linear or branched, unsubstituted -O-Ci- 6 alkyl radical; an unsubstituted or at least mono-substituted 6-, 10- or 14- membered mono-, bi- or tricyclic aryl radical; or an -O-Si(R 30 ) 3 radical, with R 30 representing a linear or branched, unsubstituted or at least mono-substituted C-i- 6 alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -O-C 1-6 alkyl radical; an unsubstituted or at least mono-substituted 6-, 10- or 14- membered mono-, bi- or tricyclic aryl radical;
- radicals R 5 , R 6 and R 7 represents a radical of general formula (II) as defined above;
- R 7 represents a radical of general formula (III)
- n 0, 1 , 2, 3, 4 or 5;
- X represents an oxygen atom or an unsubstituted or at least mono-substituted C- ⁇ - 4 alkylene radical
- R 31 , R 32 , R 33 and R 34 independent of one another, each represents a linear or branched, unsubstituted or at least mono-substituted C- ⁇ - 6 alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -O-Ci- ⁇ alkyl radical;
- an unsubstituted or at least mono-substituted 6-, 10- or 14-membered mono-, bi- or tricyclic aryl radical which may be condensed with an unsubstituted or at least mono-substituted aromatic mono- or bicyclic ring system;
- R 30 representing a linear or branched, unsubstituted or at least mono-substituted C-i- ⁇ alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -0-C 1-6 alkyl radical or an unsubstituted or at least mono-substituted 6-, 10- or 14-membered mono-, bi- or tricyclic aryl radical;
- R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 and R 24 , independent of one another, have the above-defined meaning;
- heterocycloalkyl radicals contain in each case optionally 1 , 2 or 3 additional heteroatom(s) independently selected from the group consisting of nitrogen, sulphur and oxygen as ring member(s);
- C 3-9 cycloalkyl radicals contain in each case optionally 1 , 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, sulphur and oxygen as ring member(s);
- the aforementioned d ⁇ alkylene preferably -(CH 2 )-, -(CH 2 ) 2 -, -(CH 2 ) 3 - and -(CH 2 ) 4 - groups are in each case linear or branched, unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br 1 I, -CN, -CF 3 , -OCF 3 , -SCF 3 , -OH, -SH, -NH 2 , -O-C 1-6 -alkyl, -S-C 1-6 -alkyl, -NH(Ci -6 -alkyl) and -N(C 1-6 -alkyl) 2 ;
- Ci -6 alkylene preferably -(CH 2 )-, -(CH 2 ) 2 -, -(CH 2 ) 3 -, -(CH 2 ) 4 - , -(CH 2 ) 5 - and -(CH 2 ) 6 - groups are in each case unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, I, -CN, -CF 3 , -OCF 3 , -SCF 3 , -OH, -SH, -NH 2 , -O-C 1-6 -alkyl, -S-C 1-6 -alkyl, -NH(C 1-6 -alkyl) and -N(C 1-6 -alkyl) 2 ;
- the rings of the aforementioned ring systems are in each case independently of each other 5-, 6-, 7-, 8-, 9,- or 10-membered and may in each case independently of one another optionally contain 1 , 2, 3 or 4 heteroatom(s) independently selected from the group consisting of nitrogen, sulphur and oxygen;
- enantiomers or di- astereomers optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 and R 30 have the above-defined meaning
- radicals R 5 , R 6 and R 7 represents a radical of general formula (II) as defined above;
- enantiomers or di- astereomers optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 30 , R 31 , R 32 , R 33 and R 34 have the above-defined meaning;
- enantiomers or diastereomers optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoi- somers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- R 20 , R 21 , R 22 , R 23 , R 24 , R 30 , R 31 , R 32 , R 33 and R 34 have the above-defined meaning
- enantiomers or diastereomers optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- R 20 , R 21 , R 22 , R 23 , R 24 , R 30 , R 31 , R 32 , R 33 and R 34 have the above-defined meaning
- enantiomers or diastereomers optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoi- somers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- R 20 , R 21 , R 22 , R 23 , R 24 , R 30 , R 31 , R 32 , R 33 and R 34 have the above-defined meaning
- enantiomers or diastereomers optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- R 20 , R 21 , R 22 , R 23 , R 24 , R 30 , R 31 , R 32 , R 33 and R 34 have the above-defined meaning
- enantiomers or diastereomers optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoi- somers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- R 1 and R 2 independently from one another, each represents a a hydrogen atom; F; Cl; Br; I; -NO 2 ; -OR 8 ; -SR 9 ; -CN; -NR 10 R 11 ; -COOR 12 ; -COR 13 ; -CONR 14 R 15 ; -OCOR 16 ; -NR 17 -COR 18 ; -NR 19 -COO-R 20 ; -SO 2 -R 21 ; -SO 2 -O-R 22 ; -SO 2 -NR 23 R 24 ;
- R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 and R 34 have the above-defined meaning;
- radicals R 5 , R 6 and R 7 represents a radical of general formula (II) as defined above;
- enantiomers or di- astereomers optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 and R 34 have the above-defined meaning;
- radicals R 5 , R 6 and R 7 represents a radical of general formula (II) as defined above;
- enantiomers or di- astereomers optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 and R 34 have the above-defined meaning;
- radicals R 5 , R 6 and R 7 represents a radical of general formula (II) as defined above;
- enantiomers or di- astereomers optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- a linear or branched, unsubstituted or at least mono-substituted -0-C M8 alkyl radical which is unsubstituted or substituted with 1 , 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of F, Cl, Br, I, -CN, -CF 3 , -OCF 3 , -SCF 3 , -SO 3 Na, -SO 3 K, -SO 3 H, -OH, -SH, -NH 2 , -O-C 1-8 -alkyl, -O-Si-(C 1-8 -alkyl) 3 , -Si-(Ci -8 -alkyl) 3 , -S-C 1-8 -alkyl, -NH(C 1-8 -alkyl), -N(C 1-8 -alkyl) 2 , -N(Ci -8 -alkyl) 3 + , phenyl, benz
- R 5 , R 6 and R 7 independently from one another, each represents a radical of general formula (II)
- radicals R 5 , R 6 and R 7 represents a radical of general formula (II) as defined above;
- R1 , D ⁇ 17 , D ⁇ 18 , Dr ⁇ 19 , Dr ⁇ 20 , Dr ⁇ 21 , Dr ⁇ 22 , r D ⁇ 23 and R 24 have the above-defined meaning
- enantiomers or di- astereomers optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- R 7 represents a radical of general formula (III)
- n 0, 1 , 2, 3, 4 or 5;
- X represents an oxygen atom or an unsubstituted or at least mono-substituted Ci -4 alkylene radical
- a linear or branched, unsubstituted or at least mono-substituted -0-C-M 8 alkyl radical which is unsubstituted or substituted with 1 , 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of F, Cl, Br, I, -CN, -CF 3 , -OCF 3 , -SCF 3 , -SO 3 Na, -SO 3 K, -SO 3 H, -OH, -SH, -NH 2 , -O-C 1-8 -alkyl, -O-Si-(Ci -8 -alkyl) 3 , -Si-(Ci -8 -alkyl) 3 , -S-C 1-8 -alkyl, -NH(C 1-8 -alkyl), -N(C 1-8 -alkyl) 2 , -N(Ci -8 -alkyl) 3 + , phenyl,
- R1 D2 D3 D4 D8 D9 D10 D 2 3 1 R 1 R 1 K 1 FX i H i R , and R 24 have the above-defined meaning;
- enantiomers or di- astereomers optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- R 3 represents a (hetero)cycloaliphatic radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, azetidinyl, tetrahydrofuranyl, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, n-pentyl, -O-CH 3 , -0-C 2 H 5 , -0-CH 2 -CH 2 -CH 3 , -O-
- an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, pyridinyl, pyrrolyl, imidazolyl, pyrazolyl, indolyl, benzotriazolyl, quinolyl and isoquinolyl, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, n-pentyl, -0-CH 3 , -0-C 2 H 5 , -0-CH 2 -CH 2 -CH 3 , -O-CH(CH 3 ) 2 , -O-C(CH 3 ) 3 , -S-CH 3 , -S-C 2 H 5 , -S-CH 2 -CH 2 -CH
- R 4 represents a hydrogen atom; or a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted; and whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
- R 5 , R 6 and R 7 independently from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted or substituted with 1 , 2, 3, 4, or 5 substituents independently selected from the group consisting of F, Cl, Br, I 1 -OH, -SH, -NH 2 , -CN, -CF 3 , -OCF 3 , -SCF 3 , -SO 3 Na, -SO 3 K, -SO 3 H, -0-CH 3 , -0-C 2 H 5 , -S-CH 3 , -O-Si-(CH 3 ) 3 , -0-Si-(CH 2 -
- R 5 , R 6 and R 7 independently from one another, each represents a radical of general formula (II)
- R 25 , R 26 , R 27 , R 28 and R 29 independently from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted; and whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
- a radical selected from the group consisting of -0-CH 3 , -0-CH 2 -CH 3 , -0-CH 2 -CH 2 -CH 3 , -0-CH 2 -CH 2 -CH 3 , -0-CH 2 -CH 2 -CH 2 -CH 3 , -0-CH 2 -CH 2 -CH 2 -CH 3 , -0-CH 2 -CH 2 -CH 2 -CH 2 -CH 3 and -0-CH 2 -CH 2 -CH 2 -CH 2 -CH 2 -CH 2 -CH 3 ; whereby in each occurrence the alkyl chain of these radicals is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
- R 7 represents a radical of general formula (III)
- n 0, 1 or 2;
- X represents an oxygen atom or an unsubstituted or at least mono-substituted
- R 31 , R 32 , R 33 and R 34 independently of one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted; and whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
- a radical selected from the group consisting of -CH 2 -Phenyl and -CH 2 - CH 2 -Phenyl;
- an unsubstituted phenyl or naphthyl radical a radical selected from the group consisting of -O-CH 3l -O-CH 2 -CH 3 , -0-CH 2 -CH 2 -CH 3 , -0-CH 2 -CH 2 -CH 2 -CH 3 , -0-CH 2 -CH 2 -CH 2 -CH 31 -0-CH 2 -CH 2 -CH 2 -CH 2 -CH 2 -CH 3 and -0-CH 2 -CH 2 -CH 2 -CH 2 -CH 2 -CH 2 -CH 3 ; whereby in each occurrence the alkyl chain of these radicals is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
- R 30 represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, pentyl and hexyl;
- enantiomers or di- astereomers optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- R 4 represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
- R 5 , R 6 and R 7 independently from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
- a radical selected from the group consisting of -CH 2 -Phenyl and -CH 2 - CH 2 -Phenyl;
- radicals R 5 , R 6 and R 7 independently from one another, each represents a radical of general formula (II)
- R 25 , R 26 , R 27 , R 28 and R 29 independently from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted; and whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
- a radical selected from the group consisting of -CH 2 -Phenyl and -CH 2 - CH 2 -Phenyl;
- R 7 represents a radical of general formula (III)
- n 0, 1 or 2;
- X represents an oxygen atom or an unsubstituted or at least mono-substituted
- C- I-4 alkylene radical preferably an oxygen atom or an unsubstituted Ci -4 alkylene radical
- R 31 , R 32 , R 33 and R 34 independently of one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted; and whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
- a radical selected from the group consisting of -CH 2 -Phenyl and -CH 2 -CH 2 -Phenyl; an unsubstituted phenyl or naphthyl radical;
- R 30 represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, pentyl and hexyl, which is unsubstituted;
- enantiomers or di- astereomers optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- At least one silylated substituted benzotriazolylphenol compound of general formula (IB) is particularly preferred.
- R 4b represents a radical selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl, which is unsubstituted;
- R 5b , R 6b and R 7b independent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
- R 5b , R 6b and R 7b independently of one another, each represents a radical of general formula (Mb)
- R 25b , R 26b , R 27b , R 28b and R 29b independently from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n- butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
- R >7b represents a radical of general formula (IMb)
- nr ,fb _ O 1 1 or 2, preferably O;
- X b represents an oxygen atom or an unsubstituted or at least mono-substituted C 1 - 4 alkylene radical; preferably an oxygen atom or an unsubstituted C 1 - 4 alkylene radical;
- R 31b , R 32b , R 33b and R 346 independently of one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
- a radical selected from the group consisting of -CH 2 -Phenyl and -CH 2 - CH 2 -Phenyl;
- enantiomers or di- astereomers optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- At least one silylated substituted benzotriazolylphenol compound of general formula (IC) is also preferred.
- n 0, 1 , or 2; preferably 1 ;
- R 4c represents a radical selected from the group consisting of methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl, which is unsubstituted;
- R 5c , R 6c and R 7c independent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
- a radical selected from the group consisting of -CH 2 -Phenyl and -CH 2 - CH 2 -Phenyl;
- R 5c , R 6c and R 7c independently of one another, each represents a radical of general formula (lie)
- a radical selected from the group consisting of -CH 2 -Phenyl and -CH 2 - CH 2 -Phenyl;
- a radical selected from the group consisting of -O-Si-(CH 3 ) 3 , -O-Si-(C 2 H 5 ) 3 , -0-Si-(C 4 Hg) 3 , -0-Si-(Ph) 3 , -CH 2 -Si-(CH 3 ) 3 and -CH 2 -Si-(C 2 Hs) 3 ;
- R represents a radical of general formula (MIc)
- m c 0, 1 or 2, preferably 0;
- X c represents an oxygen atom or an unsubstituted or at least mono-substituted
- Ci- 4 alkylene radical preferably an oxygen atom or an unsubstituted Ci-4 alkylene radical
- en t of one another each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
- a radical selected from the group consisting of -CH 2 -Phenyl and -CH 2 - CH 2 -Phenyl;
- enantiomers or di- astereomers optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- silylated substituted benzotriazolylphenol compounds of general formulae (ID), (IE) and (IF)
- R 4b represents a radical selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl, which is unsubstituted;
- m b O, 1 , 2, 3, 4 or 5;
- en t of one another each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
- a radical selected from the group consisting of -CH 2 -Phenyl and -CH 2 - CH 2 -Phenyl;
- a radical selected from the group consisting of -O-Si-(CH 3 ) 3 , -O-Si-(C 2 H 5 ) 3 , -0-Si-(C 4 Hg) 3 , -0-Si-(Ph) 3 , -CH 2 -Si-(CH 3 ) 3 and -CH 2 -Si-(C 2 Hs) 3 ;
- enantiomers or di- astereomers optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoi- somers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- silylated substituted benzotriazolylphenol compounds of general formulae (IG), (IH) and (IJ)
- m c , R 1c , R 2c , R 40 , R 31c , R 32c , R 33c and R 34c have the same meaning as the above defined m b , R 1b , R 2b , R 4b , R 31b , R 32b , R 33b and R 34b for the silylated substituted benzotriazolylphenol compounds of general formulae (ID), (IE) and (IF);
- enantiomers or di- astereomers optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- enantiomers or di- astereomers optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
- Another aspect of the present invention relates to a process for the preparation of at least one silylated substituted benzotriazolylphenol compound of general formula (I), which comprises the step of reacting at least one compound of general formula (P9)
- R 1 , R 2 , R 3 and R 4 have the above-defined meaning, with at least one suitable silyl derivative of general formula (P10)
- a catalyst comprising an electron-rich complex of a late transition metal such as e.g. Co(I), Rh(I), Ni(O), Pd(O), or Pt(O), preferably with Speier catalyst (H 2 [PtCI 6 ]
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 have the above-defined meaning.
- At least one silylated substituted benzotriazolylphenol compound of general formula (I) is obtained by reacting at least one compound of general formula (P1 )
- R 1 and R 2 have the above-defined meaning, with sodium nitrite (NaN ⁇ 2) in a suitable reaction media, preferably an aqueous reaction media, preferably in the presence of a mineral acid such as e.g. HCI, at usual temperatures, preferably at a temperature ranging from -20 to 2O 0 C, more preferably at a temperature between O 0 C and 5 0 C until the reaction is completed to yield at least one compound of general formula (P2)
- a suitable reaction media preferably an aqueous reaction media, preferably in the presence of a mineral acid such as e.g. HCI, at usual temperatures, preferably at a temperature ranging from -20 to 2O 0 C, more preferably at a temperature between O 0 C and 5 0 C until the reaction is completed to yield at least one compound of general formula (P2)
- R 3 has the above-defined meaning, in the presence of a base, preferably a mineral base such as e.g. sodim hydroxide (NaOH), to activate the phenol in the form of a phenoxide ion, in a suitable solvent, preferably in a protic and/or aqueous solvent such as e.g. H 2 O, ethanol (EtOH), isopropanol or mixtures thereof, at usual temperatures, preferably at a temperature ranging from -20° to 5O 0 C, more preferably at a temperature between O 0 C and room temperature until the reaction is completed to yield at least one compound of general formula (P4)
- a base preferably a mineral base such as e.g. sodim hydroxide (NaOH)
- a suitable solvent preferably in a protic and/or aqueous solvent such as e.g. H 2 O, ethanol (EtOH), isopropanol or mixtures thereof, at usual temperatures, preferably at a temperature
- a base preferably an alkaline base such as e.g. NaOH, preferably in suitable solvent, more preferably a protic and/or aqueous solvent such as e.g. H 2 O, EtOH, isopropanol or mixtures thereof, at usual temperatures, preferably at a temperature ranging from O 0 C to the boiling point of the solvent, more preferably at a temperature between 5O 0 C and the boiling point of the solvent, until the reaction is completed to yield at least one compound of general formula (P6)
- a base more preferably an alkaline base such as e.g. NaOH
- suitable solvent more preferably a protic and/or aqueous solvent such as e.g. H 2 O, EtOH, isopropanol or mixtures thereof
- R 4 has the above-defined meaning and X represents a leaving group preferably chorine, bromine, methanesulfonyl or toluenesulfonyl, more preferably chlorine, preferably in the presence of a base, preferably a mineral base, more preferably K 2 CO 3 , optionally in the presence of iodine salt, preferably Kl 1 in a suitable solvent, preferably an organic solvent such as e.g. ketone or 2-butanone, more preferably 2-butanone, preferably at a temperature ranging from O 0 C to the boiling point of the solvent, more preferably at a temperature between 5O 0 C and the boiling point of the solvent until the reaction is completed to yield at least one compound of general formula (P8)
- a suitable solvent preferably an organic solvent such as e.g. ketone or 2-butanone, more preferably 2-butanone, preferably at a temperature ranging from O 0 C to the boiling point of the solvent, more preferably at a temperature between 5
- R 1 , R 2 , R 3 and R 4 have the above-defined meaning, which is preferably reacted according to typical Aromatic Claisen Rearrangement conditions, preferably with the presence of a catalyst, preferably in the presence of a solvent, preferably in the presence of an amine such as e.g. N.N-diethylaniline, preferably at a temperature ranging from O 0 C to 200 0 C 1 more preferably at a temperature between 5O 0 C and 17O 0 C until the reaction is completed to yield at least one compound of general formula (P9)
- a catalyst preferably in the presence of a solvent, preferably in the presence of an amine such as e.g. N.N-diethylaniline, preferably at a temperature ranging from O 0 C to 200 0 C 1 more preferably at a temperature between 5O 0 C and 17O 0 C until the reaction is completed to yield at least one compound of general formula (P9)
- R 1 , R 2 , R 3 and R 4 have the above-defined meaning, which is preferably reacted with at least one suitable silyl derivative of general formula (P10)
- a catalyst comprising an electron-rich complex of a late transition metal such as e.g. Co(I), Rh(I), Ni(O) 1 Pd(O), or Pt(O), preferably with Speier catalyst (H 2 [PtCIe]
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 have the above-defined meaning.
- the compounds of general formula P6 can be prepared according to the disclosure Of DE 2727386, JP 52113974, CH 476745, US 3399173, GB 991630 or GB 980886.
- the respective parts of the literature are hereby incorporated by reference.
- Aromatic Claisen Rearrangement conditions are known to those of ordinary skill in the art and are e.g. described in Tarbell et al., Organic Reactions, Vol. 2 , John Willey, NY, 1944, page 1 or EP 0 392 883.
- Microwave assisted organic synthesis provides processes of efficiently preparing these compounds in a short time by using microwave irradiation.
- Microwave assisted chemistry is relatively new compared to some other techniques; however, it has become well established and accepted.
- Microwave assisted chemical synthesis refers to the use of electromagnetic radiation within the microwave frequencies to provide the energy required to initiate, drive, or accelerate certain chemical reactions. As chemists have long been aware, the application of heat energy is one of the most significant factors in increasing the rate of a wide variety of chemical reactions. Microwave assisted reactions can be completed in a much shorter period of time than conventional thermal-treatment techniques requiring long reaction time.
- pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, i.e. about 1 atmosphere, is preferred as a matter of convenience. Under microwave-assisted heating, sealed reactors are indicated, resulting in high-pressure reactions up to as much as 350 psi.
- the microwave irradiation may be performed at a power level of 1 to 1600 W 1 preferably 1 to 300 W, and particularly preferably about 70 W.
- the duration for the microwave irradiation may vary according to conditions such as the amount or reactant but may be in the range from 20 seconds to 60 minutes, preferably from 1 minute to 20 minutes.
- the reaction can be carried out at a temperature of 50-280 0 C, preferably 80-200 0 C, and more preferably 120-150 0 C, with of without solvent, under microwave irradiation.
- a presently preferred microwave furnace is commercially available from CEM, Inc., as model Discover ® .
- the Discover ® System incorporates temperature and pressure feedback systems, for example, an infrared temperature sensor positioned below the reaction vessel, for complete control of the reaction.
- the compounds of general formula (I), including compounds of general formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH) and (IJ), in the following only referred to as compounds of general formula (I) herein given above may be purified and/or isolated according to methods well known to those skilled in the art.
- the compounds of general formula (I) may be isolated by evaporating the reaction medium, addition of water and adjusting the pH value to obtain the compound in form of a solid that can be isolated by filtration, or by extraction with a solvent that is not miscible with water such as chloroform and purification by chromatography or recrystallization from a suitable solvent.
- the protection of sensitive or reactive groups may be necessary and/or desirable. This can be performed by using conventional protective groups like those described in Protective groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; T.W. Greene & P. G. M. Wuts and Protective Groups in Organic Chemistry, John Wiley & sons, 1991. The respective parts of the description are hereby incorporated by reference and forms part of the disclosure.
- the protective groups may be eliminated when convenient by means well known to those skilled in the art.
- silylated substituted benzotriazolylphenol compounds of general formula (I) are obtained in form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or crystallization with chiral reagents.
- silylated substituted benzotriazolylphenol compounds of general formula (I) and in each case stereoisomers thereof may be obtained in form of a corresponding salt according to methods well known to those skilled in the art, e.g. by reacting said compound with at least one inorganic and/or organic acid, preferably in a suitable reaction medium.
- suitable reaction media include, for example, any of the ones given above.
- Suitable inorganic acids include but are not limited to hydrochloric acid, hydrobromic acid, phosphoric acid, oxalic acid, sulfuric acid, nitric acid
- suitable organic acids include but are not limited to citric acid, maleic acid, fumaric acid, tartaric acid, or derivatives thereof, p-toluenesulfonic acid, methanesulfonic acid or camphersulfonic acid.
- salt is to be understood as meaning any form of the silylated substituted benzotriazolylphenol compounds in which they assume an ionic form or are charged and are coupled with a counter-ion (a cation or anion) or are in solution.
- a counter-ion a cation or anion
- physiologically acceptable salt is understood in particular, in the context of this invention, as salt (as defined above) formed either with a physiologically tolerated acid, that is to say salts of the particular active compound with inorganic or organic acids which are physiologically tolerated - especially if used on humans and/or mammals - or with at least one, preferably inorganic, cation which are physiologically tolerated - especially if used on humans and/or mammals.
- physiologically tolerated salts of particular acids are salts of: hydrochloric acid, hydrobromic acid, sulfuric acid, hydrobromide, monohydrobromide, monohydrochloride or hydrochloride, methiodide, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid, hippuric acid picric acid and/or aspartic acid.
- physiologically tolerated salts of particular bases are salts of alkali metals, such as e.g. sodium or potassium and alkaline earth metals such as e.g. magnesium or calcium and with NH 4 .
- Particularly preferred are silylated substituted benzotriazolylphenol compounds in form of a sodium, potassium or triethanolamine salt.
- Solvates, preferably hydrates, of the silylated substituted benzotriazolylphenol compounds of general formula (I) and in each case of corresponding stereoisomers may also be obtained by standard procedures known to those skilled in the art.
- solvate is to be understood as meaning any form of the silylated substituted benzotriazolylphenol compounds in which they have attached to it via non-covalent binding another molecule (most likely a polar solvent) especially including hydrates and alcoholates, e.g. methanolate.
- a further aspect of the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above, optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, and optionally at least one physiologically acceptable auxiliary agent.
- silylated substituted benzotriazolylphenol compound of general formula (I) given above optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solv
- a further aspect of the present invention relates to a cosmetic composition
- a cosmetic composition comprising at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above, optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, and optionally at least one physiologically acceptable auxiliary agent.
- silylated substituted benzotriazolylphenol compound of general formula (I) given above optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solv
- inventive silylated benzotriazolylphenol compounds of general formula (I) given above also show remarkable absorption capacities in UV- C radiation range. Since the sunlight radiation intensity continuously increases due to the continuous reduction of stratospheric ozone, the importance of pharmaceutical/cosmetic compositions having such UV-C protecting properties is growing.
- Said pharmaceutical and/or cosmetic composition is particularly suitable for the prophylaxis and/or care and/or treatment of diseases caused by and/or associated with exposure to ultraviolet radiation, preferably of the lips, the face and/or of the body of mammals, preferably human beings, more preferably for the prophylaxis and/or care and/or treatment of/against non-desired skin conditions comprising polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing, sunburn and/or chronic actinic dermatitis.
- the amount of at least one silylated substituted benzotriazolylphenol compound for the inventive pharmaceutical or cosmetical composition is preferably in each case in the range of 0.01 % to 30% per weight, more preferably 0.01 % to 20% per weight, most preferably 0.1 % to 15% per weight, with respect to the total weight of the composition.
- At least one of the inventive silylated substituted benzotriazolylphenol compound(s) may be preferably used in micronized form, wherein the size of the particles is preferably in the range of 0.01 to 4 ⁇ m, more preferably in the range of 0.05 to 2 ⁇ m, most preferably in the range of 0,05 to 1 ⁇ m.
- auxiliary agents can independently from each other be present in either the inventive pharmaceutical or the inventive cosmetical composition: gelling agents, oils, waxes, thickening agents, hydrophilic or hydrophobic polymers, emulsifying agents, emollients, fatty acids, organic solvents, antioxidants, stabilizers, sequestering agents, acidifying or basifying agents, emulsifiers, emollients, surfactants, film formers, biological additives to enhance performance and/or consumer appeal such as amino acids, proteins, vanilla, aloe extract or bioflavinoids, buffering agents, chelating agents such as ethylenediaminetetra-acetic acid (EDTA) or oxalic acid, colorants, dyes, propellants, antifoaming agents, wetting agents, vitamins, emulsion stabilizers, pH adjusters, thickening agents, fragrances, preservatives, opacifying agents, water and/or alcohols.
- EDTA ethylenediaminetetra-acetic acid
- oils for the inventive compositions oils from animal or vegetable sources or synthetic are preferably used. Particularly preferred are oils selected from the group comprising liquid petrolatum, liquid paraffin, volatile and non-volatile silicone oils, isoparaffins, polyalphaolefins, fluorated and perfluorated oils.
- non-ionic, anionic, cationic and amphiphilic tensides can be used, which are preferably selected from the group comprising polyethylenglycol (PEG) and derivatives thereof, tweens, tritons, spans, polygycerines, polyalkyl glycerides, alkyl sulfonates, aryl sulfonates, alkyl phosphates, derivatives of alkyl-betaine and phosphatidylglycerole.
- PEG polyethylenglycol
- Emulsifiers are preferably used in certain formulations of the inventive compositions in amounts effective to provide uniform blending of ingredients of the composition.
- Useful emulsifiers include anionics such as fatty acid soaps, e.g., potassium stearate, sodium stearate, ammonium stearate, and triethanolamine stearate; polyol fatty acid monoesters containing fatty acid soaps, e.g., glycerol monostearate containing either potassium or sodium salt; sulfuric esters (sodium salts), e.g., sodium lauryl 5 sulfate, and sodium acetyl sulfate; and polyol fatty acid monoesters containing sulfuric esters, e.g., glyceryl monostearate containing sodium lauryl surfate; (ii) cationics chloride such as N(stearoyl colamino formylmethyl) pyridium; N-soya-N-eth
- Emollients may be used in the formulations of the inventive compositions in such amounts to prevent or relieve dryness.
- Useful emollients include, without limitation hydrocarbon oils and waxes; silicone oils; triglyceride esters; acetoglyceride esters; ethoxylated glyceride; alkyl esters; alkenyl esters; fatty acids; fatty alcohols; fatty alcohol ethers; etheresters; lanolin and derivatives; polyhydric alcohols (polyols) and polyether derivatives; polyhydric alcohol (polyol) esters; wax esters; beeswax derivatives; vegetable waxes; phospholipids; sterols; and/or amides.
- Surfactants can be used in certain formulations of the inventive compositions. Suitable surfactants are for example those surfactants generally grouped as cleansing agents, emulsifying agents, foam boosters, hydrotropes, solubilizing agents, suspending agents and non-surfactants, which facilitate the dispersion of solids in liquids.
- Suitable film formers which are preferably used in the formulations of the inventive compositions should keep the composition smooth and even and are preferably, without limitation, at least one substance selected from the group comprising acrylamide/sodium acrylate copolymer; ammonium acrylates copolymer; Balsam Peru; cellulose gum; ethylene/maleic anhydride copolymer; hydroxyethylcellulose; hydroxypropylcellulose; polyacrylamide; polyethylene; polyvinyl alcohol; pvm/MA copolymer (vinyl methylether/maleic anhydride copolymer); PVP (polyvinylpyrrolidone); maleic anhydride polymer, vinylpyrrolidon/hexadecene copolymer; acryliclacrylate copolymer and the like.
- pH adjusters may also be used in certain formulations of the inventive compositions. These pH adjusters preferably comprise, but are not limited to ammonium hydroxide, triethanolamine or citric acid.
- Thickening agents used for the formulations of the inventive compositions preferably are, but are not limited to candelilla, carnauba, and microcrystalline waxes, crosslinked acrylic-acid polymers, carbomer, methylhydroxyethylcellulose, hydroxypropylmethylcellulose or hydroxyethylcellulose. and polyethylene thickeners.
- Examples of preferred organic solvents for the inventive compositions include lower aliphatic alcohols and polyols.
- Suitable antioxidants suitable for the inventive compositions are preferably selected from the group comprising ascorbic acid (vitamin C), sodium-L-ascorbate, calcium-L- ascorbate, ascorbyl palmitate, butylhydroxyanisole, butylhydroxytoluene, calcium- disodium-EDTA, isoascorbic acid, lecitine, lactic acid, polyphosphate, tocopherol (vitamin E), like ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, propylgallate, octylgallate, dodecylgallate, sodium-isoascorbate, citric acid, sodium citrate, potassium citrate and tin-ll-chloride.
- Gelling agents which are preferably used in the formulations of the inventive compositions, can be natural or synthetic polymers. Natural polymers are preferably selected from the group comprising Agar-Agar, alginate, pectin, carbomer, carrageenan, casein, dextrine, gelatine, arabic gum, keratine, locust bean gum, xanthan gum and the like. Preferred synthetic polymers, which can be used in the formulations of the inventive compositions are selected from the group comprising acylic acid polymers, polyacryl amides and alkylene oxide polymers.
- the respective components shall be used in amounts which are in compliance with the Council Directives 76/768/EEC and Commission Directive 95/17/EC on the approximation of the laws of the Member States relating to cosmetic products.
- the inventive pharmaceutical or cosmetic composition is preferably adapted at least for a once a day, twice or three, four or five times a day, preferably for twice a day application.
- the inventive pharmaceutical or cosmetical composition may be formulated in liquid or in semi-solid form, preferably as liquid, fluid, foam, cream, gel, paste, balsam, spray, ointment, lotion, conditioner, tonic, milk, mousse, emulsion, serum, oil, stick, shampoo, jelly, suspension, dispersion, lacquer, paint, elixir, drop or aerosol.
- inventive pharmaceutical or cosmetical compositions are suitable for protecting the skin of UV radiation, either in the range of UV-A or UV-B or UV-C or in the whole UV-A and UV-B range and optionally UV-C range.
- a further aspect of the present invention relates to the use of at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of diseases caused by and/or associated with exposure to ultraviolet radiation, preferably of the lips, the face and/or of the body of mammals, preferably human beings.
- a preferred embodiment of the present invention is related to the use of at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above for the preparation of a pharmaceutical composition for the prophylaxis and/or care and/or treatment against non-desired skin conditions comprising polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing, sunburn and/or chronic actinic dermatitis.
- At least one silylated substituted benzotriazolylphenol compound of general formula (I) given above for the prophylaxis and/or care against non-desired skin conditions comprising polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing, sunburn and/or chronic actinic dermatitis.
- At least one silylated substituted benzotriazolylphenol compound of general formula (I) given above for protecting the skin preferably of the lips, the face and/or of the body of a mammal, preferably a human, against ultraviolet radiation, preferably UV-A and/or UV-B radiation and optionally UV-C radiation.
- Another aspect of the present invention relates to the use of at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above as a light-stabilizer in polymer compositions, preferably in textile fibers.
- Such polymer compositions comprising the inventive silylated substituted benzotriazolylphenol compounds of general formula (I) given above as light stabilizers may be in form of articles, moulds, sheets, foils, paintings, coatings, fibers or films.
- the films comprising the inventive silylated substituted benzotriazolylphenol compounds of general formula (I) given above as light stabilizers are single-layer or multilayer films, which can be used for medical or agricultural applications.
- the articles, moulds, sheets, foils or films comprising the inventive silylated substituted benzotriazolylphenol compounds of general formula (I) given above as light stabilizers are preferably suitable for outdoor carpeting, awnings, tarps, umbrellas, non-food or food-packaging applications such as rice, corn and flour bags, tapes, ropes, artificial turf, stretch-films, shrink wraps, heavy-duty bags, pool covers, garden furniture, trash cans, bottle and fruit crates, toys, interior and exterior automotive parts such as auto bumpers and interior or exterior trim, outdoor sporting and leisure goods, roofings and window shutters.
- light stabilizer means, according to the present invention a chemical compound that protects the material like a polymer composition against photodegradation against deterioriating and/or decomposing effects caused by its exposure to light.
- photostabilizer also referred to as "photostabilizer” or “photoprotecting agent”
- photoprotecting agent means, according to the present invention a chemical compound that protects the material like a polymer composition against photodegradation against deterioriating and/or decomposing effects caused by its exposure to light.
- IUPAC International Union of Pure and Applied Chemistry
- light stabilizers can also be classified according to their special possibility of stabilizing against the impact of light into absorbers, quenchers, peroxide decomposers or free radical scavengers.
- So called absorbers and quenchers are preferably agents that reduce the impact caused by exposure to light either by absorbing, extincting, filtering, scattering, deflecting or reflecting light.
- a peroxide decomposer is preferably an agent that transforms peroxides into stable compounds without the formation of free radicals and a free radical scavenger is preferably an agent that eliminates free radicals by binding.
- the inventive light-stabilized polymer composition comprises as the light- stabilizing component at least one absorber, quencher, peroxide decomposer and/or free radical scavenger.
- absorption means any of the following means of reducing the exposure to UV radiation like absorbing, extincting, filtering, scattering, deflecting or reflecting of radiation, since absorption only means the ratio of transmitted radiation to the incident radiation, without determining the mechanism according to which the radiation is reduced.
- Polymers can be preferably classified into four main groups:
- thermoplastic polymers made of thermoplastic polymers is deformable, melts to a liquid when heated and freezes to a brittle, glassy state when cooled sufficiently.
- Most thermoplastic polymers are high molecular weight polymers whose chains associate through weak van der Waals forces (polyethylene), stronger dipole-dipole interactions and hydrogen bonding (nylon) or even stacking of aromatic rings (polystyrene). Thermoplastic polymers can be remelted and remolded.
- thermosets are materials that cure, through the addition of energy, to a stronger form.
- the energy may be in the form of heat (generally above 200°C), through a chemical reaction (two-part epoxy, for example), or irradiation.
- Thermoset materials are usually liquid, powder, or malleable prior to curing, and designed to be moulded into their final form, or used as adhesives.
- the curing process transforms the resin into a plastic or rubber by a cross-linking process.
- Energy and/or catalysts are added that cause the molecular chains to react at chemically active sites (unsaturated or epoxy sites, for example), linking into a rigid, 3-D structure.
- the cross-linking process forms a molecule with a larger molecular weight, resulting in a material with a higher melting point.
- the material forms into a solid material.
- Subsequent uncontrolled reheating of the material results in reaching the decomposition temperature before the melting point is obtained.
- a thermoset material cannot be melted and re-shaped after it is cured.
- Thermoset materials are generally stronger than thermoplastic materials due to this 3-D network of bonds and are also better suited to high-temperature applications up to the decomposition temperature of the material.
- elastomer is often used interchangeably with the term rubber, and is preferred when referring to vulcanisates. They are amorphous polymers existing above their glass transition temperature, so that considerable segmental motion is possible. At ambient temperatures rubbers are thus relatively soft and deformable. Their primary uses are for seals, adhesives and molded flexible parts. 4. Coordination polymers
- Coordination polymers are compounds where the metals are bridged by polyatomic ligands, such as e.g. cyanide or carboxylates.
- thermoplastic polymer is preferably at least one thermoplastic polymer selected from the group comprising acrylonitrile-butadiene-styrene (ABS) copolymer; cellulose derivatives such as cellulose acetate, cellulose acetate propionate, cellulose acetate butyrate, cellulose triacetate, cellulose ether, methyl cellulose, ethylcellulose, propyl- cellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl- cellulose and carboxy methylcellulose; ethylene-vinyl acetate (EVA) copolymer; ethylene vinyl alcohol (EVAL) copolymer; polyolefines such as ethylen-propylen copolymer, ethylene-buten-1 copoly
- styrene-isopren-styrene block copolymer polysulfone (PSU); polyurethane (PU); polyvinyl ether; polyvinylalcohol; polyvinylidenechloride; polyvinylpyrrolidone; polyvinyl chloride (PVC); vinyl chloride- vinyl acetate copolymer; vinyl chloride-vinylidene dichloride copolymer and vinyl pyrrolidon-ethylen-vinylacetate copolymer.
- Another preferred embodiment of the present invention relates to the use of at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above as a light-stabilizer in elastomer compositions, whereby the elastomer is preferably at least one elastomer selected from the group comprising homo-, co- or block polymer of butadiene; natural rubber (NR); polyisoprene (IR); butyl rubber; halogenated butyl rubbers such as chloro butyl rubber or bromo butyl rubber; polybutadiene (BR); styrene-butadiene rubber (SBR); nitrile rubber; hydrated nitrile rubbers (HNBR); chloroprene rubber (CR); polychloroprene; neoprene; ethylene propylene rubber (EPM); ethylene propylene diene rubber (EPDM); epichlorohydrin rubber (ECO); polyacrylic rubber; silicone rubber; silicone; silcone
- thermosetting polymer is preferably at least one polymer selected from the group comprising vulcanized rubber; polyoxybenzylmethylenglycolanhydride; duroplast; urea-formaldehyde resins; melamine; cured polyester resins and epoxy resins.
- Polymer compositions usually comprise additives, which improve the properties of these compositions.
- Suitable additives used in the inventive light-stabilized composition preferably include, but are not limited to anti-blocking-agents, anti- fogging agents, antistatic agents, antioxidants, biocides, blowing agents, defoamers, dyes, emulsifiers, fillers, flame retardants, heat stabilizers, impact modifiers, lubricants, metal deactivators, hydrocalcites, mould-release agents, optical brighteners, plastisizers, processing agents, pigments, phosphites, phosphonites, reinforcing agents, rheology additives, slip agents and surfactants, whereby each of these aforementioned additives is used in usual amounts known by those skilled in the art.
- example compound 1 absorbs more than half of the amount of the radiation in the UV-C radiation range, when compared with Mexoryl XL ® (compare: figure 2). Moreover it can be seen that example compound 1 absorbs more amounts of UV radiation at ⁇ max values of approx. 300 nm (UV-B) and approx. 340 nm (UV-A), respectively in comparison to Mexoryl XL ® (compare: figure 2).
- Example 3 Procedure for synthesis of 2-(2/-/-benzotriazol-2-yl)-4-cyclohexyl-6-[2- methyl-3-(1 ,1 ,3,3,3-pentamethyl-disiloxanyl)-propyl]-phenol
- Example 4 Procedure for synthesis of 2-(2/-/-benzotriazol-2-yl)-4-cyclohexyl-6-[2- methyl-S-ti .S.S.S-tetramethyl-i- ⁇ trimethylsilyOoxyJdisiloxany ⁇ propylj-phenol
- Example 7 2- ⁇ 4-Hydroxy-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl-disiloxanyl)-propyl]- biphenyl-3-yl ⁇ -2/-/-benzotriazole-5-carbonitrile
- Example 8 2- ⁇ 4-Hydroxy-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl-disiloxanyl)-propyl]- biphenyl-3-yl ⁇ -2/-/-benzotriazole-5-carboxylic acid
- Example 9 2- ⁇ 4-Hydroxy-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl-disiloxanyl)-propyl]- biphenyl-3-yl ⁇ -2/-/-benzotriazole-5-carboxylic acid
- a cream formulation with the composition % by weight
- % by weight of the respective components are based on the total weight of the composition.
- a polymer composition comprising 3-(5-Methoxy-2H-benzotriazol-2-yl)-5-[2- methyl-3-(1 ,1 ,3,3,3-pentamethyl-disiloxanyl)-propyl]-biphenyl-4-ol (example compound 6) as light stabilizer.
- the composition is extruded through a flat nozzle to obtain a film with a thickness adjusted to the requirements of the accelerated weathering test according to ASTM D-5208.
- the film is then exposed to such weathering test.
- the light stability of the sample is assessed by measuring the extent of carbonyl oxidation of the polymer by means of infrared spectroscopy. The measurement is carried out after 1000 hours exposition to accelerated weathering (UV-A).
- UV-A accelerated weathering
- Mexoryl XL ® absorbs less than half of the amount of the radiation in the UV-C radiation range, when compared with the inventive example compound 1 (compare: figure 1 ). Moreover it can be seen that Mexoryl XL ® absorbs less amounts of UV radiation at ⁇ max values of approx. 300 nm (UV-B) and approx. 340 nm (UV-A), respectively in comparison to example compound 1 (compare: figure 1 ).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to silylated substituted benzotriazolylphenol compounds of general formula (I) a process for their preparation, a pharmaceutical and/or cosmetic composition comprising these compounds, their use for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of diseases caused by and/or associated with exposure to ultraviolet radiation, their use for the prophylaxis and/or care against non-desired skin conditions, as well as their use as a light-stabilizer in polymer compositions.
Description
Silylated, substituted benzotriazolylphenol compounds
The present invention relates to silylated substituted benzotriazolylphenol compounds of general formula (I)
(I)
a process for their preparation, a pharmaceutical and/or cosmetic composition comprising these compounds, their use for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of diseases caused by and/or associated with exposure to ultraviolet radiation, their use for the prophylaxis and/or care against non-desired skin conditions, as well as their use as a light-stabilizer in polymer compositions.
Ultraviolet (UV) radiation is part of the electromagnetic spectrum emitted by the sun. UV-C radiation (λ = 100-280 nm) is to a great extent absorbed by atmospheric ozone and has minimal penetration to the surface of the earth. 90% or more of UV-B radiation (λ = 280-320 nm) is absorbed by atmospheric ozone, while UV-A radiation (λ = 320-400 nm) passes through the atmosphere without being absorbed substantially. Thus, mainly UV-A and UV-B radiation is of considerable concern to human health. While UV-A radiation penetrates the human skin more deeply than UV-B radiation, action spectra for biological responses indicate that it is radiation in
the UV-B range that is absorbed by DNA - subsequent damage to DNA appears to be a key factor in the initiation of the carcinogenic process in skin. In recent years, however, there is increasing evidence that UV-A not only may be an important factor in photoaging but also causes genetic damage to skin cells that can lead to skin cancer.
Evidence of harm associated with overexposure to UV radiation has been demonstrated in many studies. Skin cancer and malignant melanoma are among the most severe health effects, but a series of other health impacts, such as polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing, sunburn and/or chronic actinic dermatitis have been identified.
Despite the great diversity of commercially available sunscreens, there still exists a need for sunscreens, which are preferably effective in the UV-A and/or the UV-B and/or optionally in the UV-C radiation range, more preferably in the UV-A and the UV-B and in the UV-C radiation range, since the sunlight radiation intensity, and in consequence the UV radiation, has been increasing continuously. As a consequence there exists a need for a sufficient protection against such increased UV radiation in order to reduce the risk of suffering of diseases such as e.g. skin cancer, malignant melanoma, polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing, sunburn and/or chronic actinic dermatitis caused by UV- A and/or UV-B radiation and optionally UV-C radiation.
Therefore, it was an object of the present invention to provide new compounds having UV-absorbing properties in the UV-A and/or the UV-B and/or optionally in the UV-C radiation range, preferably in the UV-A and UV-B radiation and optionally in the UV-C radiation range, in order to provide sufficient protection against these UV radiations, especially in order to provide sufficient care and prophylaxis against diseases caused by or associated with the exposure to UV radiation.
It has surprisingly found that substituted, silylated benzotriazolylphenol compounds of general formula (I) given below show remarkable absorption capacities in the UV-A and/or the UV-B and/or UV-C radiation range. These compounds are therefore particularly suitable as UV protecting agents in pharmaceutical and/or cosmetic
compositions as well as light-stabilizers in polymer compositions, preferably in textile fibers.
Thus, in one of its aspects the present invention refers to at least one silylated substituted benzotriazolylphenol compound of general formula (I)
(I)
wherein
k= 0 or 1 ; q = 1 or 2;
R1 and R2, independent from one another, each represents a hydrogen atom; a halogen atom; -NO2; -OR8; -SR9; -CN; -NR10R11; -C(=O)-OR12; -C(=O)R13; -C(=O)-NR14R15; -OC(=O)R16; -NR17-C(=O)R18; -NR19-C(=O)-O-R20; -S(=O)2-R21; -S(=O)2-O-R22; -S(=O)2-NR23R24;
a linear or branched, saturated, unsubstituted or at least mono-substituted CMS aliphatic radical;
an unsubstituted or at least mono-substituted aryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene
group and/or which may be condensed with an unsubstituted or at least mono- substituted, saturated or aromatic mono- or bicyclic ring system;
or
R1 and R2 are fused to form together an additional aromatic mono- or polycyclic ring system having from 4 to 10 carbon atoms;
R3 represents an unsubstituted or at least mono-substituted, saturated, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be condensed with an unsubstituted or at least mono-substituted saturated or aromatic mono- or bicyclic ring system;
or
an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted, saturated or aromatic mono- or bicyclic ring system;
R4 represents a hydrogen atom; a linear or branched, saturated, unsubstituted or at least mono-substituted CMS aliphatic radical;
with the provision that if q = 1 , then
k = 1 ;
R5 and R6 and R7, independent from one another, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted CMS aliphatic radical; a linear or branched, saturated, unsubstituted or at least mono-substituted -O-Ci-18 aliphatic radical;
an unsubstituted or at least mono-substituted, saturated cycloaliphatic radical;
an unsubstituted or at least mono-substituted aryl radical, which may be condensed with an unsubstituted or at least mono-substituted aromatic mono- or bicyclic ring system;
or
R5, R6 and R7, independent from one another, each represents a radical of general formula (II)
(") wherein
p = 0, 1 , 2 or 3;
R25, R26, R27, R28 and R29, independent from one another, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted CMS aliphatic radical; a linear or branched, saturated, unsubstituted or at least mono-substituted -O-Ci-18 aliphatic radical; an unsubstituted or at least mono-substituted aryl radical; or an -O-Si(R30)3 radical, with R30 representing a linear or branched, unsubstituted or at least mono-substituted C-MS alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -O-Ci-i8 alkyl radical or an unsubstituted or at least mono-substituted aryl radical;
with the condition that if q = 1 and at the same time k = 1 , at least one of the radicals R5, R6 and R7 represents a radical of general formula (II) as defined above;
or, with the provision that if q = 2, then
k = 0;
R7 represents a radical of general formula (III)
(III) wherein
m = 0, 1 , 2, 3, 4 or 5;
X represents an oxygen atom or an unsubstituted or at least mono-substituted
Ci-6 alkylene radical;
R31, R32, R33 and R34, independent of one another, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted Ci-i8 aliphatic radical; a linear or branched, saturated, unsubstituted or at least mono-substituted -O-Ci-18 aliphatic radical;
an unsubstituted or at least mono-substituted, saturated cycloaliphatic radical;
an unsubstituted or at least mono-substituted aryl radical, which may be condensed with an unsubstituted or at least mono-substituted aromatic mono- or bicyclic ring system;
or an -O-Si(R30)3 radical, with R30 representing a linear or branched, unsubstituted or at least mono-substituted Ci-i8 alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -O-Ci-i8 alkyl radical or an unsubstituted or at least mono-substituted aryl radical;
R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R23 and R24, independent of one another, each represents a hydrogen atom; a linear or branched, saturated, unsubstituted or at least mono-substituted Ci-i8 aliphatic radical, an unsubstituted or at least mono-substituted, saturated, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an unsubstituted or at least mono- substituted aryl radical;
R20 and R21, independent of one another, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted CM8 aliphatic radical, an unsubstituted or at least mono-substituted, saturated, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an unsubstituted or at least mono-substituted aryl radical;
and
R22 independent of one another, each represents a hydrogen atom; or an unsubstituted or at least mono-substituted, saturated, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an unsubstituted or at least mono-substituted aryl radical;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixture ratio, or a salt, preferably a corresponding, physiologically acceptable salt, or a corresponding solvate.
If any of the substituents in any of the herein defined formulae represents a saturated Ci-18-aliphatic radical, i.e. an alkyl radical, said aliphatic radical is - if not defined otherwise - unsubstituted or substituted with one or more substituents, preferably unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituent(s). Said substituent(s) is/are preferably independently selected from the group consisting of oxo (=0), F, Cl, Br, I1 -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-d-β-alkyl, -O-Si-(Ci-8-alkyl)3, -Si-(Ci-8-alkyl)3, -Si-(phenyl)3, -S-C1-8-alkyl, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -N(C1-8-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy, whereby in each occurrence Ci-i8-aliphatic and/or Ci-8-alkyl is linear or
branched. More preferably said substituent(s) is/are preferably independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH2, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -O-CH3, -0-C2H5, -0-CH2-CH2-CH3, -O-CH(CH3)2, -O-C(CH3)3, -S-CH3, -S-C2H5, -S-CH2-CH2-CH3, -S-CH(CH3)2, -S-C(CH3)3, -O-Si-(CH3)3l -O-Si-(CH2-CH3)3, -O-Si-[CH(-CH3)2]3, -Si-(CH3)3, -Si-(CH2-CH3)3> -Si-[CH(-CH3)2]3, -NH-CH3, -NH-C2H5, -NH-CH2-CH2-CH3, -NH-CH(CH3)2, -NH-C(CH3)3, -N(CH3)2, -N(C2H5)2, phenyl, benzyl, phenethyl and phenoxy.
Suitable alkyl radicals, which may be substituted by one or more substituents are preferably selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl.
If any of the substituents in any of the herein defined formulae represents an -0-Ci-I8 alkyl radical, said -O-Ci-i8 alkyl radical is - if not defined otherwise - unsubstituted or substituted with one or more substituents, preferably unsubstituted or optionally substituted with 1 , 2, 3, 4 or 5 substituent(s). Said substituent(s) is/are preferably independently selected from the group consisting of oxo (=0), F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-Ci-8-alkyl, -0-Si-(C1-8- alkyl)3, -Si-(Ci-8-alkyl)3, -Si-(phenyl)3, -S-C1-8-alkyl, -NH(Ci-8-alkyl), -N(Ci-8-alkyl)2, -N(Ci-8-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy, whereby in each occurrence the alkyl chain of the aforementioned -O-Ci-i8-alkyl and/or Ci-8-alkyl radicals is linear or branched. More preferably said substituent(s) are preferably independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH2, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -0-CH3, -0-C2H5, -0-CH2-CH2-CH3, -O-CH(CH3)2, -O-C(CH3)3) -S-CH3, -S-C2H5, -S-CH2-CH2-CH3, -S-CH(CH3J2, -S-C(CH3)3, -O-Si-(CH3)3, -O-Si-(CH2-CH3)3, -O-Si-[CH(-CH3)2]3, -NH-CH3, -NH-C2H5, -NH-CH2-CH2-CH3, -NH-CH(CH3)2, -NH-C(CHg)3, -N(CH3)2, -N(C2Hs)2, phenyl, benzyl, phenethyl and phenoxy.
If any of the substituent(s) in any of the herein defined formulae represents or comprises a (hetero)cycloaliphatic radical, i.e. a cycloaliphatic radical or a heterocycloaliphatic, including a C3.g (hetero)cycloalkyl radical, i.e. a C3-g cycloalkyl or a C3-9 heterocycloalkyl radical, said (hetero)cycloaliphatic radical is - if not defined otherwise - unsubstituted or optionally substituted with one or more substituents,
preferably unsubstituted or optionally substituted with 1 , 2, 3, 4 or 5 substituent(s). Said substituent(s) are preferably independently selected from the group consisting of oxo (=0), d-8-alkyl, -O-Ci-8-alkyl, -S-C1-8-alkyl, -C(=O)-OH, -C(=O)-Ci-8-alkyl, -C(=O)-O-C1-8-alkyl, -O-C(=O)-C1-5-alkyl> F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH(Ci-8-alkyl), -N(C1-8-alkyl)2, -N(C1-8-alkyl)3 +, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(C1-8-alkyl), -C(=O)-N(C1-8-alkyl)2, -S(=O)2-Ci-8-alkyl, -S(=O)2-phenyl, phenyl, phenethyl, phenoxy and benzyl, whereby in each occurrence Ci-8-alkyl is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n- propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, I -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2 and -NO2.
More preferably said substituent(s) are preferably independently selected from the group consisting Of -CH3, -C2H5, -CH2-CH2-CH3, -CH(CH3)2, -C(CH3)3> F, Cl, Br, I, -OH, -SH, -NH2, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -0-CH3, -0-C2H5, -0-CH2-CH2-CH3, -O-CH(CH3)2, -O-C(CH3)3, -S-CH3, -S-C2H5, -S-CH2-CH2-CH3, -S-CH(CHa)2, -S-C(CH3)3, -O-Si-(CH3)3, -O-Si-(CH2-CH3)3, -O-Si-[CH(-CH3)2]3, -NH-CH3, -NH-C2H5, -NH-CH2-CH2-CH3, -NH-CH(CH3)2, -NH-C(CH3)3, -N(CH3)2, -N(C2H5)2, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence the alkyl chain in these radicals is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, I -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, - SH, -NH2 and -NO2.
If any of the substituent(s) in any of the herein defined formulae represents or comprises a (hetero)cycloaliphatic radical, i.e. a cycloaliphatic or a heterocycloaliphatic radical, including a C3-g (hetero)cycloalkyl radical, i.e. a C3-9cycloalkyl radical or a C3-g heterocycloalkyl radical, which contains one or more, preferably 1 , 2 or 3 heteroa- tom(s) as ring member(s), unless defined otherwise, each of these heteroatom(s) is/are preferably independently selected from the group consisting of nitrogen, oxygen and sulphur.
If any of the substituent(s) in any of the herein defined formulae represents or comprises a C3-9(hetero)cycloalkyl radical, i.e. a C3-9 cycloalkyl or a C3-9 heterocycloalkyl radical, which contains optionally 1 or 2 additional heteroatom(s) as ring member(s), unless defined otherwise, each of these heteroatom(s) is/are preferably independently selected from the group consisting of nitrogen, oxygen and sulphur.
Suitable saturated, optionally at least one heteroatom as ring member containing (hetero)cycloaliphatic radicals, i.e. cycloaliphatic or heterocycloaliphatic radicals, C3-9 (hetero)cycloalkyl radicals, i.e. C3-9 cycloalkyl or C3-9 heterocycloalkyl radicals are preferably selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, azetidinyl, tetrahydrofuranyl, azepanyl, diazepanyl and azocanyl.
If any of the substituents in any of the herein defined formulae represents an alkylene group, including an C-ι-6 alkylene group said alkylene group or C-i-β alkylene group, is unsubstituted or substituted with one or more substituents, preferably unsubstituted or optionally substituted with 1 , 2, 3, 4 or 5 substituent(s). Said substituent(s) is/are preferably independently selected from the group consisting of -O-C1-5-alkyl, -S-Ci-5- alkyl, -F, Cl, Br, I1 -CN, -CF3, -OCF3, -SCF3, -OH, -SH, -NH2, -NH(C1-5-alkyl) and -N(Ci-5-alkyl)2, whereby in each occurrence C-ι-5-alkyl may be linear or branched.
Suitable alkylene groups include -(CH2)-, -CH(CH3)-, -(CH2J2-, -(CH2)3-, -(CH2J4-, -(CH2J5 and -(CH2J6-.
If any of the substituents in any of the herein defined formulae represents or comprises an aryl radical, including a 6-membered aryl radical such as phenyl or a 10- membered aryl radical such as naphthyl or a 14-membered aryl radical such as an- thracenyl radical, said aryl radical is - if not defined otherwise - unsubstituted or substituted with one or more substituents, preferably unsubstituted or optionally substituted with 1 , 2, 3, 4 or 5 substituent(s). Said substituent(s) is/are preferably independently selected from the group consisting of oxo (=O), Ci-8-alkyl, -O-Ci-8-alkyl, -S-Ci-8-alkyl, -C(=O)-OH, -C(=O)-C1-8-alkyl, -C(=O)-O-Ci.8-alkyl, -O-C(=O)-C1-8-alkyl, F, Cl, Br1 I, -CN1 -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H1
-OH, -SH, -NH2, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -N(C1-8-alkyl)3 +, -NO2, -CHO, -CF2H1 -CFH2, -C(=O)-NH2, -C(=O)-NH(C1-8-alkyl), -C(=O)-N(C1-8-alkyl)2, -S(=O)2-Ci-8-alkyl, -S(=O)2-phenyl, -O-Si-(C1-8-alkyl)3, -CH2-Si-(C1-8-alkyl)3, -Si-(Ci-8-alkyl)3, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence Ci-8-alkyl is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, I -CN, - CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2 and -NO2.
More preferably said substituent(s) is/are preferably independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH2, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -O-CH3, -0-C2H5, -0-CH2-CH2-CH3, -O-CH(CH3)2, -O-C(CH3)3, -S-CH3, -S-C2H5, -S-CH2-CH2-CH3, -S-CH(CH3)2, -S-C(CH3)3, -O-Si-(CH3)3, -O-Si-(CH2-CH3)3, -O-Si-[CH(-CH3)2]3, -Si-(CH3)3, -CH2-Si-(CH3)3, -NH-CH3, -NH-C2H5, -NH-CH2-CH2-CH3, -NH-CH(CH3)2, -NH-C(CH3)3, -N(CH3)2, -N(C2H5)2, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence the alkyl chain in these radicals is linear or branched the cyclic part(s) of said substituent(s) is/are unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, I -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2 and -NO2.
Preferred aryl radicals, which are unsubstituted or at least mono-substituted, are phenyl and naphthyl.
If any of the substituents in any of the herein defined formulae represents or comprises a heteroaryl radical, including a monocyclic 5- or 6-membered heteroaryl radical or a bi- or tricyclic 8-, 9-, 10-, 11-, 12-, 13- or 14- membered heteroaryl radical, said heteroaryl radical is - if not defined otherwise - unsubstituted or substituted with one or more substituents, preferably unsubstituted or optionally substituted with 1 , 2, 3, 4 or 5 substituent(s). Said substituent(s) is/are preferably independently selected from the group consisting of oxo (=0), Ci-8-alkyl, -O-Ci-8-alkyl, -S-Ci-8-alkyl, -C(=O)-OH, -C(=O)-C1-8-alkyl, -C(=O)-O-Ci-8-alkyl, -O-C(=O)-C1-8-alkyl, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH(Ci-8-alkyl), -N(C1-8-alkyl)2l -N(C1-8-alkyl)3\ -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2>
-C(=O)-NH(C1-8-alkyl), -C(=O)-N(Ci-8-alkyl)2, -S(=O)2-C1-8-alkyl, -S(=O)2-phenyl, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence Ci-β-alkyl is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, I -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2 and -NO2.
More preferably said substituent(s) is/are preferably independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH2, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -CH3, -C2H5, -CH2-CH2-CH3, -0-CH3, -O-C2H5, -0-CH2-CH2-CH3, -O-CH(CH3)2, -O-C(CH3)3, -S-CH3, -S-C2H5, -S-CH2-CH2-CH3, -S-CH(CH3)2) -S-C(CH3J3, -O-Si-(CH3)3, -O-Si-(CH2-CH3)3, -O-Si-[CH(-CH3)2]3, -NH-CH3, -NH-C2H5, -NH-CH2-CH2-CH3, -NH-CH(CHa)2, -NH-C(CH3)3, -N(CH3)2, -N(C2H5)2, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence Ci.8-alkyl is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, I -CN, - CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2 and -NO2.
The heteroatom(s), which are present as ring member(s) in the heteroaryl radical, may, unless defined otherwise, independently be selected from the group consisting of nitrogen, oxygen and sulphur. Preferably the heteroaryl radical comprises 1 , 2, 3 or 4 heteroatom(s).
Suitable heteroaryl radicals, which are optionally at least mono-substituted, are preferably selected from the group consisting of pyridinyl, pyrrolyl, imidazolyl, pyrazolyl, indolyl, benzotriazolyl, quinolyl and isoquinolyl.
Suitable monocyclic 5- or 6-membered heteroaryl radicals, which are unsubstituted or at least mono-substituted, are preferably selected from the group consisting of pyridinyl, pyrrolyl, imidazolyl and pyrazolyl.
A mono-, bi-, or polycyclic ring system according to the present invention - if not defined otherwise - means a mono-, bi-, or polycyclic hydrocarbon ring system that is
saturated or aromatic. Optionally each of the rings of the mono- or bicyclic ring system may contain one or more, preferably 1 , 2 or 3, heteroatom(s) as ring member(s), which may be independent from one another and which can preferably be selected from the group consisting of nitrogen, oxygen and sulphur. The rings of the mono- or bicyclic ring system are preferably 5-, 6- or 7-membered.
Preferably an aromatic mono-or bicyclic ring system according to the present invention is a phenyl or naphthyl ring system.
The term "condensed" according to the present invention means that a ring or ring system is attached to another ring or ring system, whereby the terms "annulated" or "annelated" are also used by those skilled in the art to designate this kind of attachment.
Such a mono-, bi-, or polycyclic ring system is - if not defined otherwise - unsubstituted or substituted with one or more substituents, preferably unsubstituted or optionally substituted with 1 , 2, 3, 4 or 5 substituent(s). Said substituent(s) is/are preferably independently selected from the group consisting of oxo (=O), Ci-8-alkyl, -O-d-8-alkyl, -S-C1-8-alkyl, -C(=O)-OH, -C(=O)-C1-8-alkyl, -C(=O)-O-Ci-8-alkyl, -O-C(=O)-C1-8-alkyl, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -N(C1-8-alkyl)3\ -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(Ci-8-alkyl), -C(=O)-N(C1-8-alkyl)2> -S(=O)2-C1-8-alkyl, -S(=O)2-phenyl, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence Ci-8-alkyl is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, I -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2 and -NO2.
More preferably said substituent(s) is/are preferably independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH2, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -CH3, -C2H5, -CH2-CH2-CH3, -CH(CH3)2, -C(CH3)3, -0-CH3, -0-C2H5, -0-CH2-CH2-CH3, -O-CH(CH3)2, -O-C(CH3)3, -S-CH3, -S-C2H5, -S-CH2-CH2-CH3, -S-CH(CH3)2, -S-C(CHa)3, -O-Si-(CH3)3, -O-Si-(CH2-CH3)3l -O-Si-[CH(-CH3)2]3, -Si-(CH3)3, -CH2-Si-(CH3)3, -NH-CH3, -NH-C2H5, -NH-CH2-CH2-CH3, -NH-CH(CH3)2,
-NH-C(CH3)3, -N(CH3)2, -N(C2Hs)2, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence the alkyl chain in these radicals is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl1 Br, I -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2 and -NO2.
Preferred is a compound of general formula (I),
wherein
R1 and R2, independent from one another, each represents a hydrogen atom; a halogen atom; -NO2; -OR8; -SR9; -CN; -NR10R11; -COOR12; -COR13; -CONR14R15; -OCOR16; -NR17-COR18; -NR19-COO-R20; -SO2-R21; -SO2-O-R22; -SO2-NR23R24;
a linear or branched, unsubstituted or at least mono-substituted CMS alkyl radical;
an unsubstituted or at least mono-substituted 6-, 10- or 14-membered mono-, bi- or tricyclic aryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted
group and/or which may be condensed with an unsubstituted or at least mono-substituted, saturated or aromatic mono- or bicyclic ring system; or
R1 and R2 are fused to form together an additional aromatic mono- or polycyclic ring system having from 4 to 10 carbon atoms;
R3 represents an unsubstituted or at least mono-substituted, saturated, optionally at least one heteroatom as ring member containing C3-9(hetero)cycloalkyl radical, which may be condensed with an unsubstituted or at least mono-substituted saturated or aromatic mono- or bicyclic ring system;
or
an unsubstituted or at least mono-substituted 6-, 10- or 14-membered mono-, bi- or tricyclic aryl or a 5-, 6-, 8-, 9-, 10-, 11 -, 12-, 13- or 14-membered mono-, bi- or tricyclic heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted saturated or aromatic mono- or bicyclic ring system;
R4 represents a hydrogen atom; a linear or branched, unsubstituted or at least mono- substituted C-1-6 alkyl radical;
with the provision that if q = 1 , then
k = 1 ;
R5, R6 and R7, independent from one another, each represents a linear or branched, unsubstituted or at least mono-substituted Ci-6 alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -O-C-ι-6 alkyl radical;
an unsubstituted or at least mono-substituted C3-g cycloalkyl radical;
an unsubstituted or at least mono-substituted 6-, 10- or 14-membered mono-, bi- or tricyclic aryl radical which may be condensed with an unsubstituted or at least mono-substituted aromatic mono- or bicyclic ring system;
or R5, R6 and R7, independent from one another, each represents a radical of general formula (II)
(H) wherein
P = O, 1 , 2 or 3;
R25, R26, R27, R28 and R29, independent from one another, each represents a linear or branched, unsubstituted C1-6 alkyl radical; a linear or branched, unsubstituted -O-Ci-6 alkyl radical; an unsubstituted or at least mono-substituted 6-, 10- or 14- membered mono-, bi- or tricyclic aryl radical; or an -O-Si(R30)3 radical, with R30 representing a linear or branched, unsubstituted or at least mono-substituted C-i-6 alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -O-C1-6 alkyl radical; an unsubstituted or at least mono-substituted 6-, 10- or 14- membered mono-, bi- or tricyclic aryl radical;
with the condition that if q = 1 and at the same time k = 1 , at least one of the radicals R5, R6 and R7 represents a radical of general formula (II) as defined above;
or, with the provision that if q = 2, then
k = 0;
R7 represents a radical of general formula (III)
(III) wherein
m = 0, 1 , 2, 3, 4 or 5;
X represents an oxygen atom or an unsubstituted or at least mono-substituted C-ι-4 alkylene radical;
R31, R32, R33 and R34, independent of one another, each represents a linear or branched, unsubstituted or at least mono-substituted C-ι-6 alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -O-Ci-β alkyl radical;
an unsubstituted or at least mono-substituted C3-9 cycloalkyl radical;
an unsubstituted or at least mono-substituted 6-, 10- or 14-membered mono-, bi- or tricyclic aryl radical which may be condensed with an unsubstituted or at least mono-substituted aromatic mono- or bicyclic ring system;
or an -O-Si(R30)3 radical, with R30 representing a linear or branched, unsubstituted or at least mono-substituted C-i-β alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -0-C1-6 alkyl radical or an unsubstituted or at least mono-substituted 6-, 10- or 14-membered mono-, bi- or tricyclic aryl radical;
R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23 and R24, independent of one another, have the above-defined meaning;
whereby
the aforementioned CMS alkyl radicals are in each case unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (=0), F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-d-β-alkyl, -O-Si-(Ci-8-alkyl)3, -Si-(C1-8-alkyl)3, -Si-(phenyl)3, -S-C1-8-alkyl, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -N(Ci-8-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence the alkyl chain of the aforementioned Ci-i8- alkyl and/or Ci-8-alkyl radicals is linear or branched;
the aforementioned Ci-β alkyl radicals are in each case unsubstituted or substituted with 1 , 2, 3, 4 or 5, substituent(s) independently selected from the group consisting of oxo (=0), F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-C1-6-alkyl, -O-Si-(Ci-6-alkyl)3 ,-S-Ci-6-alkyl, -Si-(Ci-6-alkyl)3, -Si-(phenyl)3, -NH(C1-6-alkyl), -N(Ci-6-alkyl)2) -N(d-6-alkyl)3 +, phenyl, benzyl, phenethyl and
phenoxy; whereby in each occurrence the alkyl chain of the aforementioned Ci-6-alkyl radicals is linear or branched;
the aforementioned -O-C1-6 alkyl radicals are in each case unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (=0), F, Cl, Br, I1 -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-d-e-alkyl, -O-Si-(C1-6-alkyl)3, -S-d-e-alkyl, -Si-(C1-6-alkyl)3l -Si-(phenyl)3, -NH(C1-6-alkyl), -N(C1-6-alkyl)2, -N(C1.6-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence the alkyl chain of the aforementioned Ci-6-alkyl radicals is linear or branched;
the aforementioned C3-g (hetero)cycloalkyl radicals are in each case unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (=0), Ci-8-alkyl, -O-Ci-8-alkyl, -S-Ci-8-alkyl, -C(=O)-OH, -C(=O)-C1-8-alkyl, -C(=O)-O-Ci-8-alkyl, -O-C(=O)-C1-5-alkyl, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -NCd^-alky!^, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(C1-8-alkyl), -C(=O)-N(Ci-8-alkyl)2, -S(=O)2-C1-8-alkyl, -S(=O)2-phenyl, phenyl, phenethyl, phenoxy and benzyl, whereby in each occurrence C-i-8-alkyl is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, I -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2 and -NO2;
the aforementioned C3-g heterocycloalkyl radicals contain in each case optionally 1 , 2 or 3 additional heteroatom(s) independently selected from the group consisting of nitrogen, sulphur and oxygen as ring member(s);
the aforementioned C3-9 cycloalkyl radicals contain in each case optionally 1 , 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, sulphur and oxygen as ring member(s);
the aforementioned d^ alkylene, preferably -(CH2)-, -(CH2)2-, -(CH2)3- and -(CH2)4- groups are in each case linear or branched, unsubstituted or substituted with 1 , 2 or
3 substituent(s) independently selected from the group consisting of F, Cl, Br1 I, -CN, -CF3, -OCF3, -SCF3, -OH, -SH, -NH2, -O-C1-6-alkyl, -S-C1-6-alkyl, -NH(Ci-6-alkyl) and -N(C1-6-alkyl)2;
the aforementioned Ci-6 alkylene, preferably -(CH2)-, -(CH2)2-, -(CH2)3-, -(CH2)4- , -(CH2)5- and -(CH2)6- groups are in each case unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -OH, -SH, -NH2, -O-C1-6-alkyl, -S-C1-6-alkyl, -NH(C1-6-alkyl) and -N(C1-6-alkyl)2;
the rings of the aforementioned ring systems are in each case independently of each other 5-, 6-, 7-, 8-, 9,- or 10-membered and may in each case independently of one another optionally contain 1 , 2, 3 or 4 heteroatom(s) independently selected from the group consisting of nitrogen, sulphur and oxygen;
and the rings of the aforementioned mono-, bi- or polycyclic ring systems are in each case unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (=0), Ci-8-alkyl, -O-Ci-8-alkyl, -S-C1-8-alkyl, -C(=O)-OH, -C(=O)-C1-8-alkyl, -C(=O)-O-C1-8-alkyl, -O-C(=O)-C1-5-alkyl, F, Cl, Br1 I, -CN, -CF3, -OCF3, -SCF3, -SO3Na1 -SO3K1 -SO3H1 -OH1 -SH1 -NH2, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -N(Ci-8-alkyl)3 +, -NO2, -CHO1 -CF2H1 -CFH2, -C(=O)-NH2l -C(=O)-NH(C1-8-alkyl), -C(=O)-N(C1-8-alkyl)2, -S(=O)2-C1-8-alkyl, -S(=O)2-phenyl, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence Ci-8-alkyl is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl1 Br1 I -CN, -CF3, -OCF3, -SCF3, -SO3Na1 -SO3K1 -SO3H1 -OH1 -SH1 -NH2 and -NO2;
the 6-, 10- or 14-membered, mono-, bi- or tricyclic aryl or 5-, 6-, 8-, 9-, 10-, 11-, 12-, 13- or 14-membered mono-, bi- or tricyclic heteroaryl radicals are unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (=0), C1-8-alkyl, -O-C1-8-alkyl, -S-C1-8-alkyl, -C(=O)-OH, -C(=O)-C1-8-alkyl, -C(=O)-O-C1-8-alkyl, -O-C(=O)-C1-8-alkyl, F, Cl1 Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH(Ci-8-alkyl),
-N(C1-8-alkyl)2, -N(C1-8-alkyl)3 +, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(C1-8-alkyl), -C(=O)-N(Ci-8-alkyl)2, -S(=O)2-Ci-8-alkyl, -S(=O)2-phenyl, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence Ci-8-alkyl is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, I -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2 and -NO2;
the aforementioned aromatic mono- or polycyclic ring system having from 4 to 10 carbon atoms are in each case unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (=O), C1-8-alkyl, -O-C1-8-alkyl, -S-Ci-8-alkyl, -C(=O)-OH, -C(=O)-C1-8-alkyl, -C(=O)-O-C1-8-alkyl, -O-C(=O)-C1-5-alkyl, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -N(C1-8-alkyl)3 +, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2> -C(=O)-NH(C1-8-alkyl), -C(=O)-N(C1-8-alkyl)2> -S(=O)2-Ci-8-alkyl, -S(=O)2-phenyl, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence Ci-β-alkyl is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, I -CN1 -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2 and -NO2;
and the aforementioned 5-, 6-, 8-, 9-, 10-, 11-, 12-, 13- or 14-membered mono-, bi- or tricyclic heteroaryl radicals in each case contain 1 , 2, 3 or 4 heteroatom(s) independently selected from the group consisting of nitrogen, sulphur and oxygen as ring member(s);
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred is a compound of general formula (I),
wherein
q = 1 ; k= 1 ;
and
r P>1 K D1 1 DK2 1 DK3 1 I CX?4 1 DK5 1 D(A6 I DrA7 1 DK8i DK9i DK10 , CK?1 1 , DK12 , DK13 , DK14 , OK15 , DK16 , EK?17 , OK18 , DK19 ,
R20, R21, R22, R23, R24, R25, R26, R27, R28, R29 and R30 have the above-defined meaning;
with the condition that at least one of the radicals R5, R6 and R7 represents a radical of general formula (II) as defined above;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred is a compound of general formula (I),
wherein
q = 2; k = 0;
and
m, p, X, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R30, R31, R32, R33 and R34 have the above-defined meaning;
optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoi-
somers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred is a compound of general formula (I),
wherein
q = 2; k = 0; m = 0;
and
r-» V D1 D2 D3 D4 D5 nδ D? D8 O9 D1O D-H D12 D"I3 D14 D1S D16 D1? D18 D19 p, Λ, r\ , ι\ , Γ\ , IX , Γ\ , r\ I IΛ I IΛ , IΛ , Γ\ , r\ , r\ i r\ , r\ , r\ , r\ , r\ , r\ , r\ ,
R20, R21, R22, R23, R24, R30, R31, R32, R33 and R34 have the above-defined meaning;
optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred is a compound of general formula (I),
wherein
q = 2; k = 0; m = 1;
and
r% V D-I D2 D3 D4 D5 D6 D? D8 D9 D1O D11 D12 D13 CS14 D1S D16 T~>W D18 D19 P, Λ, R 1 R 1 R I rX 1 R i R 1 R i R 1 R 1 R , R , R , R , R , R , R , R , R , R ,
R20, R21, R22, R23, R24, R30, R31, R32, R33 and R34 have the above-defined meaning;
optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoi-
somers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred is a compound of general formula (I),
wherein
q = 2; k = 0; m = 2;
and
r P>, Λ Y, P1 R2 D3 P4 P5 P6 P7 P8 P9 P10 , P R11 , P R12 , PR13 , P R14 , P R15 , PPA16 , PIA17 , PR18 , P R19 ,
R20, R21, R22, R23, R24, R30, R31, R32, R33 and R34 have the above-defined meaning;
optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred is a compound of general formula (I),
wherein
q = 2; k = 0; m = 3;
and
n V D1 D2 D3 D4 D5 D6 D7 D8 D9 p10 D11 p12 D13 D-I4 p15 D16 D17 D18 D19 P, Λ, R , R , R , R , R , R , R , R 1 R , R , R , R , R , R , R , R , R , R , R ,
R20, R21, R22, R23, R24, R30, R31, R32, R33 and R34 have the above-defined meaning;
optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoi-
somers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred is a compound of general formula (I),
wherein
R1 and R2, independent from one another, each represents a a hydrogen atom; F; Cl; Br; I; -NO2; -OR8; -SR9; -CN; -NR10R11; -COOR12; -COR13; -CONR14R15; -OCOR16; -NR17-COR18; -NR19-COO-R20; -SO2-R21; -SO2-O-R22; -SO2-NR23R24;
a linear or branched, unsubstituted or at least mono-substituted Ci--I8 alkyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (=0), F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-C1-8-alkyl, -O-Si-(C1-8-alkyl)3, -Si-(C1-8-alkyl)3, -S-C1-8-alkyl, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -N(Ci-8-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy;
a phenyl or naphthyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of Ci-8-alkyl, -O-C1-8-alkyl, -S-C1-8-alkyl, -C(=O)-OH, -C(=O)-C1-8-alkyl, -C(=O)-O-C1-8-alkyl, -O-C(=O)-C1-5-alkyl, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -N(C1-8-alkyl)3 +, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(C1-8-alkyl), -C(=O)-N(Ci-8-alkyl)2, -S(=O)2-Ci-8-alkyl, -S(=O)2-phenyl, phenyl, phenethyl, phenoxy and benzyl;
or
R1 and R2 are fused to form together a phenyl or naphthyl radical which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of C1-8-alkyl, -O-Ci-8-alkyl, -S-Ci-8-alkyl, -C(=O)-OH, -C(=O)-C1-8-alkyl, -C(=O)-O-Ci-8-alkyl, -O-C(=O)-C1-5-alkyl, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH(C1-8-alkyl), -N(Ci-8-alkyl)2, -N(C1-8-alkyl)3 +, -NO2, -CHO, -CF2H, -CFH2,
-C(=O)-NH2, -C(=O)-NH(C1-8-alkyl), -C(=O)-N(Ci-8-alkyl)2, -S(=O)2-Ci-8-alkylI -S(=O)2-phenyl, phenyl, phenethyl, phenoxy and benzyl; and
m, k, p, q, X, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33 and R34 have the above-defined meaning;
with the condition that if q = 1 and at the same time k = 1 , at least one of the radicals R5, R6 and R7 represents a radical of general formula (II) as defined above;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred is a compound of general formula (I),
wherein
R3 represents a (hetero)cycloaliphatic radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, azetidinyl, tetrahydrofuranyl, azepanyl, diazepanyl and azocanyl, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (=O), Ci-8-alkyl, -O-Ci-8-alkyl, -S-d-β-alkyl, -C(=O)-OH, -C(=O)-C1-8-alkyl, -C(=O)-O-C1-8-alkyl, -O-C(=O)-C1-5-alkyl, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH(C1-8-alkyl), -N(Ci-8-alkyl)2, -N(C1-8-alkyl)3 +, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(C1-8-alkyl), -C(=O)-N(C1-8-alkyl)2, -S(=O)2-Ci-8-alkyl, -S(=O)2-phenyl, phenyl, phenethyl, phenoxy and benzyl;
or
an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, pyridinyl, pyrrolyl, imidazolyl, pyrazolyl, indolyl, benzotriazolyl, quinolyl and isoquinolyl, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 sub- stituent(s) independently selected from the group consisting of Ci-8-alkyl, -O-d-β-alkyl, -S-Ci-8-alkyl, -C(=O)-OH, -C(=O)-Ci^-alkyl, -C(=O)-O-C1-8-alkyl, -O-C(=O)-C1-5-alkyl, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -N(C1-8-alkyl)3 +, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(C1-8-alkyl), -C(=O)-N(Ci-8-alkyl)2, -S(=O)2-Ci-8-alkyl, -S(=O)2-phenyl, phenyl, phenethyl, phenoxy and benzyl;
and
m, k, p, q, X, R1, R2, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26R27, R28, R29, R30, R31, R32, R33 and R34 have the above-defined meaning;
with the condition that if q = 1 and at the same time k = 1 , at least one of the radicals R5, R6 and R7 represents a radical of general formula (II) as defined above;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred is a compound of general formula (I),
wherein
R4 represents a hydrogen atom; a linear or branched, unsubstituted or at least mono- substituted Ci-i8 alkyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of oxo (=0), F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-C1-8-alkyl, -O-Si-(Ci-8-alkyl)3, -Si-(C1-8-alkyl)3, -S-Ci-8-alkyl, -NH(Ci-8-alkyl), -N(Ci-8-alkyl)2) -N(C1-8-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy;
and
m, k, p, q, X, R1, R2, R3, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26R27, R28, R29, R30, R31, R32, R33 and R34 have the above-defined meaning;
with the condition that if q = 1 and at the same time k = 1 , at least one of the radicals R5, R6 and R7 represents a radical of general formula (II) as defined above;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred is a compound of general formula (I),
wherein
q = 1 k = 1 ;
R5, R6 and R7, independent from one another, each represents a linear or branched, unsubstituted or at least mono-substituted Ci--I8 alkyl radical which is unsubstituted or substituted with 1 , 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of oxo (=O), F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-C1-8-alkyl, -O-Si-(Ci-8-alkyl)3, -O-Si-(phenyl)3) -Si-(C-i-8-alkyl)3, -Si-(phenyl)3,-S-Ci-8-alkyl, -NH(Ci-8-alkyl), -N(Ci-8-alkyl)2, -N(Ci-8-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy;
a linear or branched, unsubstituted or at least mono-substituted -0-CM8 alkyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-C1-8-alkyl,
-O-Si-(C1-8-alkyl)3, -Si-(Ci-8-alkyl)3, -S-C1-8-alkyl, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -N(Ci-8-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy;
a phenyl or naphthyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of Ci-8-alkyl, -O-C1-8-alkyl, -S-C1-8-alkyl, -C(=O)-OH, -C(=O)-Ci-8-alkyl, -C(=O)-O-Ci-8-alkyl, -O-C(=O)-C1-5-alkyl, F, Cl, Br1 I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -N(C1-8-alkyl)3\ -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(C1-8-alkyl), -C(=O)-N(C1-8-alkyl)2, -S(=O)2-Ci-8-alkyl, -S(=O)2-phenyl, phenyl, phenethyl, phenoxy and benzyl;
or
R5, R6 and R7, independent from one another, each represents a radical of general formula (II)
("I) wherein
P = O, 1 , 2 or 3;
R25, R26, R27, R28 and R29, independent from one another, each represents a linear or branched, unsubstituted Ci-i8 alkyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of oxo (=0), F, Cl, Br, I1 -CN, -CF3, -OCF3, -SCF3, -SO3Na1 -SO3K1 -SO3H, -OH1 -SH1 -NH2, -O-C1-8-alkyl, -O-Si-(C1-8-alkyl)3> -O-Si-(phenyl)3l -Si-(C1-8- alkyl)3, -Si-(phenyl)3, -S-C1-8-alkyl, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -N(C1-8-alkyl)3\ phenyl, benzyl, phenethyl and phenoxy;
a linear or branched, unsubstituted or at least mono-substituted -O-C-MS alkyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of F1 Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-C1-8-alkyl,
-Si-(Ci-8-alkyl)3, -Si-(phenyl)3, -S-Ci-8-alkyl, -NH(C1-8-alkyl), -N(Ci-8-alkyl)2, -N(Ci-8-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy;
a phenyl or naphthyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of C-i-8-alkyl, -O-Ci-8-alkyl, -S-Ci-8-alkyl, -C(=O)-OH, -C(=O)-C1-8-alkyl, -C(=O)-O-C1-8-alkyl, -O-C(=O)-Ci-5-alkyl, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH(Ci-8-alkyl), -N(C1-8-alkyl)2, -N(Ci-8-alkyl)3\ -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(C1-8-alkyl), -C(=O)-N(C1-8-alkyl)2, -S(=O)2-Ci-8-alkyl, -S(=O)2-phenyl, phenyl, phenethyl, phenoxy and benzyl;
or an -O-Si(R30)3 radical, with R30 representing a linear or branched, unsubstituted or at least mono-substituted Ci-6 alkyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5, substituent(s) independently selected from the group consisting of oxo (=0), F, Cl, Br, I, -CN1 -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H1 -OH1 -SH1 -NH2, -O-C1-6-alkyl, -O-Si-(C1-6-alkyl)3, -S-C1-6-alkyl, -Si-(Ci-6-alkyl)3l -NH(Ci-6-alkyl), -N(Ci-6-alkyl)2, -N(C1-6-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence the alkyl chain of the aforementioned C-ι-6-alkyl radicals is linear or branched; a linear or branched, unsubstituted or at least mono-substituted -O-Ci-β alkyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5, substituent(s) independently selected from the group consisting of F1 Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na1 -SO3K, -SO3H, -OH1 -SH1 -NH2, -O-C1-6-alkyl, -O-Si-(C1-6-alkyl)3l -S-C1-6-alkyl, -Si-(C1-6-alkyl)3, -NH(Ci-6-alkyl), -N(C1-6-alkyl)2, -Ntd-e-alkyl)^, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence the alkyl chain of the aforementioned Ci-6-alkyl radicals is linear or branched;
with the condition that at least one of the radicals R5, R6 and R7 represents a radical of general formula (II) as defined above;
and
R1 ,
, Dι\17 , D ΓΛ18 , Dr\19 , Dr\20 , Dr\21 , Dr\22 , r D\23 and R24 have the above-defined meaning;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred is a compound of general formula (I),
wherein
q = 2; k = 0;
R7 represents a radical of general formula (III)
(III) wherein
m = 0, 1 , 2, 3, 4 or 5;
X represents an oxygen atom or an unsubstituted or at least mono-substituted Ci-4 alkylene radical;
R31, R32, R33 and R34, independent of one another, each represents a linear or branched, unsubstituted or at least mono-substituted CMS alkyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of oxo (=0), F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-Ci-8-alkyl, -O-Si-(C1-8-alkyl)3, -Si-(Ci-8-alkyl)3, -S-C1-8-alkyl, -NH(Ci-8-alkyl), -N(C1-8-alkyl)2, -N(Ci-8-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy;
a linear or branched, unsubstituted or at least mono-substituted -0-C-M8 alkyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-C1-8-alkyl, -O-Si-(Ci-8-alkyl)3, -Si-(Ci-8-alkyl)3, -S-C1-8-alkyl, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -N(Ci-8-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy;
a C3-9 cycloalkyl radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of Ci-8-alkyl, -O-Ci-8-alkyl, -S-Ci-8-alkyl, -C(=O)-OH, -C(=O)-C1-8-alkyl, -C(=O)-O-Ci-8-alkyl, -O-C(=O)-C1-5-alkyl, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH1 -NH2, -NH(C1-8-alkyl), -N(Ci-8-alkyl)2, -N(C1-8-alkyl)3 +, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2) -C(=O)-NH(Ci-8-alkyl), -C(=O)-N(C1-8-alkyl)2, -S(=O)2-C1-8-alkyl, -S(=O)2-phenyl, phenyl, phenethyl, phenoxy and benzyl, whereby in each occurrence Ci-8-alkyl is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, I -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2 and -NO2;
a phenyl or naphthyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of Ci-8-alkyl, -O-d-β-alkyl, -S-C1-8-alkyl, -C(=O)-OH, -C(=O)-Ci-8-alkyl, -C(=O)-O-C1-8-alkyl, -O-C(=O)-C1-5-alkyl, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H,
-OH, -SH, -NH2, -NH(Ci-8-alkyl), -N(C1-8-alkyl)2, -N(C1-8-alkyl)3 +, -NO2, -CHO1 -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(Ci-8-alkyl), -C(=O)-N(C1-8-alkyl)2, -S(=O)2-Ci-8-alkyl, -S(=O)2-phenyl, phenyl, phenethyl, phenoxy and benzyl;
or an -O-Si(R30)3 radical, with R30 representing a linear or branched, unsubstituted or at least mono-substituted Ci-6 alkyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5, substituent(s) independently selected from the group consisting of oxo (=O), F, Cl, Br, I1 -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-C1-6-alkyl, -O-Si-(C1-6-alkyl)3, -S-d-β-alkyl, -Si-(C1-6-alkyl)3, -NH(Ci-6-alkyl), -N(C1-6-alkyl)2, -N(C1-6-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence the alkyl chain of the aforementioned Ci-6-alkyl radicals is linear or branched; a linear or branched, unsubstituted or at least mono-substituted -O-d-β alkyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5, substituent(s) independently selected from the group consisting of F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-Ci-6-alkyl, -O-Si-(C1-6-alkyl)3, -S-d-6-alkyl, -Si-(Ci-6-alkyl)3, -NH(d-6-alkyl), -N(C1-6-alkyl)2, -N(Ci-6-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence the alkyl chain of the aforementioned d-6-alkyl radicals is linear or branched;!
and
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred is a compound of general formula (I),
wherein
q = 1 or 2;
k = 0 or 1 ;
R1 and R2, independent from one another, each represents a hydrogen atom; F; Cl; Br; I; -NO2; -NH2; -SH; -OH; -CN; -C(=O)-OH; -C(=O)-OCH3, -C(=O)-OCH2CH3, -C(=O)-NH2; -S(=O)2-OH; -S(=O)2-NH2; -S(=O)2-Phenyl;
a radical selected from the group consisting of -0-CH3, -0-CH2-CH3, -0-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH2-CH3 and -0-CH2-CH2-CH2-CH2-CH2-CH2-CH3; whereby in each occurrence the alkyl chain is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of F, Cl, Br, I, -OH1 -SH, -NH2, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -0-CH3, -0-C2H5, -S-CH3, -O-Si-(CH3)3, -O-Si-(CH2-CH3)3> -Si-[CH(-CH3)2]3, -Si-(CH3)3) -Si-(CH2-CH3)3, -Si-[CH(-CH3)2]3, -NH-CH3 and -N(-CH3)2; and whereby in each occurrence the alkyl chain of these radicals is linear or branched; or
a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted or substituted with 1 , 2, 3, 4, or 5 substituents independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH2, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K1 -SO3H, -0-CH3, -0-C2H5, -S-CH3, -O-Si-(CH3)3) -O-Si-(CH2-CH3)3, -O-Si-[CH(-CH3)2]3, -Si-[CH(-CH3)2]s, -Si-(CH3)3, -Si-(CH2-CH3)3, -Si-[CH(-CH3)2]3, -NH-CH3 and -N(-CH3)2; whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
R3 represents a (hetero)cycloaliphatic radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, azetidinyl, tetrahydrofuranyl, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, n-pentyl, -O-CH3, -0-C2H5, -0-CH2-CH2-CH3, -O-CH(CH3)2, -O-C(CH3)3> -S-CH3, -S-C2H5,
-S-CH2-CH2-CH3, -S-CH(CHa)2, -S-C(CH3)3, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-CH2-CH2-CH3, -C(=O)-CH(CH3)2, -C(=O)-C(CH3)3> F, Cl, Br1 I, -CN, -CF3, -OCF3, -SCF3, -S(=O)2-Phenyl, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH-CH3, phenyl, phenethyl, phenoxy and benzyl;
or
an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, pyridinyl, pyrrolyl, imidazolyl, pyrazolyl, indolyl, benzotriazolyl, quinolyl and isoquinolyl, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, n-pentyl, -0-CH3, -0-C2H5, -0-CH2-CH2-CH3, -O-CH(CH3)2, -O-C(CH3)3, -S-CH3, -S-C2H5, -S-CH2-CH2-CH3, -S-CH(CH3)2, -S-C(CH3)3, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-CH2-CH2-CH3, -C(=O)-CH(CH3)2, -C(=O)-C(CH3)3, F, Cl, Br1 I, -CN, -CF3, -OCF3, -SCF3, -S(=O)2-Phenyl, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH-CH3, phenyl, phenethyl, phenoxy and benzyl;
R4 represents a hydrogen atom; or a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted; and whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
with the provision that if q = 1 , then
k = 1 ;
R5, R6 and R7, independent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted or substituted with 1 , 2, 3, 4, or 5 substituents independently selected from the group consisting of F, Cl, Br, I1 -OH, -SH, -NH2, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -0-CH3, -0-C2H5, -S-CH3, -O-Si-(CH3)3,
-0-Si-(CH2-CHa)3, -O-Si-[CH(-CH3)2]3, -Si-[CH(-CH3)2]3, -Si-(CH3)3, -Si-(CH2-CH3)3, -Si-[CH(-CH3)2]3, -NH-CH3, -N(-CH3)2 and phenyl; whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
a radical selected from the group consisting Of -O-CH3, -0-CH2-CH3, -0-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH2-CH3 and -0-CH2-CH2-CH2-CH2-CH2-CH2-CH3; whereby in each occurrence the alkyl chain is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH2, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -0-CH3, -0-C2H5, -S-CH3, -O-Si-(CH3)3, -O-Si-(CH2-CH3)3, -O-Si-[CH(-CH3)2]3, -Si-[CH(-CH3)2]3, -Si-(CH3)3, -Si-(CH2-CH3)3, -Si-[CH(-CH3)2]3, -NH-CH3 and -N(-CH3)2; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
a phenyl or naphthyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, n-pentyl, -0-CH3, -0-C2H5, -0-CH2-CH2-CH3, -O-CH(CH3)2> -O-C(CH3)3, -S-CH3, -S-C2H5, -S-CH2-CH2-CH3, -S-CH(CH3)2, -S-C(CH3)3, -C(=O)-OH, -C(=O)-CH3> -C(=O)-C2H5, -C(=O)-CH2-CH2-CH3, -C(=O)-CH(CH3)2, -C(=O)-C(CH3)3) F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K1 -SO3H, -OH, -SH, -NH2, -NH-CH3, phenyl, phenethyl, phenoxy and benzyl;
or
CD wherein
P = O, 1 or 2;
R25, R26, R27, R28 and R29, independent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted; and whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
a radical selected from the group consisting Of -CH2-Ph and -CH2- CH2-Ph;
a radical selected from the group consisting of -0-CH3, -0-CH2-CH3, -0-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH2-CH3 and -0-CH2-CH2-CH2-CH2-CH2-CH2-CH3; whereby in each occurrence the alkyl chain of these radicals is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
an unsubstituted phenyl or naphthyl radical;
or
an -O-Si(R30)3 radical, with R30 representing a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, pentyl and hexyl, which is unsubstituted;
with the condition that if q = 1 and at the same time k = 1 , at least one of the radicals R5, R6 and R7 represents a radical of general formula (II) as defined above;
or, with the provision that if q = 2, then
k = 0;
R7 represents a radical of general formula (III)
(III) wherein
m = 0, 1 or 2;
X represents an oxygen atom or an unsubstituted or at least mono-substituted
C-1-4 alkylene radical;
R31, R32, R33 and R34, independent of one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted; and whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
an unsubstituted phenyl or naphthyl radical;
a radical selected from the group consisting of -O-CH3l -O-CH2-CH3, -0-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH31 -0-CH2-CH2-CH2-CH2-CH2-CH3 and -0-CH2-CH2-CH2-CH2-CH2-CH2-CH3; whereby in each occurrence the alkyl chain of these radicals is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
or
an -O-Si(R30)3 radical, with R30 representing a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, pentyl and hexyl;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred is a compound of general formula (I),
wherein
q = 1 or 2; k = 0 or 1 ;
R1 and R2, independent from one another, each represents a hydrogen atom; methyl; ethyl; F; Cl; Br; I; -OH; -CN; -CF3; -C(=O)-OH; -CH2-C≡N; -C(=O)-OCH3, -C(=O)-OCH2CH3, -S(=O)2-Phenyl, -0-CH3; or -0-CH2-CH3;
R3 represents a radical selected from the group consisting of phenyl, naphthyl, cyclopentyl, cyclohexyl and cycloheptyl, which is 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, n-pentyl, -0-CH3, -0-C2H5, -0-CH2-CH2-CH3, -O-CH(CH3)2, -O-C(CH3)3, -S-CH3, -S-C2H5, -S-CH2-CH2-CH3,
-S-CH(CHa)2, -S-C(CHa)3, -C(=O)-OH, -C(=O)-OCH3, -C(=O)-OCH2CH3, -S(=O)2-Phenyl, -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-CH2-CH2-CH3, -C(=O)-CH(CH3)2, -C(=O)-C(CH3)3, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH-CH3, phenyl, phenethyl, phenoxy and benzyl;
R4 represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
with the provision that if q = 1 , then
k = 1 ;
R5, R6 and R7, independent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
a radical selected from the group consisting of -0-CH3, -0-CH2-CH3, -0-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH2-CH3 and -0-CH2-CH2-CH2-CH2-CH2-CH2-CH3; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
an unsubstituted phenyl or naphthyl radical;
or at least one of the radicals R5, R6 and R7, independent from one another, each represents a radical of general formula (II)
(») wherein
p = 0 or 1 ;
R25, R26, R27, R28 and R29, independent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted; and whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
a radical selected from the group consisting of -0-CH3, -0-CH2-CH3, -0-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH2-CH3 and -0-CH2-CH2-CH2-CH2-CH2-CH2-CH3; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
or
an -O-Si(R30)3 radical, with R30 representing a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, pentyl and hexyl, which is unsubstituted;
with the condition that if q = 1 and at the same time k = 1 , at least one of the radicals R5, R6 and R7 represents a radical of general formula (II) as defined above;
or, with the provision that if q = 2, then
k = 0;
R7 represents a radical of general formula (III)
(III) wherein
m = 0, 1 or 2;
X represents an oxygen atom or an unsubstituted or at least mono-substituted
C-I-4 alkylene radical; preferably an oxygen atom or an unsubstituted Ci-4 alkylene radical;
R31, R32, R33 and R34, independent of one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted; and whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
a radical selected from the group consisting of -CH2-Phenyl and -CH2-CH2-Phenyl;
an unsubstituted phenyl or naphthyl radical;
a radical selected from the group consisting of -O-CH3, -0-CH2-CH3, -0-CH2-CH2-CHs, -O-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CHs, -0-CH2-CH2-CH2-CH2-CH2-CH3 and -0-CH2-CH2-CH2-CH2-CH2-CH2-CH3; whereby in each occurrence the alkyl chain of these radicals is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
or
an -O-Si(R30)3 radical, with R30 representing a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, pentyl and hexyl, which is unsubstituted;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred is at least one silylated substituted benzotriazolylphenol compound of general formula (IB)
wherein
qb = 1 or 2; kb = 0 or 1 ;
R1b and R2b, independent of one another, each represents a hydrogen atom; methyl; ethyl; F; Cl; Br; I; -OH; -CN; -CF3; -C(=O)-OH; -C(=O)-OCH3, -C(=O)-OCH2CH3, -S(=O)2-Phenyl, -0-CH3; or -0-CH2-CH3;
R3b and R3bb, independent of one another, each represents a hydrogen atom; methyl; ethyl; F; Cl; Br; I; -OH; -CN; -CF3; -C(=O)-OH; -C(=O)-OCH3, -C(=O)-OCH2CH3, -S(=O)2-Phenyl, -0-CH3; or -0-CH2-CH3;
R4b represents a radical selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl, which is unsubstituted;
with the provision that if q b _ = 1, then
kb = 1 ;
R5b, R6b and R7b, independent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -0-CH3, -O-C2H5, -O-C3H7, -0-C-1H9, -0-C5H11 and -O-CeH^; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
an unsubstituted phenyl or naphthyl radical;
or R5b, R6b and R7b, independent of one another, each represents a radical of general formula (Mb)
(Hb)
wherein
pb = O or 1 ;
R25b, R26b, R27b, R28b and R29b, independent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n- butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
a radical selected from the group consisting of -0-CH3; -0-C2H5; -0-C3H7; -O-C4H9; -O-C5H11; and -O-C6H13; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
a radical selected from the group consisting of -O-Si-(CH3)3; -O-Si-(C2H5)3; -0-Si-(C4Hg)3; -O-Si-(Phenyl)3; -CH2-Si-(CH3)3 and -CH2-Si-(C2Hs)3;
an unsubstituted phenyl or naphthyl radical;
with the condition that if qb = 1 and at the same time kb =1 , at least one of the radicals R5b, R6b and R7b represents a radical of general formula (Mb) as defined above;
or, with the provision that if q b _ = 2, then
k ,bD _ = 0;
R >7b represents a radical of general formula (IMb)
(HIb)
wherein
nr ,fb _ = O1 1 or 2, preferably O;
Xb represents an oxygen atom or an unsubstituted or at least mono-substituted C1-4 alkylene radical; preferably an oxygen atom or an unsubstituted C1-4 alkylene radical;
R31b, R32b, R33b and R346, independent of one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
a radical selected from the group consisting of -O-CH3; -0-C2H5; -O-C3H7; -O-C4H9; -O-C5H11; and -0-CeH13; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
a radical selected from the group consisting of -O-Si-(CH3)3; -O-Si-(C2H5)3; -0-Si-(C4Hg)3; -O-Si-(Phenyl)3; -CH2-Si-(CH3)3 and -CH2-Si-(C2Hs)3;
or
an unsubstituted phenyl or naphthyl radical;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred is at least one silylated substituted benzotriazolylphenol compound of general formula (IC)
wherein
n = 0, 1 , or 2; preferably 1 ;
R1c and R2c, independent of one another, each represents a hydrogen atom; methyl; ethyl; F; Cl; Br; I; -OH; -CN; -CF3; -C(=O)-OH; -C(=O)-OCH3, -C(=O)-OCH2CH3, -S(=O)2-Ph, -O-CH3; or -0-CH2-CH3;
R3c and R3cc, independent of one another, each represents a hydrogen atom; methyl; ethyl; F; -OH; -CN; -CF3; -C(=O)-OH; -C(=O)-OCH3, -C(=O)-OCH2CH3, -S(=O)2-Ph, -0-CH3; or -0-CH2-CH3;
R4c represents a radical selected from the group consisting of methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl, which is unsubstituted;
with the provision that if q = 1, then
kc = 1 ;
R5c, R6c and R7c, independent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
a radical selected from the group consisting of -O-CH3, -0-C2H5, -O-C3H7, -O-C4H9> -0-C5H11, and -0-CeH13; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
an unsubstituted phenyl or naphthyl radical;
or
R5c, R6c and R7c, independent of one another, each represents a radical of general formula (lie)
(lie)
wherein
pc = O or 1 ;
R25c R 26Cj R 27c R 28c and R 29c jnc|epencjent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
a radical selected from the group consisting of -0-CH3, -0-C2H5, -O-C3H7, -O-C4H9, -O-C5H11, and -O-C6Hi3; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
a radical selected from the group consisting of -O-Si-(CH3)3, -O-Si-(C2H5)3, -0-Si-(C4Hg)3, -0-Si-(Ph)3, -CH2-Si-(CH3)3 and -CH2-Si-(C2Hs)3;
an unsubstituted phenyl or naphthyl radical;
with the condition that if qc = 1 and at the same time kc =1 , at least one of the radicals R 5c R 6c and R 7c represents a radical of general formula (lie) as defined above;
or, with the provision that if qc = 2, then
kc = 0;
R represents a radical of general formula (MIc)
(MIc)
wherein
mc = 0, 1 or 2, preferably 0;
Xc represents an oxygen atom or an unsubstituted or at least mono-substituted
Ci-4 alkylene radical; preferably an oxygen atom or an unsubstituted Ci-4 alkylene radical;
R 3ic R 32c R 33c and R 34c jncjepenc|ent of one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
a radical selected from the group consisting Of -O-CH3, -0-C2H5, -0-C3H7, -O-C4H9, -O-C5H11 and -0-C6Hi3; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
a radical selected from the group consisting of -O-Si-(CH3)3, -O-Si-(C2H5)3> -0-Si-(C4Hg)3, -0-Si-(Ph)3, -CH2-Si-(CH3)3 and -CH2-Si-(C2Hs)3;
an unsubstituted phenyl or naphthyl radical;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred are silylated substituted benzotriazolylphenol compounds of general formulae (ID), (IE) and (IF)
(ID)
(IE)
(IF)
wherein
R1b and R2b, independent of one another, each represents a hydrogen atom; methyl; ethyl; F; Cl; Br; I; -OH; -CN; -CF3; -C(=O)-OH; -C(=O)-OCH3; -C(=O)-OCH2CH3; -S(=O)2-Phenyl; -0-CH3; or -0-CH2-CH3;
R3b and R3bb, independent of one another, each represents a hydrogen atom; methyl; ethyl; F; Cl; Br; I; -OH; -CN; -CF3; -C(=O)-OH; -C(=O)-OCH3; -C(=O)-OCH2CH3; -S(=O)2-Phenyl; -O-CH3; or -0-CH2-CH3;
R4b represents a radical selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl, which is unsubstituted;
mb = O, 1 , 2, 3, 4 or 5;
R 3ib R 32b ^ R 33b and R 34b 7 jncjepenc|ent of one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
a radical selected from the group consisting of -0-CH3, -0-C2H5, -0-C3H7, -O-C4H9, -O-C5H11 and -O-C6Hi3; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
a radical selected from the group consisting of -O-Si-(CH3)3, -O-Si-(C2H5)3, -0-Si-(C4Hg)3, -0-Si-(Ph)3, -CH2-Si-(CH3)3 and -CH2-Si-(C2Hs)3;
an unsubstituted phenyl or naphthyl radical;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoi-
somers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Also preferred are silylated substituted benzotriazolylphenol compounds of general formulae (IG), (IH) and (IJ)
(IH)
(IJ)
wherein
mc, R1c, R2c, R40, R31c, R32c, R33c and R34c have the same meaning as the above defined mb, R1b, R2b, R4b, R31b, R32b, R33b and R34b for the silylated substituted benzotriazolylphenol compounds of general formulae (ID), (IE) and (IF);
and
R3c and R3cc, independent of one another, each represents a hydrogen atom; methyl; ethyl; F; -OH; -CN; -CF3; -C(=O)-OH; -C(=O)-OCH3, -C(=O)-OCH2CH3, -S(=O)2-Phenyl, -0-CH3; Or -O-CH2-CH3;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Particularly preferred is at least one silylated substituted benzotriazolylphenol compound of general formula (I) selected from the group consisting of
[1 ] 3-(2H-benzotriazol-2-yl)-5-[2-methyl-3-[1 ,3,3,3-tetramethyM - [(trimethylsilyl)oxy]disiloxanyl]propyl]biphenyl-4-ol,
[2] 3-(2H-benzotriazol-2-yl)-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl-disiloxanyl)- propyl]-biphenyl-4-ol,
[3] 2-(2H-benzotriazol-2-yl)-4-cyclohexyl-6-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl- disiloxanyl)-propyl]-phenol,
[4] 2-(2H-benzotriazol-2-yl)-4-cyclohexyl-6-[2-methyl-3-[1 ,3,3,3-tetramethyl-i - [(trimethylsilyl)oxy]disiloxanyl]propyl]-phenol,
[5] 3-(5-Chloro-2H-benzotriazol-2-yl)-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl- disiloxanyl)-propyl]-biphenyl-4-ol,
[6] 3-(5-Methoxy-2H-benzotriazol-2-yl)-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl- disiloxanyl)-propyl]-biphenyl-4-ol,
[7] 2-{4-Hydroxy-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl-disiloxanyl)-propyl]- biphenyl-3-yl}-2/-/-benzotriazole-5-carbonitrile,
and
[8] 2-{4-Hydroxy-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl-disiloxanyl)-propyl]- biphenyl-3-yl}-2/-/-benzotriazole-5-carboxylic acid,
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
Another aspect of the present invention relates to a process for the preparation of at least one silylated substituted benzotriazolylphenol compound of general formula (I), which comprises the step of reacting at least one compound of general formula (P9)
wherein R1, R2, R3 and R4 have the above-defined meaning, with at least one suitable silyl derivative of general formula (P10)
wherein R5, R6, R7 and k have the above-defined meaning, following typical hydrosilylation of carbon-carbon double bonds conditions, according to general methods known for the person skilled in the art, preferably in the presence of a catalyst, more preferably in the presence of a catalyst comprising an electron-rich complex of a late transition metal such as e.g. Co(I), Rh(I), Ni(O), Pd(O), or Pt(O), preferably with Speier catalyst (H2[PtCI6]), PtO2 or Karstedt catalyst (Pt2[(CH2=CH)Me2Si]2O)3), more preferably using Karstedt catalyst, preferably in the presence of an organic solvent, more preferably an aromatic solvent such as e.g. xylene, preferably at a temperature ranging from O0C to the boiling point of the solvent, more preferably at a temperature between 5O0C and the boiling point of the solvent, even more preferably at 1000C until the reaction is completed to yield at least one compound of general formula (I)
wherein R1, R2, R3, R4, R5, R6 and R7 have the above-defined meaning.
At least one silylated substituted benzotriazolylphenol compound of general formula (I) is obtained by reacting at least one compound of general formula (P1 )
(P1)
wherein R1 and R2 have the above-defined meaning, with sodium nitrite (NaNθ2) in a suitable reaction media, preferably an aqueous reaction media, preferably in the presence of a mineral acid such as e.g. HCI, at usual temperatures, preferably at a temperature ranging from -20 to 2O0C, more preferably at a temperature between O0C and 50C until the reaction is completed to yield at least one compound of general formula (P2)
(P2)
wherein R1 and R2 have the above-defined meaning, which is reacted with at least one compound of general formula (P3)
(P3)
wherein R3 has the above-defined meaning, in the presence of a base, preferably a mineral base such as e.g. sodim hydroxide (NaOH), to activate the phenol in the form of a phenoxide ion, in a suitable solvent, preferably in a protic and/or aqueous solvent such as e.g. H2O, ethanol (EtOH), isopropanol or mixtures thereof, at usual temperatures, preferably at a temperature ranging from -20° to 5O0C, more preferably at a temperature between O0C and room temperature until the reaction is completed to yield at least one compound of general formula (P4)
(P4)
wherein R1, R2 and R3 have the above-defined meaning, which is preferably reacted with at least one reducing agent such as e.g., ammonium sulphide, hydroxylamine, sodium dithionite or formamidinesulfinic acid (P5)
(P5)
preferably in the presence of a base, more preferably an alkaline base such as e.g. NaOH, preferably in suitable solvent, more preferably a protic and/or aqueous solvent such as e.g. H2O, EtOH, isopropanol or mixtures thereof, at usual temperatures, preferably at a temperature ranging from O0C to the boiling point of the solvent, more preferably at a temperature between 5O0C and the boiling point of the solvent, until the reaction is completed to yield at least one compound of general formula (P6)
(P6)
wherein R1, R2 and R3 have the above-defined meaning, which is reacted with at least one compound of general formula (P7)
(P7)
wherein R4 has the above-defined meaning and X represents a leaving group preferably chorine, bromine, methanesulfonyl or toluenesulfonyl, more preferably chlorine, preferably in the presence of a base, preferably a mineral base, more preferably K2CO3, optionally in the presence of iodine salt, preferably Kl1 in a suitable solvent, preferably an organic solvent such as e.g. ketone or 2-butanone, more preferably 2-butanone, preferably at a temperature ranging from O0C to the boiling point of the solvent, more preferably at a temperature between 5O0C and the boiling point of the solvent until the reaction is completed to yield at least one compound of general formula (P8)
wherein R1, R2, R3 and R4 have the above-defined meaning, which is preferably reacted according to typical Aromatic Claisen Rearrangement conditions, preferably with the presence of a catalyst, preferably in the presence of a solvent, preferably in the presence of an amine such as e.g. N.N-diethylaniline, preferably at a temperature ranging from O0C to 2000C1 more preferably at a temperature between 5O0C and 17O0C until the reaction is completed to yield at least one compound of general formula (P9)
wherein R1, R2, R3 and R4 have the above-defined meaning, which is preferably reacted with at least one suitable silyl derivative of general formula (P10)
(P10)
wherein R5, R6, R7 and k have the above-defined meaning, following typical hydrosilylation of carbon-carbon double bonds conditions, according to general methods known for the person skilled in the art, preferably in the presence of a catalyst, more preferably in the presence of a catalyst comprising an electron-rich complex of a late transition metal such as e.g. Co(I), Rh(I), Ni(O)1 Pd(O), or Pt(O), preferably with Speier catalyst (H2[PtCIe]), PtO2 or Karstedt catalyst (Pt2I(CH2=CH)Me2Si]2O)3), more preferably using Karstedt catalyst, preferably in the presence of an organic solvent, more preferably an aromatic solvent such as e.g. xylene, preferably at a temperature ranging from O0C to the boiling point of the solvent, more preferably at a temperature between 5O0C and the boiling point of the solvent, even more preferably at 1000C until the reaction is completed to yield at least one compound of general formula (I)
(I)
wherein R1, R2, R3, R4, R5, R6 and R7 have the above-defined meaning.
The compounds of general formulae P1 , P2, P3, P4, P5, P7, P8, P9 and P10 are commercially available or may be prepared according to standard methods known in the prior art, as e.g. according to JP 4046333, JP 61054982 or EP 0 031 302. The respective parts of the literature are hereby incorporated by reference.
The compounds of general formula P6 can be prepared according to the disclosure Of DE 2727386, JP 52113974, CH 476745, US 3399173, GB 991630 or GB 980886. The respective parts of the literature are hereby incorporated by reference.
The aforementioned hydrosilylation of carbon-carbon double bonds with a suitable silyl derivative is known to those skilled in the art and described e.g. in Organic Reactions, Vol. 13 , John Willey, NY, 1963, page 209 or in Organic Letters, 2002, Vol. 4(13), page 2117-9.
The aforementioned Aromatic Claisen Rearrangement conditions are known to those of ordinary skill in the art and are e.g. described in Tarbell et al., Organic Reactions, Vol. 2 , John Willey, NY, 1944, page 1 or EP 0 392 883.
Any of the aforementioned steps, which requires heating, can also be carried out in a microwave oven, employing a typical procedure of MAOS (microwave assisted organic synthesis). The present invention provides processes of efficiently preparing
these compounds in a short time by using microwave irradiation. Microwave assisted chemistry is relatively new compared to some other techniques; however, it has become well established and accepted. Microwave assisted chemical synthesis refers to the use of electromagnetic radiation within the microwave frequencies to provide the energy required to initiate, drive, or accelerate certain chemical reactions. As chemists have long been aware, the application of heat energy is one of the most significant factors in increasing the rate of a wide variety of chemical reactions. Microwave assisted reactions can be completed in a much shorter period of time than conventional thermal-treatment techniques requiring long reaction time. In each of the reactions discussed or illustrated above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, i.e. about 1 atmosphere, is preferred as a matter of convenience. Under microwave-assisted heating, sealed reactors are indicated, resulting in high-pressure reactions up to as much as 350 psi.
Common microwave equipment may be used in preparation processes according to the present invention. The microwave irradiation may be performed at a power level of 1 to 1600 W1 preferably 1 to 300 W, and particularly preferably about 70 W. The duration for the microwave irradiation may vary according to conditions such as the amount or reactant but may be in the range from 20 seconds to 60 minutes, preferably from 1 minute to 20 minutes. The reaction can be carried out at a temperature of 50-280 0C, preferably 80-200 0C, and more preferably 120-1500C, with of without solvent, under microwave irradiation. A presently preferred microwave furnace is commercially available from CEM, Inc., as model Discover®. The Discover® System incorporates temperature and pressure feedback systems, for example, an infrared temperature sensor positioned below the reaction vessel, for complete control of the reaction.
The general process for the preparation of compounds of general formula (I) as described above, is also depicted in general scheme (I):
Scheme (I)
The compounds of general formula (I), including compounds of general formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH) and (IJ), in the following only referred to as compounds of general formula (I) herein given above may be purified and/or isolated according to methods well known to those skilled in the art. Preferably, the compounds of general formula (I) may be isolated by evaporating the reaction medium, addition of water and adjusting the pH value to obtain the compound in form of a solid that can be isolated by filtration, or by extraction with a solvent that is not miscible with water such as chloroform and purification by chromatography or recrystallization from a suitable solvent.
During some synthetic reactions described above or while preparing the compounds of general formula (I) the protection of sensitive or reactive groups may be necessary and/or desirable. This can be performed by using conventional protective groups like
those described in Protective groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; T.W. Greene & P. G. M. Wuts and Protective Groups in Organic Chemistry, John Wiley & sons, 1991. The respective parts of the description are hereby incorporated by reference and forms part of the disclosure. The protective groups may be eliminated when convenient by means well known to those skilled in the art.
If the silylated substituted benzotriazolylphenol compounds of general formula (I) are obtained in form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or crystallization with chiral reagents.
The silylated substituted benzotriazolylphenol compounds of general formula (I) and in each case stereoisomers thereof may be obtained in form of a corresponding salt according to methods well known to those skilled in the art, e.g. by reacting said compound with at least one inorganic and/or organic acid, preferably in a suitable reaction medium. Suitable reaction media include, for example, any of the ones given above. Suitable inorganic acids include but are not limited to hydrochloric acid, hydrobromic acid, phosphoric acid, oxalic acid, sulfuric acid, nitric acid, suitable organic acids include but are not limited to citric acid, maleic acid, fumaric acid, tartaric acid, or derivatives thereof, p-toluenesulfonic acid, methanesulfonic acid or camphersulfonic acid.
The term "salt" is to be understood as meaning any form of the silylated substituted benzotriazolylphenol compounds in which they assume an ionic form or are charged and are coupled with a counter-ion (a cation or anion) or are in solution. By this are also to be understood complexes of the active compound with other molecules and ions, in particular complexes which are complexed via ionic interactions.
The term "physiologically acceptable salt" is understood in particular, in the context of this invention, as salt (as defined above) formed either with a physiologically tolerated acid, that is to say salts of the particular active compound with inorganic or organic acids which are physiologically tolerated - especially if used on humans and/or
mammals - or with at least one, preferably inorganic, cation which are physiologically tolerated - especially if used on humans and/or mammals. Examples of physiologically tolerated salts of particular acids are salts of: hydrochloric acid, hydrobromic acid, sulfuric acid, hydrobromide, monohydrobromide, monohydrochloride or hydrochloride, methiodide, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid, hippuric acid picric acid and/or aspartic acid. Examples of physiologically tolerated salts of particular bases are salts of alkali metals, such as e.g. sodium or potassium and alkaline earth metals such as e.g. magnesium or calcium and with NH4. Particularly preferred are silylated substituted benzotriazolylphenol compounds in form of a sodium, potassium or triethanolamine salt.
Solvates, preferably hydrates, of the silylated substituted benzotriazolylphenol compounds of general formula (I) and in each case of corresponding stereoisomers may also be obtained by standard procedures known to those skilled in the art.
The term "solvate" according to this invention is to be understood as meaning any form of the silylated substituted benzotriazolylphenol compounds in which they have attached to it via non-covalent binding another molecule (most likely a polar solvent) especially including hydrates and alcoholates, e.g. methanolate.
A further aspect of the present invention relates to a pharmaceutical composition comprising at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above, optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, and optionally at least one physiologically acceptable auxiliary agent.
A further aspect of the present invention relates to a cosmetic composition comprising at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above, optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a
physiologically acceptable salt thereof, or a corresponding solvate thereof, and optionally at least one physiologically acceptable auxiliary agent.
It has surprisingly found that the inventive silylated benzotriazolylphenol compounds of general formula (I) given above also show remarkable absorption capacities in UV- C radiation range. Since the sunlight radiation intensity continuously increases due to the continuous reduction of stratospheric ozone, the importance of pharmaceutical/cosmetic compositions having such UV-C protecting properties is growing.
Said pharmaceutical and/or cosmetic composition is particularly suitable for the prophylaxis and/or care and/or treatment of diseases caused by and/or associated with exposure to ultraviolet radiation, preferably of the lips, the face and/or of the body of mammals, preferably human beings, more preferably for the prophylaxis and/or care and/or treatment of/against non-desired skin conditions comprising polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing, sunburn and/or chronic actinic dermatitis.
The amount of at least one silylated substituted benzotriazolylphenol compound for the inventive pharmaceutical or cosmetical composition is preferably in each case in the range of 0.01 % to 30% per weight, more preferably 0.01 % to 20% per weight, most preferably 0.1 % to 15% per weight, with respect to the total weight of the composition.
For the inventive pharmaceutical or cosmetical composition at least one of the inventive silylated substituted benzotriazolylphenol compound(s) may be preferably used in micronized form, wherein the size of the particles is preferably in the range of 0.01 to 4 μm, more preferably in the range of 0.05 to 2 μm, most preferably in the range of 0,05 to 1 μm.
The following auxiliary agents mentioned below can independently from each other be present in either the inventive pharmaceutical or the inventive cosmetical composition: gelling agents, oils, waxes, thickening agents, hydrophilic or hydrophobic polymers, emulsifying agents, emollients, fatty acids, organic solvents,
antioxidants, stabilizers, sequestering agents, acidifying or basifying agents, emulsifiers, emollients, surfactants, film formers, biological additives to enhance performance and/or consumer appeal such as amino acids, proteins, vanilla, aloe extract or bioflavinoids, buffering agents, chelating agents such as ethylenediaminetetra-acetic acid (EDTA) or oxalic acid, colorants, dyes, propellants, antifoaming agents, wetting agents, vitamins, emulsion stabilizers, pH adjusters, thickening agents, fragrances, preservatives, opacifying agents, water and/or alcohols. The aforementioned auxiliary agents for the inventive compositions are used in the usual amounts known by those skilled in the art.
As oils for the inventive compositions oils from animal or vegetable sources or synthetic are preferably used. Particularly preferred are oils selected from the group comprising liquid petrolatum, liquid paraffin, volatile and non-volatile silicone oils, isoparaffins, polyalphaolefins, fluorated and perfluorated oils.
As stabilizers for the inventive compositions preferably non-ionic, anionic, cationic and amphiphilic tensides can be used, which are preferably selected from the group comprising polyethylenglycol (PEG) and derivatives thereof, tweens, tritons, spans, polygycerines, polyalkyl glycerides, alkyl sulfonates, aryl sulfonates, alkyl phosphates, derivatives of alkyl-betaine and phosphatidylglycerole.
Emulsifiers are preferably used in certain formulations of the inventive compositions in amounts effective to provide uniform blending of ingredients of the composition. Useful emulsifiers include anionics such as fatty acid soaps, e.g., potassium stearate, sodium stearate, ammonium stearate, and triethanolamine stearate; polyol fatty acid monoesters containing fatty acid soaps, e.g., glycerol monostearate containing either potassium or sodium salt; sulfuric esters (sodium salts), e.g., sodium lauryl 5 sulfate, and sodium acetyl sulfate; and polyol fatty acid monoesters containing sulfuric esters, e.g., glyceryl monostearate containing sodium lauryl surfate; (ii) cationics chloride such as N(stearoyl colamino formylmethyl) pyridium; N-soya-N-ethyl morpholinium ethosulfate; alkyl dimethyl benzyl ammonium chloride; diisobutylphenoxytheoxyethyl dimethyl benzyl ammonium chloride; and acetyl pyridium chloride; and (iii) nonionics such as polyoxyethylene fatty alcohol ethers, e.g., monostearate; polyoxyethylene lauryl alcohol; polyoxypropylene fatty alcohol ethers, e.g., propoxylated oleyl alcohol;
polyoxyethylene fatty acid esters, e.g., polyoxyethylene stearate; polyoxyethylene sorbitan fatty acid esters, e.g., polyoxyethylene sorbitan monostearate; sorbitan fatty acid esters, e.g., sorbitan; polyoxyethylene glycol fatty acid esters, e.g., polyoxyethylene glycol monostearate; and polyol fatty acid esters, e.g., glyceryl monostearate and propylene glycol monostearate; and ethoxylated lanolin derivatives, e.g., ethoxylated lanolins, ethoxylated lanolin alcohols and/or ethoxylated cholesterol.
Emollients may be used in the formulations of the inventive compositions in such amounts to prevent or relieve dryness. Useful emollients include, without limitation hydrocarbon oils and waxes; silicone oils; triglyceride esters; acetoglyceride esters; ethoxylated glyceride; alkyl esters; alkenyl esters; fatty acids; fatty alcohols; fatty alcohol ethers; etheresters; lanolin and derivatives; polyhydric alcohols (polyols) and polyether derivatives; polyhydric alcohol (polyol) esters; wax esters; beeswax derivatives; vegetable waxes; phospholipids; sterols; and/or amides.
Surfactants can be used in certain formulations of the inventive compositions. Suitable surfactants are for example those surfactants generally grouped as cleansing agents, emulsifying agents, foam boosters, hydrotropes, solubilizing agents, suspending agents and non-surfactants, which facilitate the dispersion of solids in liquids.
Suitable film formers which are preferably used in the formulations of the inventive compositions should keep the composition smooth and even and are preferably, without limitation, at least one substance selected from the group comprising acrylamide/sodium acrylate copolymer; ammonium acrylates copolymer; Balsam Peru; cellulose gum; ethylene/maleic anhydride copolymer; hydroxyethylcellulose; hydroxypropylcellulose; polyacrylamide; polyethylene; polyvinyl alcohol; pvm/MA copolymer (vinyl methylether/maleic anhydride copolymer); PVP (polyvinylpyrrolidone); maleic anhydride polymer, vinylpyrrolidon/hexadecene copolymer; acryliclacrylate copolymer and the like.
pH adjusters may also be used in certain formulations of the inventive compositions. These pH adjusters preferably comprise, but are not limited to ammonium hydroxide, triethanolamine or citric acid.
Thickening agents used for the formulations of the inventive compositions preferably are, but are not limited to candelilla, carnauba, and microcrystalline waxes, crosslinked acrylic-acid polymers, carbomer, methylhydroxyethylcellulose, hydroxypropylmethylcellulose or hydroxyethylcellulose. and polyethylene thickeners.
Examples of preferred organic solvents for the inventive compositions include lower aliphatic alcohols and polyols.
Suitable antioxidants suitable for the inventive compositions are preferably selected from the group comprising ascorbic acid (vitamin C), sodium-L-ascorbate, calcium-L- ascorbate, ascorbyl palmitate, butylhydroxyanisole, butylhydroxytoluene, calcium- disodium-EDTA, isoascorbic acid, lecitine, lactic acid, polyphosphate, tocopherol (vitamin E), like α-tocopherol, γ-tocopherol, δ-tocopherol, propylgallate, octylgallate, dodecylgallate, sodium-isoascorbate, citric acid, sodium citrate, potassium citrate and tin-ll-chloride.
Gelling agents, which are preferably used in the formulations of the inventive compositions, can be natural or synthetic polymers. Natural polymers are preferably selected from the group comprising Agar-Agar, alginate, pectin, carbomer, carrageenan, casein, dextrine, gelatine, arabic gum, keratine, locust bean gum, xanthan gum and the like. Preferred synthetic polymers, which can be used in the formulations of the inventive compositions are selected from the group comprising acylic acid polymers, polyacryl amides and alkylene oxide polymers.
For the inventive cosmetic composition marketed in Europe the respective components shall be used in amounts which are in compliance with the Council Directives 76/768/EEC and Commission Directive 95/17/EC on the approximation of the laws of the Member States relating to cosmetic products.
The inventive pharmaceutical or cosmetic composition is preferably adapted at least for a once a day, twice or three, four or five times a day, preferably for twice a day application.
For the application, preferably topical application, the inventive pharmaceutical or cosmetical composition may be formulated in liquid or in semi-solid form, preferably as liquid, fluid, foam, cream, gel, paste, balsam, spray, ointment, lotion, conditioner, tonic, milk, mousse, emulsion, serum, oil, stick, shampoo, jelly, suspension, dispersion, lacquer, paint, elixir, drop or aerosol.
Preferably the inventive pharmaceutical or cosmetical compositions are suitable for protecting the skin of UV radiation, either in the range of UV-A or UV-B or UV-C or in the whole UV-A and UV-B range and optionally UV-C range.
A further aspect of the present invention relates to the use of at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of diseases caused by and/or associated with exposure to ultraviolet radiation, preferably of the lips, the face and/or of the body of mammals, preferably human beings.
Human exposure to solar ultraviolet radiation has important public health implications. Evidence of harm associated with overexposure to UV radiation has been demonstrated in many studies (see e.g. Environmental Burden of Disease Series, No. 13, 2006; Solar Ultraviolet Radiation - Global burden of disease from solar ultraviolet radiation, World Health Organization). Skin cancer and malignant melanoma are among the most severe health effects, but a series of other health effects, such as polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing, sunburn, chronic actinic dermatitis or sunburn have been identified.
Thus, a preferred embodiment of the present invention is related to the use of at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above for the preparation of a pharmaceutical composition for the prophylaxis and/or care and/or treatment against non-desired skin conditions comprising polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing, sunburn and/or chronic actinic dermatitis.
Also particularly preferred is the use of at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above for the prophylaxis and/or care against non-desired skin conditions comprising polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing, sunburn and/or chronic actinic dermatitis.
Also particularly preferred is the use of at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above for protecting the skin preferably of the lips, the face and/or of the body of a mammal, preferably a human, against ultraviolet radiation, preferably UV-A and/or UV-B radiation and optionally UV-C radiation.
Yet, another aspect of the present invention relates to the use of at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above as a light-stabilizer in polymer compositions, preferably in textile fibers.
Such polymer compositions comprising the inventive silylated substituted benzotriazolylphenol compounds of general formula (I) given above as light stabilizers may be in form of articles, moulds, sheets, foils, paintings, coatings, fibers or films. The films comprising the inventive silylated substituted benzotriazolylphenol compounds of general formula (I) given above as light stabilizers are single-layer or multilayer films, which can be used for medical or agricultural applications.
The articles, moulds, sheets, foils or films comprising the inventive silylated substituted benzotriazolylphenol compounds of general formula (I) given above as light stabilizers are preferably suitable for outdoor carpeting, awnings, tarps, umbrellas, non-food or food-packaging applications such as rice, corn and flour bags, tapes, ropes, artificial turf, stretch-films, shrink wraps, heavy-duty bags, pool covers, garden furniture, trash cans, bottle and fruit crates, toys, interior and exterior automotive parts such as auto bumpers and interior or exterior trim, outdoor sporting and leisure goods, roofings and window shutters.
The term "light stabilizer" (also referred to as "photostabilizer" or "photoprotecting agent") means, according to the present invention a chemical compound that
protects the material like a polymer composition against photodegradation against deterioriating and/or decomposing effects caused by its exposure to light. With respect to the definition of "light stabilizer" reference is made to the International Union of Pure and Applied Chemistry (IUPAC) Definitions of terms relating to polymer chemistry, Pure and Appl. Chem., Vol. 68, No.12, pp. 2313-2323, 1996.
Preferably, light stabilizers can also be classified according to their special possibility of stabilizing against the impact of light into absorbers, quenchers, peroxide decomposers or free radical scavengers.
So called absorbers and quenchers are preferably agents that reduce the impact caused by exposure to light either by absorbing, extincting, filtering, scattering, deflecting or reflecting light. A peroxide decomposer is preferably an agent that transforms peroxides into stable compounds without the formation of free radicals and a free radical scavenger is preferably an agent that eliminates free radicals by binding.
Preferably, the inventive light-stabilized polymer composition comprises as the light- stabilizing component at least one absorber, quencher, peroxide decomposer and/or free radical scavenger.
The term "absorption" according to the present invention means any of the following means of reducing the exposure to UV radiation like absorbing, extincting, filtering, scattering, deflecting or reflecting of radiation, since absorption only means the ratio of transmitted radiation to the incident radiation, without determining the mechanism according to which the radiation is reduced.
Polymers can be preferably classified into four main groups:
1. Thermoplastic polymers
2. Thermosetting polymers/thermosets
3. Elastomers
4. Coordination polymers
1. Thermoplastic polymers
Plastics made of thermoplastic polymers is deformable, melts to a liquid when heated and freezes to a brittle, glassy state when cooled sufficiently. Most thermoplastic polymers are high molecular weight polymers whose chains associate through weak van der Waals forces (polyethylene), stronger dipole-dipole interactions and hydrogen bonding (nylon) or even stacking of aromatic rings (polystyrene). Thermoplastic polymers can be remelted and remolded.
2. Thermosetting polymers
Thermosetting polymers ("thermosets") are materials that cure, through the addition of energy, to a stronger form. The energy may be in the form of heat (generally above 200°C), through a chemical reaction (two-part epoxy, for example), or irradiation. Thermoset materials are usually liquid, powder, or malleable prior to curing, and designed to be moulded into their final form, or used as adhesives. The curing process transforms the resin into a plastic or rubber by a cross-linking process. Energy and/or catalysts are added that cause the molecular chains to react at chemically active sites (unsaturated or epoxy sites, for example), linking into a rigid, 3-D structure. The cross-linking process forms a molecule with a larger molecular weight, resulting in a material with a higher melting point. During the reaction, when the molecular weight has increased to a point so that the melting point is higher than the surrounding ambient temperature, the material forms into a solid material. Subsequent uncontrolled reheating of the material results in reaching the decomposition temperature before the melting point is obtained. A thermoset material cannot be melted and re-shaped after it is cured. Thermoset materials are generally stronger than thermoplastic materials due to this 3-D network of bonds and are also better suited to high-temperature applications up to the decomposition temperature of the material.
3. Elastomers
The term elastomer is often used interchangeably with the term rubber, and is preferred when referring to vulcanisates. They are amorphous polymers existing above their glass transition temperature, so that considerable segmental motion is possible. At ambient temperatures rubbers are thus relatively soft and deformable. Their primary uses are for seals, adhesives and molded flexible parts.
4. Coordination polymers
Coordination polymers are compounds where the metals are bridged by polyatomic ligands, such as e.g. cyanide or carboxylates.
A preferred embodiment of the present invention relates to the use of at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above as a light-stabilizer in thermoplastic polymer compositions, whereby the thermoplastic polymer is preferably at least one thermoplastic polymer selected from the group comprising acrylonitrile-butadiene-styrene (ABS) copolymer; cellulose derivatives such as cellulose acetate, cellulose acetate propionate, cellulose acetate butyrate, cellulose triacetate, cellulose ether, methyl cellulose, ethylcellulose, propyl- cellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl- cellulose and carboxy methylcellulose; ethylene-vinyl acetate (EVA) copolymer; ethylene vinyl alcohol (EVAL) copolymer; polyolefines such as ethylen-propylen copolymer, ethylene-buten-1 copolymer, ethylene-hexene copolymer, ethylene- methylpentene copolymer, ethylene-heptene copolymer, ethylene octene copolymer, polybutylene (PB), polymethylpentene (PMP), polypropylene (PP) and polyethylene (PE) such as low density polyethylene (LDPE), linear low density polyethylene (LLDPE), high density polyethylene (HDPE) and metallocene-PE (mPE); ethylen- alkylacrylate copolymer such as ethylen-ethylacrylate copolymer; ethylene- alkylmethylacrylate copolymer; fluoro resins such as polytetrafluoroethylene (PTFE) or perfluoro (ethylene-propylene) copolymer (FEP); chloro-trifluoroethylene (CTFE), ethylene-chlorotrifluoroethylene (ECTFE); ethylene-tetrafluorethylene copolymer (ETFE) and tetrafluoroethylene-propylene copolymer; ionomer; liquid crystal polymer (LCP); polyacetal; polyacrylate; polymethacrylate; polyacrylonitrile; polyamide (PA); polyamide-imide; polyesters such as polybutylene terephthalate (PBT), polyethylene terephthalate (PET) and polycyclohexylene dimethylene terephthalate (PCT); polycarbonate (PC); polyhydroxyalkanoate; polyketone (PK); polyetheretherketone (PEEK); polyetherimide (PEI); polyethersulfone (PES); polyimide (Pl); polylactic acid (PLA); polyphenylene oxide (PPO); polyphenylene sulfide (PPS); polyphthalamide (PPA); homo- or copolymers of styrene such as e.g. styrene-isopren-styrene block copolymer; polysulfone (PSU); polyurethane (PU); polyvinyl ether; polyvinylalcohol; polyvinylidenechloride; polyvinylpyrrolidone; polyvinyl chloride (PVC); vinyl chloride-
vinyl acetate copolymer; vinyl chloride-vinylidene dichloride copolymer and vinyl pyrrolidon-ethylen-vinylacetate copolymer.
Another preferred embodiment of the present invention relates to the use of at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above as a light-stabilizer in elastomer compositions, whereby the elastomer is preferably at least one elastomer selected from the group comprising homo-, co- or block polymer of butadiene; natural rubber (NR); polyisoprene (IR); butyl rubber; halogenated butyl rubbers such as chloro butyl rubber or bromo butyl rubber; polybutadiene (BR); styrene-butadiene rubber (SBR); nitrile rubber; hydrated nitrile rubbers (HNBR); chloroprene rubber (CR); polychloroprene; neoprene; ethylene propylene rubber (EPM); ethylene propylene diene rubber (EPDM); epichlorohydrin rubber (ECO); polyacrylic rubber; silicone rubber; silicone; silcone derivatives such as siloxane-methacrylate polymers; fluorosilicone rubber; fluoroelastomers; perfluoroelastomers (FFKM); tetrafluoro ethylene/propylene rubbers (FEPM); chlorosulfonated polyethylene (CSM); ethylene-vinyl acetate (EVA) copolymers; thermoplastic elastomers (TPE); polyurethane rubber and polysulfide rubber.
Another preferred embodiment of the present invention relates to the use of at least one silylated substituted benzotriazolylphenol compound of general formula (I) given above as a light-stabilizer in thermosetting polymer compositions, whereby the thermosetting polymer is preferably at least one polymer selected from the group comprising vulcanized rubber; polyoxybenzylmethylenglycolanhydride; duroplast; urea-formaldehyde resins; melamine; cured polyester resins and epoxy resins.
Polymer compositions usually comprise additives, which improve the properties of these compositions. Suitable additives used in the inventive light-stabilized composition preferably include, but are not limited to anti-blocking-agents, anti- fogging agents, antistatic agents, antioxidants, biocides, blowing agents, defoamers, dyes, emulsifiers, fillers, flame retardants, heat stabilizers, impact modifiers, lubricants, metal deactivators, hydrocalcites, mould-release agents, optical brighteners, plastisizers, processing agents, pigments, phosphites, phosphonites, reinforcing agents, rheology additives, slip agents and surfactants, whereby each of
these aforementioned additives is used in usual amounts known by those skilled in the art.
The present invention is illustrated below with the aid of examples. These illustrations are given solely by way of example and do not limit the general spirit of the present invention.
EXAMPLES
Abbreviations:
H hour
0C °Celsius ml milliliter
Min minute
M molar (concentration) mol moles
N normal
HCI hydrogen chloride
NaNO2 sodium nitrite
NaOH sodium hydroxide
Mp melting point
RT room temperature
K2CO3 potassium carbonate
Kl potassium iodide
CH2CI2 dichloromethane
MgSO4 magnesium sulphate
Example 1: Procedure for synthesis of 3-(2H-benzotriazol-2-yl)-5-[2-methyl-3- [1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propyl]biphenyl-4-ol
techn. Xylene, Ar
(Ex.1)
3-(2H-1 ,2,3-Benzotriazol-2-yl)biphenyl-4-ol (P6)
To a cold (0-5 0C) suspension of 6.9 g 2-nitroaniline (0.05 mol; P1) in 25 ml concentrated HCI, 50 g crashed ice and 50 ml water was added dropwise 10 ml of a 5N solution of NaNO2. The resulting mixture was stirred at 0 0C until it turned to a clear, yellow solution (P2). This solution was then added dropwise to a cold (<5 0C) solution of 8.51 g biphenyl-4-ol (0.05 mol; P3) in 45 ml 10% aqueous NaOH solution with stirring. The reaction mixture was stirred at 00C for 1 h and at RT the precipitated pale brown crystalline compound was collected by filtration (P4). The biphenyl-4-ol (P3) did not run out completely. Yield: 17 g (100%) Mp: 1000C. Rf = 0.58 (hexane-acetone 10:4).
The suspension of 10 g (P4) (0.031 mol) in 100 ml, 4N NaOH was refluxed in the presence of 7.5 g formamidinesulphinic acid (0,069 mol; P5) for 1 h. The brown- purple color changed into pale yellow. The resulting mixture was cooled to RT and then poured into a 200 ml mixture of ice and water. The mixture was acidified with concentrated HCI (pH = 6) and the precipitated crystals were collected by filtration (P6). Impurities were dissolved with hot methanol. P6: Yield: 5.3g (67%). Mp 152- 153°C. Rf = 0.85 (hexane-acetone 10:4).
P6:
1H -NMR (CDCl3): 7.26 (d, J= 8.5 Hz, IH, C5-H), 7.35 (t, J= 7.3, IH, Ci0-H), 7,46 (t, J= 7.3, 2H, C9-H and Cu-H), 7.49 (dd, J= 6.5 and 3.0 Hz, 2H, C5-H and C6-H), 7.59 (dd, J= 8.6 and 1.9 Hz, IH, C6-H), 7.66 (d, J= 7.5 Hz, 2H, C8-H and Ci2-H), 7.93 (dd, J= 6.5 and 3.0 Hz, 2H, C4-H and C7-H), 8.65 (d, J= 1.8 Hz, IH, C2-H), 11.37 (s, IH, OH).
13C-NMR (CDCl3): 117.71 (C-4' and C-7'), 119.42 (C-5), 119.48 (C-2), 125.44 (C-3), 126.79 (C-8 and C- 12), 127.24 (C-IO), 127.81 (C-51 and C-6'), 128.86 (C-9 and C-I l), 129.04 (C- 6), 133.48 (C-I), 139.72 (C-7), 142,87 (C-3a' and C-7a'), 149.17 (C-4).
2-{4-[(2-Methylprop-2-en-1-yl)oxybiphenyl-3-yl}-2H-1,2,3-benzotriazole (P8)
To a stirred mixture of 5 g of compound P6 (0.017 mol), 2.4 g K2CO3 (0.017 mol), and 5.8 g Kl (0.035 mol.) in 120 ml butan-2-one was added dropwise 3.7 ml 3-chloro-2- methylprop-1-ene (0.035 mol) and the resultant mixture was heated at reflux for 8 h. After cooling to RT, the reaction mixture was filtered and the solvent was evaporated
in vacuo. The residue was purified by column chromatography (using toluene as eluent). Yield: 3.7 g (62%), Mp 94-95.5°C, Rf = 0.67 (hexane-acetone 10:4)
P8:
1H-NMR (CDCI3): 1.71 (s, 3H, CH3), 4.55 (s, 2H, CH2), 4.90 (s, IH, =C-H), 5.00 (s, IH, =C- H), 7.19 (d, J= 8,7 Hz, IH, C5-H), 7.33 (t, J= 7.5, IH, Ci0-H), 7.43 (m, 2H, C9-H and Cn- H, 7.45 (m, 2H, C5-H and C6-H), 7.60 (d, J= 8.5 Hz, 2H, C8-H and Ci2-H), 7.70 (dd, J= 8.7 and 2.3 Hz, IH, C6-H), 7.94 (d, J= 2.3 Hz, IH, C2-H), 7.98 (m, 2H, C4-H and C7-H).
13C-NMR (CDCl3): 19.17 (CH3), 72.78 (CH2), 112.90 (=C-H), 1 14.72 (C-51), 1 18.44 (C-4 and C-7), 126.12 (C-21), 127.37 (C- IO'), 126.82 (C-5, C-6, C-8 and C- 12'), 128.87 (C-9' and C- 10'), 129.28 (C-6'), 130.91 (C-31), 134.31 (C-I1), 139.33 (C-71), 139.87 (C=), 144.85 (C-3a and C-7a), 152.00 (C-4 ).
3-(2H-1 ,2,3-Benzotriazol-2-yl)-5-(2-methylprop-2-en-1 -yl)biphenyl-4-ol (P9)
A solution of compound P8 (3.7 g; 0.011 mol) in Λ/,Λ/-diethylaniline was heated at reflux for 3 h. After cooling to RT the reaction mixture was treated with 75 ml 15% aqueous HCI and extracted with CH2CI2 (three times, 100 ml each). The combined organic extracts were dried (MgSO4), solvent evaporated in vacuo, and the residue was recrystallized from hexane. Yield: 3.3g (86%), Mp 115.5-116,5°C, Rf = 0.88 (hexane-acetone 10:4).
P9:
1H-NMR (CDCl3): 1.84 (s, 3H, CI l3), 3.58 (s, 2H, CH2), 4.80 (s, IH, =C-H), 4.89 (s, IH, =C-H), 7.35 (t, J= 7,5 Hz, IH., Ci0-H), 7.46 (m, 3H, C6-H, C9-H and Cn- H ) , 7.49 (m, 2H, C5-H and C6-H, 7.67 (d, J= 8.5 Hz, 2H, C8-H and Ci2-H), 7.94 (m, 2H, C4-H and C7-H), 8.56 (d, J= 2,3 Hz, IH, C2-H), 11.67 (s, IH, OH).
13C-NMR (CDCl3): 22.57 (CH3), 38.07 (CH2), 111.92 (=C-H), 117.67 (C=), 117.75 (C-2), 125.39 (C-3), 126.83 (C-8 and C- 12), 127.14 (C- 10), 127.74 (C-5' and C-6 ), 128.81 (C-9 and C- 12), 129.91 (C-9' and C-10 ), 130.10 (C-5), 132,67 (C- I), 139.96 (C-7), 142.82 (C-3a' and C-7a'), 144.25 (C=), 147.52 (C-4).
3-(2H-benzotriazol-2-yl)-5-[2-methyl-3-[1,3,3J3-tetramethyl-1- [(trimethylsilyl)oxy]disiloxanyl]propyl]biphenyl-4-ol (Example compound 1)
To a mixture of compound P9 (3 g; 0.0088 mol) and 3.7 ml 1 ,1 ,1 ,3,5,5,5- heptamethyltrisiloxane (P10; 0.013 mol) in 50 ml xylene was added 10 drops of Karstedt's catalyst, and the resulting mixture was heated at 1000C for 9 h. After cooling to RT, the solvent was evaporated in vacuo and the residue was purified by column chromatography (using hexane as eluent). Yield: 4.7 g (95%). Rf = 0.91(hexane-acetone 10:4). λmax1 = 305 nm, εmaxi = 17573; λmaχ2 = 352 nm, εmaX2 = 11530.
1H NMR (CDCl3): 0.10 (s, 3H, CH3), 0.11 (s, 9H, 3CH3), 0.12 (s, 9H, 3CH3), 0.56 (dd, J= 14.8 and 9.2 Hz, IH, C3-H), 0.78 (dd, J= 14.8 and 4.7 Hz, IH, C3-H), 1.05 (d, J=6.6 Hz, 3H, CH3), 2.23 (m, IH, C2-H), 2.73 (dd, J= 13.2 and 8.2 Hz, IH, Cr-H), 2.89 (dd, J= 13.2 and 6,2 Hz, IH, Ci-H), 7.38 (t, J= 7.4 Hz, IH, C4-H), 7.49 (m, 3H, C5-H, C3 -H and Cs'-H), 7.52 (m, 2H, C5 -H and C6 -H), 7.71 (d, J= 7.5 Hz, 2H, C2-H and C6-H), 7.98 (m, 2H, C4-H and C7-H), 8.57 (d, J= 3.3 Hz, IH, C3-H), 11.60 (s, IH, OH).
13C NMR (CDCl3): 0.85 (CH3), 1.87 (CH3), 22.48 (CH3), 26.18 (C-3"'), 29.31 (C-2"'), 41.27 (C- I1"), 117.39 (C-3), 117.66 (C-41 and C-71), 125.34 (C-2), 126.83 (C-2" and C-6"), 127.03 (C-4"), 127.66 (C-5' and C-61), 128.77 (C-3" and C-5"), 130.56 (C-5), 132, 14 (C-6), 132.34 (C-4), 140.14 (C-I"), 142.81 (C-7a'), 147.66 (C-3a').
Determination of the UV-absorption profile of 3-(2H-benzotriazol-2-yl)-5-[2- methyl-3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propyl]biphenyl- 4-ol (Example compound 1):
The UV-absorption spectrum of 3-(2H-benzotriazol-2-yl)-5-[2-methyl-3-[1 ,3,3,3- tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propyl]biphenyl-4-ol (dissolved in CHCI3,
concentration: 4 μg/ml) was tested using a Hewlett Packard 8452A Diode Array Spectrophotometer.
In the chart of figure 1 it can be seen that example compound 1 absorbs more than half of the amount of the radiation in the UV-C radiation range, when compared with Mexoryl XL® (compare: figure 2). Moreover it can be seen that example compound 1 absorbs more amounts of UV radiation at λmax values of approx. 300 nm (UV-B) and approx. 340 nm (UV-A), respectively in comparison to Mexoryl XL® (compare: figure 2).
Example 2: 3-(2H-benzotriazol-2-yl)-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl- disiloxanyl)-propyl]-biphenyl-4-ol
λmaxi = 305 nm, εmaxi = 21083; λmaX2 = 352 nm, εmax2 = 13946. Melting point: 41-44°C.
Η NMR (CDCb): 0.10 (s, 9H, 3 CH3), 0.14 (s, 3H2, CH3), 0.15 (s, 3H, CH3), 0.63 (dd, J= 14.7 and 9.9 Hz, IH, C3" -H), 0.83 (dd, J= 14.7 and 4.8 Hz, IH, C3-H), 1.04 (d, J= 6.6 Hz, 3H, CH3), 2,24 (m, IH, C2-H), 2.70 (dd, J= 13.1 and 8.3 Hz, IH, Ci -H), 2,92 ((dd, J= 13.1 and 6.0 Hz, IH, Cr-H), 7.39 (t, J= 7.5 Hz, IH, C4-H), 7.49 (m, 3H, C5-H, C3-H and C5-H), 7.52 (m, 2H, C5-H and C6-H), 7.71 (d, J=7.5 Hz, 2H, C2- -H and C6-H), 7.98 (m, 2H, C4 -H and C7-H), 8.57 (d, J= 2.2 Hz, IH, C3-H), 11.61 (s, IH, OH).
"C NMR (CDCI3): 1.31 (CH3), 1.42 (CH3), 1.99 (3 CH3), 22.68 (CH3), 27.01 (C-31"), 29.54 (C- 2'"), 41.53 (C-I1"), 1 17.41 (C-3), 117.66 (C-4' and C-71), 125.34 (C-2), 126.83(C-2" and C-6"), 127.05(C-4"), 127.65 (C-5' and C-6'), 128.79 (C-3" and C-5"), 130.57 (C-5), 132.12 (C-6), 132.33 (C-4), 140.13 (C-I"), 142.81 (C-7a'), 147.65 (C-3a').
Example 3: Procedure for synthesis of 2-(2/-/-benzotriazol-2-yl)-4-cyclohexyl-6-[2- methyl-3-(1 ,1 ,3,3,3-pentamethyl-disiloxanyl)-propyl]-phenol
techn. Xylene, Ar
(Ex.3)
3-(2H-1 ,2,3-Benzo[d]triazol-2-yl)cyclohexylphenol (Q6)
To a cold (0-5 0C) suspension of 10.36 g 2-nitroaniline (0.075 mol; Q1) in 37.5 ml concentrated HCI, 75 g crashed ice and 75 ml water was added dropwise 15 ml of a 5N solution of NaNU2. The resulting mixture was stirred at 0 0C until it turned into a clear, yellow solution (Q2). This solution was then added dropwise to a cold (<5 0C) solution of 8.81 g 4-cyclohexylphenol (0.05 mol; Q3) in 45 ml 10% aqueous NaOH solution with stirring. The reaction mixture was stirred at 00C for 1 h and at RT the precipitated pale brown crystalline compound was collected by filtration (Q4). Yield: 17.72 g (=100%) Mp: «105°C. Rf = 0.53 (hexane-acetone 10:4).
The suspension of Q4 (17 g, 0.052 mol) in 100 ml, 4N NaOH was refluxed in the presence of 12.37 g formamidinesulphinic acid (0,12 mol; Q5) for 1 h. The brown- purple color changed into pale yellow. The resulting mixture was cooled to RT and then poured into a 200 ml mixture of ice and water. The mixture was acidified with concentrated HCI (pH = 6) and the precipitated crystals were collected by filtration (Q6). Q6: Yield: 15 g (98%) Mp: 135-136.5°C. Rf = 0.8 (hexane-acetone 10:4).
Q6:
1H-NMR (CDCb): 1.29 (m, IH, C4-H), 1.43 (m, 2H, C3-H and C5-H), 1.47 (m, 2H, C2-H and C6-H), 1.76 (d, J= 12.5 Hz, IH, C4-H), 1.86 (d, J= 12.5 Hz, 2H, C3-H and C5-H), 1.94 (d, J= 12.5 Hz, 2H, C2-H and C6-H), 2.57 (m, I H, Ci-H), 7.12 (d, J= 8.5 Hz, IH, C6-H), 7.20 (dd, J= 8.5 and 0.9 Hz, IH, C5-H), 7.47 (dd, J= 6.5 and 2.9 Hz, 2H, C5-H and C6-H), 7.93 (dd, J= 6.5 and 2.9 Hz, 2H, C4-H and C7-H), 8.24 (d, J= 0.8 Hz, IH, C3-H), 11.13 (s, IH, OH).
13C-NMR (CDC13): 26.09 (C-4"), 26.88 (C-3" and C-5"), 34.58 (C-2" and C-6"), 43.74 (C- I"), 117.67 (C-4' and C-7'), 118.75 (C-6), 119.03 (C-3), 124.95 (C-2), 127.61 (C-5' and C-6'), 129.12 (C-5), 140.20 (C-4), 142.81 (C 3a and C-7a), 147.75 (C- I).
2-(2-(Methylallyloxy)-5-cyclohexylphenyl)-2H-benzo[d][1,2,3]triazole (Q8)
To a stirred mixture of compound Q6 (17.5 g, 0.06 mol), 8.3 g K2CO3 (0.06 mol), and 20 g Kl (1.16 mol.) in 260 ml butan-2-one was added dropwise 13 ml 3-chloro-2- methylprop-1-ene (0.12 mol) and the resultant mixture was heated at reflux for 9 h. After cooling to RT, the reaction mixture was filtered and the solvent was evaporated
in vacuo. The residue was purified by column chromatography (using toluene as eluent). Yield: 12.5 g (60%), Rf = 0.7 (hexane-acetone 10:4)
2-(2H-Benzo[d][1,2,3]triazol-2-yl)-4-cyclohexyl-6(2-methylallyl)phenol (Q9)
A solution of compound Q8 (12 g; 0.035 mol) in Λ/,Λ/-diethylaniline (80 ml) was heated at reflux for 9 h. After cooling to RT the reaction mixture was treated with 100 ml 3% aqueous HCI. The brown precipitate was passed through a short column (using toluene as eluent). Yield: 11.3g (94%), Mp 125 - 126°C, Rf = 0.83 (hexane-acetone 10:4).
Q9:
1H-NMR (CDCl3): 1.29 (m, IH, C4-H), 1.40 (m, 2H, C3-H and C5-H), 1.47 (m, 2H, C2 -H and C6-H), 1,76 (d, J= 12.5 Hz, I H, C4-H), 1.81 (s, 3H, CH3), 1.87 (d, J= 12.5 Hz, 2H, C3- H and C5-H), 1.94 (d, J= 12.5 Hz, 2H, C2-H and C6-H), 2.55 (m, IH, Ci-H), 3.49 (CH2), 4.74 (s, IH, C=C-H), 4.86 (s, IH, C=C-H), 7.09 (d, J= 1.7 Hz, IH, C5-H), 7.46 (dd, J= 6.5 and 3.0 Hz, 2H, C5-H and C6-H), 7.92 (dd, J= 6.5 and 3.0 Hz, 2H, C4-H and C7-H), 8.13 (d, J= 1.9 Hz., IH, C3-H), 11.42 (s, IH, OH).
13C-NMR (CDCl3): 22.55 (CH3), 26.11 (C-4"), 26.90 (C-3" and C-5"), 34.60 (C-2" and C-6"), 43.78 (C-I"), 111.58 (=C), 117.19 (C-3), 117.61 (C-4' and C-7'), 124.88 (C-2), 127.53 (C-5' and C-6'), 129.26 (C-6), 130.24 (C-5), 139.39 (C-4), 142,75 (C-3a* and C-7a'), 144.56 (C=), 146,04 (C-I).
2-(2H-benzotriazol-2-yl)-4-cyclohexyl-6-[2-methyl-3-(1,1,3,3>3-pentamethyl- disiloxanyl)-propyl]-phenol (Example compound 3)
To a mixture of compound Q9 (5.5 g; 0.016 mol) and 4.83 ml pentamethyltrisiloxane (0.024 mol) in 100 ml xylene 10 drops of Karstedt's catalyst were added and the resulting mixture was heated at 1000C for 6 h. After cooling to RT the solvent was evaporated in vacuo and the residue was purified by column chromatography (using hexane as eluent). Yield: 4 g (50%). Rf = 0.87(hexane-acetone 10:0.4). λmaxi = 306 nm, εmaxi = 16180; λmaX2 = 345 nm, εmaX2 = 14924.
1H-NMR (CDCI3): 0.09 (s, 9H, 3 CH3), 0.13 (s, 6H, 2 CH3), 0.59 (dd, J = 14.8 and 8.9 Hz, IH, C3 -H), 0.79 (dd, J= 14,8 and 4.8 Hz, IH, C3 -H), 1.01 (d, J= 6.6 Hz, 3H, CH3), 1.33 (m, IH, C4-H), 1.44 (m, 2H, C3-H and C5'-H), 1.52 (m, 2H, C2-H and C6-H), 1.80 (m-d, J= 12.9 Hz, IH, C4-H), 1.90 (m-d, J= 12.5 Hz, 2H, C3-H and C5-H), 1.97 (m-d, ,J= 12.6 Hz, 2H, C2- H and C6-H), 2.16 (m, IH, C2 -H), 2.58 (m, IH, Cr-H), 2.60 (dd, J= 13.0 and 8.3 Hz, IH, Cr-H), 2.83 (dd, J= 13.0 and 6.5 Hz, IH, Cf-H), 7.07 (d, J= 1.6 Hz, IH, C5-H), 7.49 (dd, J = 6.5 and 3.0 Hz, 2H, C5-H and C6-H), 7.96 (dd, J= 6.5 and 3.0 Hz, 2H, C4-H. and C7-H), 8.13 (d, J= 1.6 Hz, IH, C3-H), 11.34 (s, IH, OH).
"C-NMR (CDCl3): 1.32 (CH3), 1.39 (C:H3), 1.99 (3 CH3), 22.70 (CH3), 26.12 (C-4"), 26.90 (C-3" and C-5"), 29.48 (C-2"'), 34.58 (C-2"), 34.62 (C-6"), 41.44 (C-I "'), 43.77 (C-I"), 116.78 (C-3), 117.59 (C-4' and C-7'), 124.79 (C-2), 127.42 (C-5' and C-6'), 130.80 (C-5), 131.31 (C- 6), 138.97 (C-4), 142.73(C-3a' and C-7a'), 146.11 (Cl).
Example 4: Procedure for synthesis of 2-(2/-/-benzotriazol-2-yl)-4-cyclohexyl-6-[2- methyl-S-ti .S.S.S-tetramethyl-i-^trimethylsilyOoxyJdisiloxany^propylj-phenol
For obtaining 2-(2H-benzotriazol-2-yl)-4-cyclohexyl-6-[2-methyl-3-[1 ,3,3,3- tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propyl]-phenol the essentially the same synthesis steps as for Example compound 3 described above were employed.
To a mixture of 5.5 g compound Q9 (0.016 mol) and 1 ,1 ,1 ,3,5,5,5- heptamethyltrisiloxane (6.7 ml, 0.024 mol) in 100 ml xylene 10 drops of Karstedt's catalyst were added and the resulting mixture was heated at 1000C for 4 h. After cooling to RT the solvent was evaporated in vacuo and the residue was purified by column chromatography (using hexane as eluent). Yield: 5 g (55%). Rf = 0.87 (hexane-acetone 10:0.4). λmaxi = 306 nm, εmaxi = 14872; Kmax2 = 344 nm, εmaχ2 = 13727.
iH-NMR (CDCl3): 0.08 (s, 311, CH3), 0.11 (s, 18H, 6 CH3), 0.51 (dd, J= 14.8 and 9.3 Hz, IH, C3-H), 0.74 (dd, J= 1.4.8 and 9.3 Hz, IH, C3-H), 1.02 (d, J= 6.6 Hz, 3H, CH3), 1.33 (m, IH, C4), 1.44 (m, 2H, C3-H and C5-H), 1.52 (m, 2H, C2-H and C6-H), 1.80 (m-d, J= 12.5 Hz, IH, C4-H), 1.90 (m-d, J= 12.5 Hz, 2H, C3-H and C5-H), 1.97 (m-d, J= 12.5 Hz, 2H, C2- H and C6-H), 2.16 (m, IH C2-H), 2.58 (m, IH, Cr-H), 2.65 (dd, J= 13.1 and 7.9 Hz, IH, Cr-H), 2.78 (dd, J= 13.1 and 6.3 Hz, IH, Ci-H), 7.07 (d, J= 1.6 Hz, IH, C5-H), 7.49 (dd, J= 6.6 and 3.0 Hz, 2H, C5-H and C6-H), 7.96 (dd, J= 6,6 and 3.0 Hz, 2H, C4-H and C7-H), 8.13 (d, J= 1.6 Hz, IH, C3-H), 11.34 (s, IH, OH).
13C-NMR (CDCl3): 0.82 (CH3), 1.86 (6 CH3), 22.51 (CH3), 26.04 (C-3m), 26.12 (C-4"), 26.90 (C-3" and C-5"), 29.26 (C-2'"), 34.62 (C-2" and C-6"), 41.22 (C-I"), 43.78 (C-I"), 116.78 (C-3), 117.60 (C-4' and C-71), 124.79 (C-2), 127.41 (C-5' and C-6'), 130.77 (C-5), 131.34 (C-6), 138.96 (C-4), 142.72 (C-3a' and C-7a'), 146.15 (C-I).
Example 5: 3-(5-Chloro-2H-benzotriazol-2-yl)-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl- disiloxanyl)-propyl]-biphenyl-4-ol
Example 6: 3-(5-Methoxy-2H-benzotriazol-2-yl)-5-[2-methyl-3-(1 ,1 ,3,3,3- pentamethyl-disiloxanyl)-propyl]-biphenyl-4-ol
Example 7: 2-{4-Hydroxy-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl-disiloxanyl)-propyl]- biphenyl-3-yl}-2/-/-benzotriazole-5-carbonitrile
Example 8: 2-{4-Hydroxy-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl-disiloxanyl)-propyl]- biphenyl-3-yl}-2/-/-benzotriazole-5-carboxylic acid
Example 9:
A cream formulation with the composition: % by weight
A) 3-(2H-benzotriazol-2-yl)-5-[2-methyl-3-(1 ,1 ,3,3,3- pentamethyl-disiloxanyl)-propyl]-biphenyl-4-ol [λmaxi = 305 nm, λmaX2 = 352 nm] 5%
B) stearyl alcohol (Nacol 18-98 (Sasol)) 1.2%
C) PEG-40 stearate (Simulsol M52 (Seppic)) 2.5%
D) cetearyl ethylhexanoate (DUB Liquide 85) 2.5%
E) caprylic/capryc triglyceride (Miglyol 812N (Sasol) 3.0%
F) CM2-I5 alkyl benzoate (Tegosoft TN (Goldschmidt)) 5.0%
G) phenoxyethanol (and) methylparaben (and) ethylparaben (and) propylparaben (and) isobutylparaben (and) butylparaben (Phenonip (Clariant)) 0.6%
H) polyacrylamide (and) Ci3-14 isoparaffin (and) Laureth-7 (Sepigel 305 (Seppic)) 2%
I) cellulose gum (Blanose Cellulose Gum 7H3SF (Hercules)) 0.25% J) water ad 100%
is prepared.
In example 9 given above the % by weight of the respective components are based on the total weight of the composition.
The inventive formulations according to the examples are prepared by standard techniques known by those skilled in the art.
Example 10:
A polymer composition comprising 3-(5-Methoxy-2H-benzotriazol-2-yl)-5-[2- methyl-3-(1 ,1 ,3,3,3-pentamethyl-disiloxanyl)-propyl]-biphenyl-4-ol (example compound 6) as light stabilizer.
Abbreviations:
MFI melt flow index
PP polypropylene
Ex.2 3-(2H-benzotriazol-2-yl)-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl- disiloxanyl)-propyl]-biphenyl-4-ol (melting point: 41-44°C)
A master batch of polypropylene (MFI=OJ g/10 min at 2300C and 2.16 kg) and 2% by weight of Ex.2, related to the total weight of the masterbatch, are prepared by dry blending the polypropylene granulate with the aforementioned components and the mixture is further processed under melting in a Brabender kneader at 2000C during 10 minutes and at a rotation speed of 75 rounds/min and under a nitrogen atmosphere.
The master batch is mixed in such an amount with polypropylene (MFI=O.7 g/10 min at 2300C and 2.16 kg) to achieve a light-stabilized PP composition containing 0.15% by weight, based on the total weight of the composition, of the light-stabilizing component and with 0 1 % by weight calcium stearate and 0.05% by weight of a phenolic antioxidant (Irganox 1010) in an extruder equipped with a double screw. The composition is extruded through a flat nozzle to obtain a film with a thickness adjusted to the requirements of the accelerated weathering test according to ASTM D-5208. The film is then exposed to such weathering test. The light stability of the sample is assessed by measuring the extent of carbonyl oxidation of the polymer by means of infrared spectroscopy. The measurement is carried out after 1000 hours exposition to accelerated weathering (UV-A).
Example 11 :
5,5'-(3,3<-(dimethylsilanediyl)bis(propane-3,1-diyl))bis(3-(2H -benzo[d][1,2,3]triazol-2-yl)biphenyl-4-ol)
= 400nm
Comparative Example 1
The UV-absorption spectrum of (2-(2H-benzotriazol-2-yl)-4-methyl-6-[2-methyl-3- [1 ,3)3>3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propyl]-phenol) Mexoryl XL® (dissolved in CHCb, concentration: 4 μg/ml) was tested using a Hewlett Packard 8452A Diode Array Spectrophotometer.
In the chart of figure 2 it can be seen that Mexoryl XL® absorbs less than half of the amount of the radiation in the UV-C radiation range, when compared with the inventive example compound 1 (compare: figure 1 ). Moreover it can be seen that Mexoryl XL® absorbs less amounts of UV radiation at λmax values of approx. 300 nm (UV-B) and approx. 340 nm (UV-A), respectively in comparison to example compound 1 (compare: figure 1 ).
Claims
1. At least one silylated substituted benzotriazolylphenol compound of general formula (I)
(I)
wherein
k= 0 or 1 ; q = 1 or 2;
R1 and R2, independent from one another, each represents a hydrogen atom; a halogen atom; -NO2; -OR8; -SR9; -CN; -NR10R11; -C(=O)-OR12; -C(=O)R13; -C(=O)-NR14R15; -OC(=O)R16; -NR17-C(=O)R18; -NR19-C(=O)-O-R20; -S(=O)2-R21; -S(=O)2-O-R22; -S(=O)2-NR23R24;
a linear or branched, saturated, unsubstituted or at least mono-substituted CM8 aliphatic radical;
an unsubstituted or at least mono-substituted aryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono- substituted, saturated or aromatic mono- or bicyclic ring system;
or
R1 and R2 are fused to form together an additional aromatic mono- or polycyclic ring system having from 4 to 10 carbon atoms;
R3 represents an unsubstituted or at least mono-substituted, saturated, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be condensed with an unsubstituted or at least mono-substituted saturated or aromatic mono- or bicyclic ring system;
or
an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted, saturated or aromatic mono- or bicyclic ring system;
R4 represents a hydrogen atom; a linear or branched, saturated, unsubstituted or at least mono-substituted C-i-iβ aliphatic radical;
with the provision that if q = 1 , then
k = 1 ;
R5 and R6 and R7, independent from one another, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted Ci-Ie aliphatic radical; a linear or branched, saturated, unsubstituted or at least mono-substituted -O-C-ι-18 aliphatic radical;
an unsubstituted or at least mono-substituted, saturated cycloaliphatic radical; an unsubstituted or at least mono-substituted aryl radical, which may be condensed with an unsubstituted or at least mono-substituted aromatic mono- or bicyclic ring system;
or
R5, R6 and R7, independent from one another, each represents a radical of general formula (II)
(") wherein
P = O, 1 , 2 or 3;
R25, R26, R27, R28 and R29, independent from one another, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted CM8 aliphatic radical; a linear or branched, saturated, unsubstituted or at least mono-substituted -0-C1-I8 aliphatic radical; an unsubstituted or at least mono-substituted aryl radical; or an -O-Si(R30)3 radical, with R30 representing a linear or branched, unsubstituted or at least mono-substituted CMS alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -O-C-|.i8 alkyl radical or an unsubstituted or at least mono-substituted aryl radical;
with the condition that if q = 1 and at the same time k = 1 , at least one of the radicals R5, R6 and R7 represents a radical of general formula (II) as defined above;
or, with the provision that if q = 2, then k = 0;
R7 represents a radical of general formula (III)
(III)
wherein
m = 0, 1 , 2, 3, 4 or 5;
X represents an oxygen atom or an unsubstituted or at least mono-substituted
Ci-6 alkylene radical;
R31, R32, R33 and R34, independent of one another, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted C-M8 aliphatic radical; a linear or branched, saturated, unsubstituted or at least mono-substituted -O-C-1-18 aliphatic radical;
an unsubstituted or at least mono-substituted, saturated cycloaliphatic radical;
an unsubstituted or at least mono-substituted aryl radical, which may be condensed with an unsubstituted or at least mono-substituted aromatic mono- or bicyclic ring system;
or an -O-Si(R30)3 radical, with R30 representing a linear or branched, unsubstituted or at least mono-substituted CMS alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -0-C1-I8 alkyl radical or an unsubstituted or at least mono-substituted aryl radical; R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R23 and R24, independent of one another, each represents a hydrogen atom; a linear or branched, saturated, unsubstituted or at least mono-substituted Ci--I8 aliphatic radical, an unsubstituted or at least mono-substituted, saturated, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an unsubstituted or at least mono-substituted aryl radical;
R20 and R21, independent of one another, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted Ci--I8 aliphatic radical, an unsubstituted or at least mono-substituted, saturated, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an unsubstituted or at least mono-substituted aryl radical;
and
R22 independent of one another, each represents a hydrogen atom; or an unsubstituted or at least mono-substituted, saturated, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an unsubstituted or at least mono-substituted aryl radical;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixture ratio, or a salt, preferably a corresponding, physiologically acceptable salt, or a corresponding solvate.
2. At least one silylated substituted benzotriazolylphenol compound according to anyone of claim 1 , characterized in that
R1 and R2, independent from one another, each represents a hydrogen atom; a halogen atom; -NO2; -OR8; -SR9; -CN; -NR10R11; -COOR12; -COR13; -CONR14R15; -OCOR16; -NR17-COR18; -NR19-COO-R20; -SO2-R21; -SO2-O-R22; -SO2-NR23R24;
a linear or branched, unsubstituted or at least mono-substituted CMS alkyl radical;
an unsubstituted or at least mono-substituted 6-, 10- or 14-membered mono- , bi- or tricyclic aryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted C1^ alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted, saturated or aromatic mono- or bicyclic ring system; or
R1 and R2 are fused to form together an additional aromatic mono- or polycyclic ring system having from 4 to 10 carbon atoms;
R3 represents an unsubstituted or at least mono-substituted, saturated, optionally at least one heteroatom as ring member containing C3-g (hetero)cycloalkyl radical, which may be condensed with an unsubstituted or at least mono-substituted saturated or aromatic mono- or bicyclic ring system;
or
an unsubstituted or at least mono-substituted 6-, 10- or 14-membered mono- , bi- or tricyclic aryl or a 5-, 6-, 8-, 9-, 10-, 11 -, 12-, 13- or 14-membered mono-, bi- or tricyclic heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted saturated or aromatic mono- or bicyclic ring system;
R4 represents a hydrogen atom; a linear or branched, unsubstituted or at least mono-substituted Ci-6 alkyl radical;
with the provision that if q = 1, then k = 1 ;
R5, R6 and R7, independent from one another, each represents a linear or branched, unsubstituted or at least mono-substituted Ci-β alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -O-Ci-6 alkyl radical;
an unsubstituted or at least mono-substituted C-3-g cycloalkyl radical;
an unsubstituted or at least mono-substituted 6-, 10- or 14-membered mono- , bi- or tricyclic aryl radical which may be condensed with an unsubstituted or at least mono-substituted aromatic mono- or bicyclic ring system;
or
R5, R6 and R7, independent from one another, each represents a radical of general formula (II)
(H) wherein
P = O, 1 , 2 or 3;
R25, R26, R27, R28 and R29, independent from one another, each represents a linear or branched, unsubstituted Ci-6 alkyl radical; a linear or branched, unsubstituted -0-Ci-6 alkyl radical; an unsubstituted or at least mono- substituted 6-, 10- or 14-membered mono-, bi- or tricyclic aryl radical; or an -O-Si(R30)3 radical, with R30 representing a linear or branched, unsubstituted or at least mono-substituted C1-6 alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -O-C-i-β alkyl radical; an unsubstituted or at least mono-substituted 6-, 10- or 14-membered mono-, bi- or tricyclic aryl radical;
with the condition that if q = 1 and at the same time k = 1 , at least one of the radicals R5, R6 and R7 represents a radical of general formula (II) as defined above;
or, with the provision that if q = 2, then
k = 0;
R7 represents a radical of general formula (III)
(III) wherein
m = 0, 1 , 2, 3, 4 or 5;
X represents an oxygen atom or an unsubstituted or at least mono- substituted C-I-4 alkylene radical;
R31, R32, R33 and R34, independent of one another, each represents a linear or branched, unsubstituted or at least mono-substituted Ci-6 alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -0-Ci-6 alkyl radical; an unsubstituted or at least mono-substituted 03.9 cycloalkyl radical;
an unsubstituted or at least mono-substituted 6-, 10- or 14-membered mono- , bi- or tricyclic aryl radical which may be condensed with an unsubstituted or at least mono-substituted aromatic mono- or bicyclic ring system;
or an -O-Si(R30)3 radical, with R30 representing a linear or branched, unsubstituted or at least mono-substituted Ci-6 alkyl radical; a linear or branched, unsubstituted or at least mono-substituted -O-d-β alkyl radical or an unsubstituted or at least mono-substituted 6-, 10- or 14-membered mono- , bi- or tricyclic aryl radical;
R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23 and R24, independent of one another, have the above-defined meaning;
whereby
the aforementioned CMS alkyl radicals are in each case unsubstituted or substituted with 1 , 2, 3, 4, 5, 6, 7, 8 or 9 substituent(s) independently selected from the group consisting of oxo (=O), F, Cl, Br, I1 -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-Ci-8-alkyl, -O-Si-(C1-8-alkyl)3, -Si-(C1- 8-alkyl)3, -Si-(phenyl)3, -S-C1-8-alkyl, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -N(Ci-8-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence the alkyl chain of the aforementioned Ci-i8-alkyl and/or Ci-8-alkyl radicals is linear or branched;
the aforementioned Ci-6 alkyl radicals are in each case unsubstituted or substituted with 1 , 2, 3, 4 or 5, substituent(s) independently selected from the group consisting of oxo (=O), F, Cl, Br, I1 -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-Ci-6-alkyl, -O-Si-(Ci-6-alkyl)3 ,-S-Ci-6-alkyl, -Si-(Ci-6-alkyl)3, -Si-(phenyl)3, -NH(d-6-alkyl), -N(C1-6-alkyl)2, -N(C1-6-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence the alkyl chain of the aforementioned C-ι-6-alkyl radicals is linear or branched; the aforementioned -O-C-ι-6 alkyl radicals are in each case unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (=0), F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -O-d-β-alkyl, -O-Si-(C1-6-alkyl)3, -S-C1-6-alkyl, -Si-(Ci-6-alkyl)3, -Si-(phenyl)3, -NH(C1-6-alkyl), -N(C1-6-alkyl)2, -N(C1.6-alkyl)3 +, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence the alkyl chain of the aforementioned d-β-alkyl radicals is linear or branched;
the aforementioned C3-g (hetero)cycloalkyl radicals are in each case unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (=0), Ci-8-alkyl, -O-C1-8-alkyl, -S-Ci-8-alkyl, -C(=O)-OH, -C(=O)-C1-8-alkyl, -C(=O)-O-C1.8-alkyl, -O-C(=O)-C1-5-alkyl, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH(Ci-8-alkyl), -N(C1-8-alkyl)2, -N(C1-8-alkyl)3 +, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(C1-8-alkyl), -C(=O)-N(Ci-8-alkyl)2, -S(=O)2-C1-8-alkyl, -S(=O)2-phenyl, phenyl, phenethyl, phenoxy and benzyl, whereby in each occurrence Ci-8-alkyl is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, I -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2 and - NO2;
the aforementioned C3.g heterocycloalkyl radicals contain in each case optionally 1 , 2 or 3 additional heteroatom(s) independently selected from the group consisting of nitrogen, sulphur and oxygen as ring member(s);
the aforementioned C3-9cycloalkyl radicals contain in each case optionally 1 , 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, sulphur and oxygen as ring member(s);
the aforementioned C1-4 alkylene, preferably -(CH2)-, -(CH2)2-, -(CH2)3- and -(CH2)4- groups are in each case linear or branched, unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, I1 -CN, -CF3, -OCF3, -SCF3, -OH, -SH, -NH2, -O-C1-6-alkyl, -S-Ci-6-alkyl, -NH(Ci.6-alkyl) and -N(C1-6-alkyl)2;
the aforementioned Ci-6 alkylene, preferably -(CH2)-, -(CH2J2-, -(CH2)3-, -(CH2)4- , -(CH2)5- and -(CH2)6- groups are in each case unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -OH, -SH, -NH2, -O-Ci-6-alkyl, -S-Ci-6-alkyl, -NH(Ci-β-alkyl) and -N(d-6-alkyl)2;
the rings of the aforementioned ring systems are in each case independently of each other 5-, 6-, 7-, 8-, 9,- or 10-membered and may in each case independently of one another optionally contain 1 , 2, 3 or 4 heteroatom(s) independently selected from the group consisting of nitrogen, sulphur and oxygen;
and the rings of the aforementioned mono-, bi- or polycyclic ring systems are in each case unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (=O), C1-8-alkyl, -0-Ci-β-alkyl, -S-C1-8-alkyl, -C(=O)-OH, -C(=O)-C1-8-alkyl, -C(=O)-O-Ci-8-alkyl, -O-C(=O)-C1-5-alkyl, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -N(C1-8-alkyl)3 +, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(Ci-8-alkyl), -C(=O)-N(C1-8-alkyl)2, -S(=O)2-Ci-8-alkyl, -S(=O)2-phenyl, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence Ci-8-alkyl is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, I -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2 and -NO2;
the 6-, 10- or 14-membered, mono-, bi- or tricyclic aryl or 5-, 6-, 8-, 9-, 10-, 11-, 12-, 13- or 14-membered mono-, bi- or tricyclic heteroaryl radicals are unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of oxo (=O), Ci-8-alkyl, -O-C-i-8-alkyl, -S-Ci-8-alkyl, -C(=O)-OH, -C(=O)-C1-8-alkyl, -C(=O)-O-C1-8-alkyl, -O-C(=O)-C1-8-alkyl, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH(Ci-β-alkyl), -N(C1-8-alkyl)2l -N(C1-8-alkyl)3 +, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(C1.8-alkyl), -C(=O)-N(Ci-8-alkyl)2, -S(=O)2-C1-8-alkyl, -S(=O)2-phenyl, phenyl, benzyl, phenethyl and phenoxy; whereby in each occurrence Ci-8-alkyl is linear or branched and whereby the cyclic part(s) of said substituent(s) is unsubstituted or substituted with 1 , 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F1 Cl, Br, I -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2 and -NO2;
and the aforementioned 5-, 6-, 8-, 9-, 10-, 11-, 12-, 13- or 14-membered mono-, bi- or tricyclic heteroaryl radicals in each case contain 1 , 2, 3 or 4 heteroatom(s) independently selected from the group consisting of nitrogen, sulphur and oxygen as ring member(s);
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
3. At least one silylated substituted benzotriazolylphenol compound according to claim 1 or 2, characterized in that
q = 1 ; k= 1 ;
and
^ P, D1 D2 C?3 D4 D5 D6 D7 D8 D9 D10 , DIA11 , f DA12 , DΪA13 , DIA14 , C IA?15 , F DA16 , DIA17 , DIA18 , CIA?19 ,
R20, R21, R22, R23, R24, R25, R26, R27, R28, R29 and R30 have the meaning according to claim 1 ;
with the condition that at least one of the radicals R5, R6 and R7 represents a radical of general formula (II) as defined above; optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
4. At least one silylated substituted benzotriazolylphenol compound according to claim 1 or 2, characterized in that
q = 2; k = 0;
and
R18, R19, R20, R21, R22, R23, R24, R30, R31, R32, R33 and R34 have the meaning according to claim 1.
5. At least one silylated substituted benzotriazolylphenol compound according to claim 1 or 2, characterized in that
q = 2; k = 0; m = 0;
and
n Y D1 D2 O3 C?4 D5 D6 D7 D8 D9 D10 D11 R12 P13 D14 D15 R16 D17 D18
R19, R20, R21, R22, R23, R24, R30, R31, R32, R33 and R34 have the meaning according to claim 1.
6. At least one silylated substituted benzotriazolylphenol compound according to claim 1 or 2, characterized in that
q = 2; k = 0; m = 1;
and
^ V D1 D2 D3 D4 D5 D6 D7 D8 D9 O10 nil D12 D13 D"I4 D15 D"I6 D-I? D18 P, Λ, IΛ , IΛ , ΓΛ , ΓΛ , IΛ , Γ\ , Γ\ , IΛ , Γ\ , Γ\ , IΛ , r\ , r\ , r\ , r\ , r\ , r\ , r\ ,
R19, R20, R21, R22, R23, R24, R30, R31, R32, R33 and R34 have the meaning according to claim 1.
7. At least one silylated substituted benzotriazolylphenol compound according to claim 1 or 2, characterized in that
q = 2; k = 0; m = 2;
and
„ v D-I D2 D3 D4 D5 D6 D7 D8 O9 D10 D11 D12 O13 D14 D1S D16 C317 D18 P, Λ, fΛ j iΛ j rΛ j lΛ j lΛ j rΛ j rΛ j rΛ j rΛ j rΛ , r\ ,
R19, R20, R21, R22, R23, R24, R30, R31, R32, R33 and R34 have the meaning according to claim 1.
8. At least one silylated substituted benzotriazolylphenol compound according to claim 1 or 2, characterized in that
q = 2; k = 0; m = 3;
and
r. V D-I D2 D3 D4 D5 D6 D7 Dδ D9 D10 D11 D12 D13 D14 D15 D16 D17 D18 P, Λ, IΛ , Γ\ , Γ\ , Γ\ , Γ\ , Γ\ , r\ , Γ\ , Γ\ , Γ\ , Γ\ , ΪΛ , IΛ , ΓΛ , Γ\ , Γ\ , ΪΛ , ΪΛ ,
R19, R20, R21, R22, R23, R24, R30, R31, R32, R33 and R34 have the meaning according to claim 1. optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
9. At least one silylated substituted benzotriazolylphenol compound according to one or more of claims 1 to 8, characterized in that
q = 1 or 2; k = 0 or 1 ;
R1 and R2, independent from one another, each represents a hydrogen atom; F; Cl; Br; I; -NO2; -NH2; -SH; -OH; -CN; -C(=O)-OH; -C(=O)-OCH3> -C(=O)-OCH2CH3, -C(=O)-NH2; -S(=O)2-OH; -S(=O)2-NH2; -S(=O)2-Phenyl;
a radical selected from the group consisting of -O-CH3, -0-CH2-CH3, -0-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH2-CH3 and -0-CH2-CH2-CH2-CH2-CH2-CH2-CH3; whereby in each occurrence the alkyl chain is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH2, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -0-CH3, -0-C2H5, -S-CH3, -O-Si-(CH3)3, -O-Si-(CH2-CH3)3, -Si-[CH(-CH3)2]3, -Si-(CH3)3, -Si-(CH2-CH3)3, -Si-[CH(-CH3)2]3, -NH-CH3 and -N(-CH3)2; and whereby in each occurrence the alkyl chain of these radicals is linear or branched; or
a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted or substituted with 1 , 2, 3, 4, or 5 substituents independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH2, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -0-CH3, -0-C2H5, -S-CH3, -O-Si-(CH3)3, -O-Si-(CH2-CH3)3, -O-Si-[CH(-CH3)2]3, -Si-[CH(-CH3)2]3, -Si-(CH3)3, -Si-(CH2-CH3)3, -Si-[CH(-CH3)2]3, -NH-CH3 and -N(-CH3)2; whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
R3 represents a (hetero)cycloaliphatic radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, azetidinyl, tetrahydrofuranyl, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec- butyl, isobutyl, n-pentyl, -O-CH3l -0-C2H5, -0-CH2-CH2-CH3, -O-CH(CH3)2, -O-C(CH3)3, -S-CH3, -S-C2H5, -S-CH2-CH2-CH3, -S-CH(CH3)2, -S-C(CH3)3, -C(=O)-OH, -C(=O)-CH3> -C(=O)-C2H5, -C(=O)-CH2-CH2-CH3, -C(=O)-CH(CH3)2, -C(=O)-C(CH3)3, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -S(=O)2-Phenyl, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH-CH3, phenyl, phenethyl, phenoxy and benzyl;
or
an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, pyridinyl, pyrrolyl, imidazolyl, pyrazolyl, indolyl, benzotriazolyl, quinolyl and isoquinolyl, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, n- pentyl, -O-CH3, -0-C2H5, -0-CH2-CH2-CH3, -O-CH(CH3)2, -O-C(CH3)3, -S-CH3, -S-C2H5, -S-CH2-CH2-CH3, -S-CH(CH3)2, -S-C(CH3)3, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-CH2-CH2-CH3, -C(=O)-CH(CH3)2, -C(=O)-C(CH3)3, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -S(=O)2-Phenyl, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH-CH3, phenyl, phenethyl, phenoxy and benzyl;
R4 represents a hydrogen atom; or a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted; and whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
with the provision that if q = 1, then
k = 1 ;
R5, R6 and R7, independent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n- butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted or substituted with 1 , 2, 3, 4, or 5 substituents independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH2, -CN, -CF3, -OCF3, -SCF3, -SO3Na1 -SO3K, -SO3H, -0-CH3, -0-C2H5, -S-CH3, -O-Si-(CH3)3, -O-Si-(CH2-CH3)3, -O-Si-[CH(-CH3)2]3, -Si-[CH(-CH3)2]3, -Si-(CH3)3, -Si-(CH2-CH3)3, -Si-[CH(-CH3)2]3, -NH-CH3, -N(-CH3)2 and phenyl; whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
a radical selected from the group consisting of -0-CH3, -0-CH2-CH3, -0-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH2-CH3 and -0-CH2-CH2-CH2-CH2-CH2-CH2-CH3; whereby in each occurrence the alkyl chain is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of F, Cl, Br, I, -OH, -SH, -NH2, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H1 -0-CH3, -0-C2H5, -S-CH3, -O-Si-(CH3)3, -O-Si-(CH2-CH3)3, -O-Si-[CH(-CH3)2]3) -Si-[CH(-CH3)2]3> -Si-(CH3J3, -Si-(CH2-CH3)3, -Si-[CH(-CH3)2]3, -NH-CH3 and -N(-CH3)2; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
a phenyl or naphthyl radical, which is unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, n- pentyl, -0-CH3, -0-C2H5, -0-CH2-CH2-CH3, -O-CH(CH3)2, -O-C(CH3)3, -S-CH3, -S-C2H5, -S-CH2-CH2-CH3, -S-CH(CH3)2, -S-C(CH3)3, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C2H5l -Cf=O)-CH2-CH2-CH3, -C(=O)-CH(CH3)2, -C(=O)-C(CH3)3, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH-CH3, phenyl, phenethyl, phenoxy and benzyl;
or
R5, R6 and R7, independent from one another, each represents a radical of general formula (II)
wherein
P = O, 1 or 2;
R25, R26, R27, R28 and R29, independent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopro- pyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted; and whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
a radical selected from the group consisting Of -CH2-Ph and -CH2- CH2-Ph;
a radical selected from the group consisting Of -O-CH3, -0-CH2-CH3, -0-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH2-CH3 and -0-CH2-CH2-CH2-CH2-CH2-CH2-CH3; whereby in each occurrence the alkyl chain of these radicals is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched; an unsubstituted phenyl or naphthyl radical;
or
an -O-Si(R30)3 radical, with R30 representing a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl and hexyl, which is unsubstituted;
with the condition that if q = 1 and at the same time k = 1 , at least one of the radicals R5, R6 and R7 represents a radical of general formula (II) as defined above;
or, with the provision that if q = 2, then
k = 0;
R7 represents a radical of general formula (III)
(III) wherein
m = 0, 1 or 2;
X represents an oxygen atom or an unsubstituted or at least mono-substituted C-I-4 alkylene radical; R31, R32, R33 and R34, independent of one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n- butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted; and whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
an unsubstituted phenyl or naphthyl radical;
a radical selected from the group consisting of -0-CH3, -0-CH2-CH3, -0-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH2-CH3 and -0-CH2-CH2-CH2-CH2-CH2-CH2-CH3; whereby in each occurrence the alkyl chain of these radicals is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
or
an -O-Si(R30)3 radical, with R30 representing a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl and hexyl;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
10. At least one silylated substituted benzotriazolylphenol compound according to one or more of claims 1 to 9, characterized in that
q = 1 or 2; k = 0 or 1 ; R1 and R2, independent from one another, each represents a hydrogen atom; methyl; ethyl; F; Cl; Br; I; -OH; -CN; -CF3; -C(=O)-OH; -CH2-C≡N; -C(=O)-OCH3, -C(=O)-OCH2CH3, -S(=O)2-Phenyl, -0-CH3; or -0-CH2-CH3;
R3 represents a radical selected from the group consisting of phenyl, naphthyl, cyclopentyl, cyclohexyl and cycloheptyl, which is 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, n-pentyl, -O-CH3, -0-C2H5, -0-CH2-CH2-CH3, -O-CH(CH3)2, -O-C(CH3)3, -S-CH3, -S-C2H5, -S-CH2-CH2-CH3, -S-CH(CH3J2, -S-C(CH3)3, -C(=O)-OH, -C(=O)-OCH3) -C(=O)-OCH2CH3, -S(=O)2-Phenyl, -C(=O)-CH3) -C(=O)-C2H5, -C(=O)-CH2-CH2-CH3, -C(=O)-CH(CH3)2, -C(=O)-C(CH3)3, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -SO3Na, -SO3K, -SO3H, -OH, -SH, -NH2, -NH-CH3, phenyl, phenethyl, phenoxy and benzyl;
R4 represents a radical selected from the group consisting of methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
with the provision that if q = 1, then
k = 1 ;
R5, R6 and R7, independent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n- butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
a radical selected from the group consisting Of -O-CH3, -0-CH2-CH3, -0-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH2-CH3 and -0-CH2-CH2-CH2-CH2-CH2-CH2-CH3; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
an unsubstituted phenyl or naphthyl radical;
or at least one of the radicals R5, R6 and R7, independent from one another, each represents a radical of general formula (II)
(") wherein
P = O oM ;
R25, R26, R27, R28 and R29, independent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopro- pyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted; and whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
a radical selected from the group consisting of -O-CH3, -0-CH2-CH3, -0-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH3, -0-CH2-CH2-CH2-CH2-CH2-CH3 and -0-CH2-CH2-CH2-CH2-CH2-CH2-CH3; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched; or
an -O-Si(R30)3 radical, with R30 representing a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl and hexyl, which is unsubstituted;
with the condition that if q = 1 and at the same time k = 1 , at least one of the radicals R5, R6 and R7 represents a radical of general formula (II) as defined above;
or, with the provision that if q = 2, then
k = 0;
R7 represents a radical of general formula (III)
(III) wherein
m = 0, 1 or 2;
X represents an oxygen atom or an unsubstituted or at least mono-substituted C-ι-4 alkylene radical;
R31, R32, R33 and R34, independent of one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n- butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, which is unsubstituted; and whereby in each occurrence the pentyl, hexyl, heptyl, octyl, nonyl or decyl radical is linear or branched;
a radical selected from the group consisting of -CH2-Phenyl and -CH2-CH2-Phenyl;
an unsubstituted phenyl or naphthyl radical;
a radical selected from the group consisting of -O-CH3, -O-CH2-CH3, -O-CH2-CH2-CH3, -O-CH2-CH2-CH2-CH3, -O-CH2-CH2-CH2-CH2-CH3, -O-CH2-CH2-CH2-CH2-CH2-CH3 and -0-CH2-CH2-CH2-CH2-CH2-CH2-CH3; whereby in each occurrence the alkyl chain of these radicals is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
or
an -O-Si(R30)3 radical, with R30 representing a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl and hexyl, which is unstubstituted;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
11. At least one silylated substituted benzotriazolylphenol compound according to claim 1 with the general formula (IB)
wherein
qb = 1 or 2; kb = 0 or 1 ;
R1b and R2b, independent of one another, each represents a hydrogen atom; methyl; ethyl; F; Cl; Br; I; -OH; -CN; -CF3; -C(=O)-OH; -C(=O)-OCH3, -C(=O)-OCH2CH3, -S(=O)2-Phenyl, -0-CH3; Or -O-CH2-CH3;
R3b and R3bb, independent of one another, each represents a hydrogen atom; methyl; ethyl; F; Cl; Br; I; -OH; -CN; -CF3; -C(=O)-OH; -C(=O)-OCH3, -C(=O)-OCH2CH3, -S(=O)2-Phenyl, -0-CH3; or -0-CH2-CH3;
R4b represents a radical selected from the group consisting of methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl, which is unsubstituted;
with the provision that if q b _ = 1, then
k ,bD _ = 1 ; R5b, R6b and R7b, independent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n- butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -0-CH3, -O-C2H5, -O-C3H7, -O-C4H9, -O-C5H11 and -O-C6Hi3; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
an unsubstituted phenyl or naphthyl radical;
or
R 5b R 6b and R 7b jn(jepenc|ent of one another, each represents a radical of general formula (Mb)
(lib)
wherein
pb = O or 1 ;
R 25b R 26b R 27b_ R 2βb and R 29b jndependent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -Chb-Phenyl and -CH2- CH2-Phenyl; a radical selected from the group consisting of -0-CH3; -0-C2H5; -0-C3H7; -0-C4H9; -O-C5H11; and -O-CβH13; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
a radical selected from the group consisting of -O-Si-(CH3)3; -O-Si-(C2H5)3; -0-Si-(C4Hg)3; -O-Si-(Phenyl)3; -CH2-Si-(CH3)3 and -CH2-Si-(C2Hs)3;
an unsubstituted phenyl or naphthyl radical;
with the condition that if qb = 1 and at the same time kb =1 , at least one of the radicals R5b, R6b and R7b represents a radical of general formula (lib) as defined above;
or, with the provision that if q b _ = 2, then
k ,bD - = 0;
represents a radical of general formula (MIb)
(MIb)
wherein
m ,bD _ = 0, 1 or 2; Xb represents an oxygen atom or an unsubstituted or at least mono- substituted C-1-4 alkylene radical;
R31b, R32b, R33b and R34b, independent of one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n- butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
a radical selected from the group consisting of -0-CH3; -0-C2H5; -O-C3H7; -O-C4H9; -O-C5Hn; and -0-CeH13; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
a radical selected from the group consisting of -O-Si-(CH3)3; -O-Si-(C2H5)3; -0-Si-(C4Hg)3; -O-Si-(Phenyl)3; -CH2-Si-(CH3)3 and -CH2-Si-(C2Hg)3;
or
an unsubstituted phenyl or naphthyl radical;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
12. At least one silylated substituted benzotriazolylphenol compound according to claim 1 with the general formula (IC)
wherein
n = 0, 1 , or 2;
R1c and R2c, independent of one another, each represents a hydrogen atom; methyl; ethyl; F; Cl; Br; I; -OH; -CN; -CF3; -C(=O)-OH; -C(=O)-OCH3, -C(=O)-OCH2CH3, -S(=O)2-Ph, -O-CH3; or -0-CH2-CH3;
R3c and R3cc, independent of one another, each represents a hydrogen atom; methyl; ethyl; F; -OH; -CN; -CF3; -C(=O)-OH; -C(=O)-OCH3, -C(=O)-OCH2CH3, -S(=O)2-Ph, -0-CH3; Or -O-CH2-CH3;
R4c represents a radical selected from the group consisting of methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl, which is unsubstituted;
with the provision that if qc = 1, then
kc = 1 ; R5c, R6c and R7c, independent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n- butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
a radical selected from the group consisting Of -O-CH3, -O-C2H5> -0-C3H7, -O-C4H9, -O-C5H11, and -0-C6Hi3; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
an unsubstituted phenyl or naphthyl radical;
or
R 5c R 6c and R 7c jnc|epenc|ent of one another, each represents a radical of general formula (lie)
(lie)
wherein
pc = 0 or 1 ; R 25c R 26c R 27c R 28c and R 29c jncjepenc|ent from one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
a radical selected from the group consisting Of -O-CH3, -0-C2H5, -0-C3H7, -O-C4H9, -0-C5H11, and -0-C6H13; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
a radical selected from the group consisting of -O-Si-(CH3)3, -O-Si-(C2H5)3l -0-Si-(C4Hg)3, -0-Si-(Ph)3, -CH2-Si-(CH3)3 and -CH2-Si-(C2Hs)3;
an unsubstituted phenyl or naphthyl radical;
with the condition that if qc = 1 and at the same time kc =1 , at least one of the radicals R5c, R6c and R7c represents a radical of general formula (lie) as defined above;
or, with the provision that if qc = 2, then
kc = 0;
R7c represents a radical of general formula (MIc)
(HIc) wherein
mc = 0, 1 or 2;
Xc represents an oxygen atom or an unsubstituted or at least mono- substituted C-1-4 alkylene radical;
R 3ic R 32c R 33c and R 34c jn(jepenc|ent of one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopro- pyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -CH2-Phenyl and -CH2- CH2-Phenyl;
a radical selected from the group consisting of -0-CH3, -0-C2H5, -O-C3H7, -O-C4H9, -O-C5H11 and -O-C-6Hi3; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
a radical selected from the group consisting of -O-Si-(CH3)3l -O-Si-(C2H5)3, -0-Si-(C4Hg)3, -0-Si-(Ph)3, -CH2-Si-(CH3)3 and -CH2-Si-(C2Hs)3;
an unsubstituted phenyl or naphthyl radical;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corre- sponding, physiologically acceptable salt, or a corresponding solvate.
13. At least one silylated substituted benzotriazolylphenol compound according to claim 1 with the general formulae (ID), (IE) and (IF)
(IE)
("F)
wherein
R1b and R2b, independent of one another, each represents a hydrogen atom; methyl; ethyl; F; Cl; Br; I; -OH; -CN; -CF3; -C(=O)-OH; -C(=O)-OCH3; -C(=O)-OCH2CH3; -S(=O)2-Ph; -0-CH3; or -0-CH2-CH3;
R3b and R3bb, independent of one another, each represents a hydrogen atom; methyl; ethyl; F; Cl; Br; I; -OH; -CN; -CF3; -C(=O)-OH; -C(=O)-OCH3; -C(=O)-OCH2CH3; -S(=O)2-Ph; -O-CH3; or -0-CH2-CH3;
R4b represents a radical selected from the group consisting of methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl, which is unsubstituted;
mb = 0, 1 , 2, 3, 4 or 5;
R 3ib R 32b R 33b and R 34b jnc|epenc|ent of one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting of -CH2-Ph and -CH2- CH2-Ph;
a radical selected from the group consisting of -O-CH3, -0-C2H5, -0-C3H7, -O-C4H9, -O-C5H11 and -0-C6Hi3; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
a radical selected from the group consisting of -O-Si-(CH3)3, -O-Si-(C2H5)3, -0-Si-(C4Hg)3, -0-Si-(Ph)3, -CH2-Si-(CH3)3 and -CH2-Si-(C2Hs)3;
an unsubstituted phenyl or naphthyl radical;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
14. At least one silylated substituted benzotriazolylphenol compound according to claim 1 with the general formulae (IG), (IH) and (IJ)
(IG)
(IJ)
wherein
R1c and R2c, independent of one another, each represents a hydrogen atom; methyl; ethyl; F; Cl; Br; I; -OH; -CN; -CF3; -C(=O)-OH; -C(=O)-OCH3; -C(=O)-OCH2CH3; -S(O)2-Ph; -0-CH3; Or -O-CH2-CH3;
R3c and R3cc, independent of one another, each represents a hydrogen atom; methyl; ethyl; F; -OH; -CN; -CF3; -C(=O)-OH; -C(=O)-OCH3l -C(=O)-OCH2CH3, -S(=O)2-Ph, -0-CH3; or -0-CH2-CH3; R4c represents a radical selected from the group consisting of methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl, which is unsubstituted;
mc = 0, 1 , 2, 3, 4 or 5;
R 3ic R 32 Cj R 33c and R 34c jnc|epenc|ent of one another, each represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, which is unsubstituted;
a radical selected from the group consisting Of -CH2-Ph and -CH2- CH2-Ph;
a radical selected from the group consisting of -0-CH3, -0-C2H5, -O-C3H7, -O-C4H9, -0-C5Hn and -O-CβHi3; whereby in each occurrence the alkyl chain is unsubstituted; and whereby in each occurrence the alkyl chain of these radicals is linear or branched;
a radical selected from the group consisting of -O-Si-(CH3)3, -O-Si-(C2H5)3, -0-Si-(C4Hg)3, -0-Si-(Ph)3, -CH2-Si-(CHa)3 and -CH2-Si-(C2Hs)3;
an unsubstituted phenyl or naphthyl radical;
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
15. At least one silylated substituted benzotriazolylphenol compound according to one or more of claims 1 to 14 selected from the group consisting of
[1 ] 3-(2H-benzotriazol-2-yl)-5-[2-methyl-3-[1 ,3,3,3-tetramethyl-1 - [(trimethylsilyl)oxy]disiloxanyl]propyl]biphenyl-4-ol,
[2] 3-(2H-benzotriazol-2-yl)-5-[2-methyl-3-(1 , 1 ,3,3,3-pentamethyl- disiloxanyl)-propyl]-biphenyl-4-ol, [3] 2-(2H-benzotriazol-2-yl)-4-cyclohexyl-6-[2-methyl-3-(1 ,1 ,3,3,3- pentamethyl-disiloxanyl)-propyl]-phenol,
[4] 2-(2H-benzotriazol-2-yl)-4-cyclohexyl-6-[2-methyl-3-[1 ,3,3,3-tetramethyl- 1-[(trimethylsilyl)oxy]disiloxanyl]propyl]-phenol,
[5] 3-(5-Chloro-2H-benzotriazol-2-yl)-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl- disiloxanyl)-propyl]-biphenyl-4-ol,
[6] 3-(5-Methoxy-2H-benzotriazol-2-yl)-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl- disiloxanyl)-propyl]-biphenyl-4-ol,
[7] 2-{4-Hydroxy-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl-disiloxanyl)-propyl]- biphenyl-3-yl}-2/-/-benzotriazole-5-carbonitrile,
and
[8] 2-{4-Hydroxy-5-[2-methyl-3-(1 ,1 ,3,3,3-pentamethyl-disiloxanyl)-propyl]- biphenyl-3-yl}-2H-benzotriazole-5-carboxylic acid,
optionally in the form of one of its stereoisomers, preferably enantiomers or di- astereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, enantiomers or diastereomers, in any mixture ratio, or a salt, a corresponding, physiologically acceptable salt, or a corresponding solvate.
16. A process for the preparation of at least one silylated substituted benzotriazolylphenol compound according to one or more of claims 1 to 15, characterized in that it comprises the step of reacting at least one compound of general formula (P9)
wherein R1, R2, R3 and R4 have the meaning according to claim 1 , with at least one suitable silyl derivative of general formula (P10)
wherein R5, R6, R7 and k have the meaning according to claim 1 , following typical hydrosilylation of carbon-carbon double bonds conditions, preferably in the presence of a catalyst, more preferably in the presence of a catalyst comprising an electron-rich complex of a late transition metal such as e.g. Co(I), Rh(I), Ni(O), Pd(O), or Pt(O), preferably with Speier catalyst (H2[PtCI6]), PtO2 or Karstedt catalyst (Pt2KCH2=CH)Me2Si]2O)3), more preferably using Karstedt catalyst, preferably in the presence of an organic solvent, more preferably an aromatic aprotic solvent such as e.g. xylene, preferably at a temperature ranging from O0C to the boiling point of the solvent, more preferably at a temperature between 5O0C and the boiling point of the solvent, even more preferably at 1000C until the reaction is completed to yield at least one compound of general formula (I)
17. A pharmaceutical composition comprising at least one silylated substituted benzotriazolylphenol compound according to anyone of claims 1 to 15, and optionally at least one pharmacologically acceptable auxiliary agent.
18. A cosmetic composition comprising at least one silylated substituted benzotriazolylphenol compound according to anyone of claims 1 to 15, and optionally at least one cosmetical vehicle.
19. Use of at least one silylated substituted benzotriazolylphenol compound according to anyone of claims 1 to 15 for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of diseases caused by and/or associated with exposure to ultraviolet radiation, preferably of the lips, the face and/or of the body of mammals, preferably human beings.
20. Use of at least one silylated substituted benzotriazolylphenol compound according to anyone of claims 1 to 15 as an agent for the preparation of a pharmaceutical composition for the prophylaxis and/or care and/or treatment against non-desired skin conditions comprising polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing, sunburn and/or chronic actinic dermatitis.
21. Use of at least one silylated substituted benzotriazolylphenol compound according to anyone of claims 1 to 15 as an agent for the prophylaxis and/or care against non-desired skin conditions comprising polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing, sunburn and/or chronic actinic dermatitis.
22. Use of at least one silylated substituted benzotriazolylphenol compound according to anyone of claims 1 to 15 for protecting the skin preferably of the lips, the face and/or of the body of a mammal, preferably a human, against ultraviolet radiation, preferably UV-A and/or UV-B radiation.
23. Use of at least one silylated substituted benzotriazolylphenol compound according to anyone of claims 1 to 15 as a light-stabilizer in polymer compositions.
24. Use of at least one silylated substituted benzotriazolylphenol compound according to anyone of claims 1 to 15 as a light-stabilizer in textile fibers.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07384024.1 | 2007-04-27 | ||
EP07384024 | 2007-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008131921A1 true WO2008131921A1 (en) | 2008-11-06 |
Family
ID=38462420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/003356 WO2008131921A1 (en) | 2007-04-27 | 2008-04-25 | Silylated, substituted benzotriazolylphenol compounds |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR066150A1 (en) |
CL (1) | CL2008001211A1 (en) |
PE (1) | PE20090242A1 (en) |
WO (1) | WO2008131921A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012055063A1 (en) * | 2010-10-25 | 2012-05-03 | L'oreal | Process for preparing 2-hydroxyphenyl alkenyl benzotriazole compounds and process for preparing siloxane compounds containing 2-hydroxyphenyl benzotrizole function |
WO2017007677A1 (en) | 2015-07-07 | 2017-01-12 | 3M Innovative Properties Company | Substituted benzotriazole phenolate salts and antioxidant compositions formed therefrom |
WO2017007672A1 (en) | 2015-07-07 | 2017-01-12 | 3M Innovative Properties Company | Substituted benzotriazole phenols |
JP2018052952A (en) * | 2011-04-07 | 2018-04-05 | コーネル ユニバーシティー | Silyl monomers capable of multimerizing in aqueous solution, and methods of using the same |
US11053373B2 (en) | 2015-07-07 | 2021-07-06 | 3M Innovative Properties Company | Polymeric matrices with ionic additives |
CN115232554A (en) * | 2022-08-15 | 2022-10-25 | 郑州中原思蓝德高科股份有限公司 | Corrosion-resistant elastic bonding protection composition and protection material |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5618520A (en) * | 1992-09-17 | 1997-04-08 | L'oreal | Photostable filtering cosmetic composition containing a UV-A filter and a filtering polymer of the benzotriazole silcone type |
DE19726184A1 (en) * | 1997-06-20 | 1998-12-24 | Beiersdorf Ag | Oil-in-water or multiple emulsion with high concentration of suspended UVB filter |
WO2003039507A1 (en) * | 2001-11-09 | 2003-05-15 | Beiersdorf Ag | Cosmetic and dermatological anti-uv formulations containing hydroxybenzophenone and triazine and/or benzotriazol derivatives |
-
2008
- 2008-04-25 PE PE2008000708A patent/PE20090242A1/en not_active Application Discontinuation
- 2008-04-25 WO PCT/EP2008/003356 patent/WO2008131921A1/en active Application Filing
- 2008-04-25 CL CL2008001211A patent/CL2008001211A1/en unknown
- 2008-04-25 AR ARP080101773A patent/AR066150A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5618520A (en) * | 1992-09-17 | 1997-04-08 | L'oreal | Photostable filtering cosmetic composition containing a UV-A filter and a filtering polymer of the benzotriazole silcone type |
DE19726184A1 (en) * | 1997-06-20 | 1998-12-24 | Beiersdorf Ag | Oil-in-water or multiple emulsion with high concentration of suspended UVB filter |
WO2003039507A1 (en) * | 2001-11-09 | 2003-05-15 | Beiersdorf Ag | Cosmetic and dermatological anti-uv formulations containing hydroxybenzophenone and triazine and/or benzotriazol derivatives |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012055063A1 (en) * | 2010-10-25 | 2012-05-03 | L'oreal | Process for preparing 2-hydroxyphenyl alkenyl benzotriazole compounds and process for preparing siloxane compounds containing 2-hydroxyphenyl benzotrizole function |
US9447123B2 (en) | 2010-10-25 | 2016-09-20 | L'oreal | Process for preparing 2-hydroxyphenyl alkenyl benzotriazole compounds; use of the said compounds obtained via the process in the synthesis of siloxane compounds containing a 2-hydroxyphenylbenzotriazole function |
JP2018052952A (en) * | 2011-04-07 | 2018-04-05 | コーネル ユニバーシティー | Silyl monomers capable of multimerizing in aqueous solution, and methods of using the same |
US10912786B2 (en) | 2011-04-07 | 2021-02-09 | Cornell University | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same |
WO2017007677A1 (en) | 2015-07-07 | 2017-01-12 | 3M Innovative Properties Company | Substituted benzotriazole phenolate salts and antioxidant compositions formed therefrom |
WO2017007672A1 (en) | 2015-07-07 | 2017-01-12 | 3M Innovative Properties Company | Substituted benzotriazole phenols |
US10669481B2 (en) | 2015-07-07 | 2020-06-02 | 3M Innovative Properties Company | Substituted benzotriazole phenolate salts and antioxidant compositions formed therefrom |
US10919867B2 (en) | 2015-07-07 | 2021-02-16 | 3M Innovative Properties Company | Substituted benzotriazole phenols |
US11053373B2 (en) | 2015-07-07 | 2021-07-06 | 3M Innovative Properties Company | Polymeric matrices with ionic additives |
US11078419B2 (en) | 2015-07-07 | 2021-08-03 | 3M Innovative Properties Company | Substituted benzotriazole phenolate salts and antioxidant compositions formed therefrom |
CN115232554A (en) * | 2022-08-15 | 2022-10-25 | 郑州中原思蓝德高科股份有限公司 | Corrosion-resistant elastic bonding protection composition and protection material |
Also Published As
Publication number | Publication date |
---|---|
AR066150A1 (en) | 2009-07-29 |
PE20090242A1 (en) | 2009-04-04 |
CL2008001211A1 (en) | 2009-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008131921A1 (en) | Silylated, substituted benzotriazolylphenol compounds | |
US5955060A (en) | Bis(resorcinyl)triazines useful as sunscreens in cosmetic preparations | |
BE1011451A5 (en) | Hydroxyphenyltriazines AS STABILIZERS FOR ORGANIC MATERIALS. | |
BE1011550A3 (en) | Compositions containing compounds and their use to stabilize an organic matter. | |
BE1014316A5 (en) | Articles polymers transparent thin. | |
JPH10158248A (en) | Use of substituted benzazole as ultraviolet light absorbent, new benzazole, and their production | |
WO2007006807A1 (en) | New derivatives of heptaazaphenalene, methods for obtaining them, and their use as protecting agents against uv radiation | |
WO2007128744A2 (en) | Triazine derivatives | |
US5332568A (en) | S-triazine derivatives having light-protecting action | |
KR20150027241A (en) | Ultraviolet radiation absorbing polymers | |
WO2010081835A2 (en) | Bis-resorcinyl-triazine derivatives as protecting agents against uv radiation | |
US6018044A (en) | Light screening compositions | |
US6111103A (en) | Diresorcinyl-alkoxy- and -aryloxy-s-triazines | |
KR20080027286A (en) | New derivatives of pyrrolyltriazine together with methods for obtaining them and their use as protecting agents against uv radiation | |
EP0173050B1 (en) | Selected 2,2,6,6-tetramethyl-4-piperidinyl derivatives and their use as light stabilizers | |
EP3022180B1 (en) | Uv absorbing compounds, compositions comprising same and uses thereof | |
JPH0241322A (en) | Organosilicone compound and its manufacture and use | |
Osyanin et al. | Reactions of indoles with 2-and 4-hydroxybenzyl alcohols | |
JP2004519470A (en) | Novel 2-benzoxazolylbenzene derivatives and their use as UV-blockers | |
Heravi et al. | Solvent free regioselective cyclization of 3-allylmercapto-1, 2, 4-triazoles to thiazolo [3, 2-b] 1, 2, 4-triazoles over sulfuric acid adsorbed on silica gel | |
Latypova et al. | Transformations of 2-Ethyl-2-methyl-2, 3-dihydro-1 H-indole at the 3-Position | |
Krysin et al. | 6-(1, 3-Dioxoindan-2-ylidenemethyl)-1, 2, 2, 4-tetramethyl-1, 2-dihydro-and 1, 2, 3, 4-Tetrahydroquinolines | |
Chaleix et al. | Microwave-assisted expeditious O-alkylation of meso-hydroxyphenylporphyrins | |
Farkas et al. | Synthesis of new potential UV-filters | |
SU1049484A1 (en) | Process for preparing derivatives of 4-amionopyridine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08749135 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08749135 Country of ref document: EP Kind code of ref document: A1 |